| Excerpt | Reference |
|---|
| "Hepatic metastasis is usually quite resistant to conventional systemic chemotherapy." | ( Lee, YT, 1978) |
| "Sometimes bony metastases are the presenting symptom but, usually the metastases occur within 5 years of the diagnosis of the primary tumour." | ( Cayla, J; Forest, M; Heisbourg, A; Meary, R; Rondier, J, 1975) |
| "A case of cerebral metastases is presented in which the initial brain scan did not demonstrate the lesion because steroid medication had been started 18 hr earlier." | ( Stebner, FC, 1975) |
| "Bone metastases are diagnosed before death in approximately 5." | ( Brennan, MF; Burt, ME, 1979) |
| "The metastases are the most variable kind of tumors." | ( Hacker, H; Vonofakos, D, 1978) |
| "Metastases are visible from the third week." | ( Benedetta Donati, M; de Gaetano, G; Garattini, S; Poggi, A; Polentarutti, N, 1977) |
| "Distant metastases are the principal cause of death from cancer." | ( Choppala, JD; Henschke, UK; Luande, GJ, 1977) |
| "Bone metastasis is a common event and a major cause of morbidity in cancer patients." | ( Arguello, F; Baggs, RB; Cohen, HJ; Frantz, CN; Graves, BT; Harwell, SE, 1992) |
| "Metastasis is a multistep process which requires highly adapted interactions of tumor cells with host target organs." | ( Edgington, TS; Mueller, BM; Reisfeld, RA; Ruf, W, 1992) |
| "The process of metastasis is not random." | ( Radinsky, R, 1991) |
| "Cancer metastasis is an ectopic growth of malignant cells." | ( Cleary, KR; Frazier, ML; Giacco, GG; Hoff, SD; Irimura, T; Matsushita, Y; Nakamori, S; Ota, DM; Yamori, T, 1991) |
| "Metastasis is a multistep process in which amoeboid chemotaxis plays a key role in the movement of tumor cells into and out of vessels." | ( Condeelis, J; Jones, JG; Segall, J, 1991) |
| "The inhibition of metastasis is likely due to a combination of events, which are currently under investigation." | ( Humphries, MJ; Newton, SA; Olden, K; White, SL, 1989) |
| "Tumour metastasis is the principal cause of death for cancer patients." | ( Barker, E; Biggs, JR; King, CR; Krutzsch, HC; Liotta, LA; Margulies, IM; Rosengard, AM; Shearn, A; Steeg, PS, 1989) |
| "Tumor cell metastasis is a complex process that depends in part on tumor cell adhesion to components of basement membranes and the extracellular matrix." | ( Furcht, LT; McCarthy, JB; Palm, SL; Skubitz, AP, 1988) |
| "Resection of metastases is beneficial to a small number of patients who develop metastatic disease." | ( Eilber, FR; Huth, JF, 1988) |
| "The development of metastases is thus integrally related to the mechanisms of tumor progression, which in turn is likely due to the instability of the tumor cell genome." | ( Fidler, IJ; Frost, P, 1986) |
| "Formation of metastases is favoured by both reduced numbers of immune cells in the bloodstream and impaired oxygen transport into tissues." | ( von Ardenne, M, 1985) |
| "Metastasis is also determined by a variety of host factors that prevent, allow or even stimulate metastatic processes." | ( Nicolson, GL, 1984) |
| "This process of metastasis is complex and consists of several steps, foremost of which is the arrest of circulating emboli in capillary beds and the formation of a thrombus at that site." | ( Sone, S; Tsubura, E; Yamashita, T, 1983) |
| "Distant metastases are more important as cause of death than loco-regional relapses, it is why adjuvant chemotherapy is necessary, especially in young patients and in those with extensive disease." | ( Auclerc, G; Auclerc, MF; Baillet, F; Blondon, J; Facchini, T; Jacquillat, C; Lefranc, JP; Weil, M, 1984) |
| "Metastasis is influenced by the mouse strain, and both inbred and F1 hybrid mice of syngeneic origin could be used as host animals." | ( Iida, H; Kawabata, H; Naganuma, K; Oh-Hara, T; Sakurai, Y; Tsukagoshi, S; Tsuruo, T; Yamori, T, 1984) |
| "Metastasis is the principal cause of failures to cure human cancers." | ( Cicone, B; Honn, KV; Skoff, A, 1981) |
| "However, metastasis is regulated by multiple other characteristics of the tumor cell and evidence suggests the participation of multiple classes of proteases." | ( Dickson, RB; Johnson, MD; Shi, YE, 1994) |
| "The frequent metastases are responsible for its poor prognosis and raise difficult methodological problems since the detection of metastatic sites depends on the sensitivity and specificity of the tests used to identify these sites." | ( Cordier, JF; Trillet-Lenoir, V, 1993) |
| "Metastases are clonal in origin and are produced by specialized subpopulations of cells that preexist in a heterogeneous primary tumor." | ( Dong, Z; Fidler, IJ; Xie, K, 1996) |
| "Bone metastasis is a common event and a major cause of morbidity in prostate cancer patients." | ( Martínez, J; Santibáñez, JF; Silva, S, 1996) |
| "Metastasis is a critical problem in the treatment of human lung cancer." | ( Izumi, K; Miyasaka, M; Nishioka, Y; Sone, S; Tanaka, T; Tsuruo, T; Yano, S, 1996) |
| "The first step of metastasis is the detachment of tumor cells." | ( Fujimoto, J, 1996) |
| "Metastasis is a complex process, almost a cascade, involving multiple steps and activities." | ( Martin, GR; Reich, R, 1996) |
| "Metastasis is a multistep process that involves alterations in a tumour cell's invasion, motility and adhesive capabilities." | ( Haites, NE; Price, JT; Wilson, HM, 1996) |
| "Metastasis is a multistep process in which protein kinase C (PKC) appears to be significantly involved." | ( Comolli, R; La Porta, CA, 1997) |
| "Although metastasis is undoubtedly multifactorial, intravascular coagulation activation and peritumor fibrin deposition seem to be important." | ( Amirkhosravi, A; Biggerstaff, J; Francis, JL, 1998) |
| "Distant metastasis is a more common pattern of failure than locoregional recurrence after adequate radiotherapy in patients with nasopharyngeal carcinoma (NPC)." | ( Hsu, CY; Jan, JS; Lin, JC, 1998) |
| "We have shown that metastasis is suppressed by low-dose total-body irradiation (TBI) in tumor-bearing rats." | ( Hashimoto, S; Hosokawa, M; Kobayashi, M; Kuramitsu, Y; Matushita, K; Miyasaka, K; Nishioka, T; Shirato, H, 1999) |
| "Tumor growth and metastasis are dependent on angiogenesis." | ( Ellis, LM; Liu, W; Shaheen, RM; Takahashi, Y, 2000) |
| "Metastasis is one of the most life-threatening aspects of cancer and the lack of effective anti-metastatic therapies has prompted research on MCP's effectiveness in blocking metastasis of certain types of cancers, including melanomas, prostate, and breast cancers." | ( , 2000) |
| "Although osseous metastases are critically relevant for prognosis, the pathogenesis of this peculiar feature of Ewing's sarcoma is poorly understood, partly due to the lack of appropriate experimental in vivo models." | ( Baldini, N; Benini, S; Chano, T; Landuzzi, L; Lollini, PL; Manara, MC; Nanni, P; Nicoletti, G; Picci, P; Scotlandi, K; Serra, M, 2000) |
| "Metastasis is a major cause of death in cancer patients and involves a multistep process including detachment of cancer cells from a primary cancer, invasion of surrounding tissue, spread through circulation, re-invasion and proliferation in distant organs." | ( Asada, M; Fujino, M; Honda, S; Hori, A; Ishibashi, Y; Kanehashi, K; Kitada, C; Kumano, S; Kurokawa, T; Masuda, Y; Matsumoto, H; Nishimura, O; Ohtaki, T; Onda, H; Shintani, Y; Suenaga, M; Takatsu, Y; Terao, Y; Usuki, S; Watanabe, T; Yamada, T, 2001) |
| "Tumor invasion and metastasis are regulated by the expression of genes such as E-cadherin, which regulates cell adhesion, and matrix metalloproteinase-9 (MMP-9), which alters the integrity of the extracellular matrix." | ( Dinney, CP; Inoue, K; Izawa, J; Karashima, T; Kedar, D; Kim, SJ; McConkey, DJ; Millikan, R; Perrotte, P; Shuin, T; Slaton, JW; Sweeney, P; Yoshikawa, C, 2001) |
| "The occurrence of metastases is the hallmark of cancer." | ( Antonaci, S; Giannelli, G, 2000) |
| "Distant metastases are the most common cause of treatment failure." | ( Adelstein, DJ; Carroll, MA; Esclamado, RM; Lavertu, P; Rybicki, LA; Saxton, JP; Strome, M; Wood, BG, 2002) |
| "Metastasis is the principal cause of death in breast cancer patients." | ( Allen, BJ; Andronicos, NM; Ranson, M; Rizvi, S; Tian, Z, 2002) |
| "Metastasis is not frequent." | ( Betel, E; Dem, A; Dembele, B; Diop, M; Diop, PS; Drabo, B; Fall, MC; Kasse, AA; Neloum, J; Timbely, G; Toure, P, 1999) |
| "Because metastasis is a multistep process, the aim of the present study was to investigate the effect of PS on some steps of the metastatic process: tumor cell invasion, adhesion, and migration." | ( Awad, AB; Fink, CS; Williams, H, 2001) |
| "The presence of metastases is the most potent predictor of poor prognosis." | ( Aronson, D; Brown, J; Chapchap, P; Czauderna, P; Keeling, J; Mackinlay, G; Otte, JB; Perilongo, G; Plaschkes, J; Pritchard, J; Shafford, E, 2002) |
| "Osteolytic bone metastasis is a frequent problem in the treatment of cancer." | ( Akedo, H; Iwasaki, T; Mukai, M; Nakamura, H; Tatsuta, M; Terada, N; Tsujimura, T, 2002) |
| "Tumor growth and metastasis are multifaceted processes that mainly involve cell adhesion, proteolytic degradation of the extracellular matrix, and cell migration." | ( Kundu, GC; Mahabeleshwar, GH, 2003) |
| "Ovarian metastasis is frequent." | ( Blanchot, J; Boucher, E; Corbinais, S; Garin, L; Le Guilcher, P; Raoul, JL, 2002) |
| "Cancer metastasis is one of the major challenges in cancer research." | ( Nishimura, Y, 2003) |
| "Metastasis is largely an unsuccessful process, because the majority of disseminating tumor cells demise shortly after reaching distant organs." | ( Huang, S; Xie, K, 2003) |
| "Bone metastasis is the major reason for death caused by breast cancer." | ( Beckedorf, A; Bieberich, E; Silva, J, 2003) |
| "The occurrence of metastasis is the main problem in HCC patients." | ( Antonaci, S; Bergamini, C; Fransvea, E; Giannelli, G; Marinosci, F, 2003) |
| "Blood-borne distant metastasis is the leading cause of cancer-related death in breast cancer." | ( Braun, S; Janni, W; Marth, C; Pantel, K; Schlimok, G; Vogl, FD, 2003) |
| "Lymph node metastasis is the most important predictor of prognosis in esophageal squamous cell carcinoma (ESCC)." | ( Ikeguchi, M; Kaibara, N; Yamaguchi, K, 2004) |
| "Bone metastasis is a frequent complication of cancer disease." | ( Kanakis, I; Karamanos, NK; Kiamouris, C; Nikolaou, M; Pectasides, D, 2004) |
| "As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice." | ( Eigentler, TK; Garbe, C, 2004) |
| "Distant metastasis is the predominant cause of death in early-stage non-small cell lung cancer (NSCLC)." | ( Berdel, WE; Bulk, E; Diederichs, S; Gerke, V; Ji, P; Lang, K; Metzger, R; Müller-Tidow, C; Schneider, PM; Serve, H; Steffen, B; Thomas, M; Tickenbrock, L; Zänker, KS, 2004) |
| "Metastasis is an impediment to the development of effective cancer therapies." | ( Jaiswal, JK; Mattoussi, H; Simon, SM; Voura, EB, 2004) |
| "Recurrence and metastasis are commonly associated with poor prognosis of hepatocellular carcinoma (HCC)." | ( Fan, ST; Ho, JW; Lee, TK; Man, K; Ng, IO; Ng, KT; Poon, RT; Sun, CK; Wang, XH; Xu, R, 2005) |
| "Cancer metastasis is infrequently evaluated in vivo, probably because of the few available models and the technical challenges associated with the detection of metastases." | ( Kimura, S; Kuroda, J; Maekawa, T; Nogawa, M; Sato, K; Segawa, H; Yokota, A; Yuasa, T, 2005) |
| "Metastasis is the major process responsible for the death in cancer patients." | ( Balassiano, IT; Cabral, MC; da Gloria da Costa Carvalho, M; De Paulo, SA; Henriques Silva, N, 2005) |
| "Tumor metastasis is the most common cause of death in cancer patients." | ( Chen, L; Danishefsky, SJ; Gaul, C; Huang, XY; Ma, X; Njardarson, JT; Shan, D, 2005) |
| "Tumor metastasis is a critical determinant of death from cancer." | ( Bourdeau, I; Burman, KD; Espinosa, AV; Ringel, MD; Saji, M; Stathatos, N; Stratakis, CA; Vasko, VV, 2005) |
| "Bone metastasis is an important cause of morbidity in advanced prostate cancer." | ( Hirano, K; Iguchi, K; Nakano, T; Usui, S, 2006) |
| "Metastasis is still the most serious reason for the high mortality of cancer patients." | ( Fichtner, I; Keil, C; Zeisig, R, 2005) |
| "Metastasis is a vital target for cancer treatment, since the majority of cancer patients die from metastatic, rather than the primary disease." | ( Berk, M; Jiang, Y; Powell, CT; Singh, LS; Tan, H; Xu, Y; Yin, L, 2005) |
| "The development of metastases is a decisive step in the course of a cancer disease." | ( Drell, TL; Entschladen, F; Lang, K; Masur, K; Niggemann, B; Palm, D; Zaenker, KS, 2006) |
| "Lung metastasis is the most crucial event affecting the treatment of osteosarcoma and is dependent on tumor angiogenesis." | ( Hioki, Y; Kusuzaki, K; Matsumine, A; Seto, M; Sonoda, J; Tomoda, R; Uchida, A, 2005) |
| "Bone metastases are the most common cause of pain in patients with malignant disease, in part due to the high frequency of axial (vertebrae, rib, and pelvis) and appendicular (femoral and humeral) fractures." | ( Slatkin, N, 2006) |
| "Metastasis is one of the most harmful aspects of malignant neoplasm." | ( Hashida, M; Nishikawa, M, 2006) |
| "Metastasis is the major cause of cancer morbidity, but strategies for direct interference with invasion processes are lacking." | ( Beug, H; Capodiecci, P; Cordon-Cardo, C; Donovan, M; Grünert, S; Jechlinger, M; Kraut, N; Moriggl, R; Seither, P; Sommer, A, 2006) |
| "Metastases are known to be more resistant to therapy than matching primary tumors, in particular they are less prone to apoptosis." | ( Abouzahr, S; Avril, MF; Chouaib, S; Diarra-Mehrpour, M; Even, J; Faure, F; Gassara, A; Gaudin, C; Jalil, A; Messai, Y; Richon, C, 2006) |
| "Tumor metastasis is a complex multistep process normally involving dysregulation of multiple signal transduction pathways." | ( Chan, KC; Conrads, TP; Hunter, KW; Issaq, HJ; Lancaster, M; Lucas, DA; Lukes, L; Stephens, RM; Veenstra, TD; Yang, H; Yi, M; Yu, LR, 2006) |
| "Distant metastasis is one of the main causes of treatment failure in nasopharyngeal carcinoma (NPC)." | ( Han, F; Hou, X; Huang, PY; Li, S; Lu, LX; Shao, JY; Zhang, L; Zhao, C, 2006) |
| "As primary osseous metastasis is the main adverse prognostic factor in patients with Ewing tumours, a NOD/scid mouse model for human Ewing tumour metastases has been established to examine the mechanisms of metastasis." | ( Franzius, C; Gabbert, HE; Hermann, S; Hotfilder, M; Jürgens, H; Poremba, C; Schäfers, K; Schäfers, M; Schober, O; Vormoor, J, 2006) |
| "Cancer metastasis is a significant contributor to breast cancer patient morbidity and mortality." | ( Halverson, DO; Horak, CE; Lee, JH; Palmieri, D; Steeg, PS, 2006) |
| "Micrometastasis is a major problem for prostate cancer (CaP) patients." | ( Abbas Rizvi, SM; Allen, BJ; Apostolidis, C; Cozzi, PJ; Li, Y; Madigan, MC; Morgenstern, A; Power, CA; Qu, CF; Russell, PJ; Wang, J, 2006) |
| "Pulmonary metastasis is a major cause of death in cases of operable cancer, and evidence suggests that postoperative immunosuppression contributes to this complication." | ( Abudarham, N; Ben-Eliyahu, S; Melamed, R; Rosenne, E; Schwartz, Y; Shakhar, G, 2007) |
| "Invasion and metastasis is the main cause of the poor prognosis and high mortality of hepatocellular carcinoma (HCC)." | ( Liu, GT; Sun, H, 2006) |
| "Metastases are more decisive for tumour prognosis than primary lesions, because of their multiple locations, low accessibility to surgery and/or radiotherapy, and generally poor responsiveness to chemotherapy." | ( Bergamo, A; Sava, G, 2007) |
| "Liver metastases are the most common cause of death in gastric ECs, and their control is very important for improving the poor prognosis associated with the disease." | ( Fujiyama, Y; Nishimura, M, 2007) |
| "Placentation and metastasis are invasive processes that require angiogenesis." | ( Davenport, AP; Kuc, RE; Maguire, JJ; Mead, EJ, 2007) |
| "Skeletal metastases are often complicated by pain." | ( de Klerk, JM; Lam, MG; van Rijk, PP; Zonnenberg, BA, 2007) |
| "Bone metastases are incurable and cause protracted, severe symptoms." | ( Chirgwin, JM; Guise, TA, 2007) |
| "Bone metastasis is often the penultimate harbinger of death for many cancer patients." | ( Dai, J; Escara-Wilke, J; Hall, CL; Ignatoski, K; Keller, ET; Keller, J; Taichman, RS, 2007) |
| "Liver metastasis is an important prognostic factor in colorectal cancer." | ( Higuchi, R; Koda, K; Kosugi, C; Sugimoto, M; Suzuki, M; Takenoue, T; Tezuka, T; Watayo, Y; Yagawa, Y; Yamamoto, S; Yamazaki, M; Yasuda, H, 2007) |
| "Distant metastases are the most common recurrence event and are associated with an increased risk of dying from breast cancer within 5 years." | ( Doughty, JC, 2008) |
| "Bone metastases are a major cause of morbidity in cancer patients." | ( Amadori, D; Barbanti, F; Giorgio-Marrano, G; Ibrahim, T; Mercatali, L; Ronconi, S; Vicini, C, 2008) |
| "Tumor metastasis is responsible for most cancer deaths, and can occur after long periods of tumor dormancy." | ( Chambers, AF, 2009) |
| "Tumor metastasis is affected by the host immune surveillance system." | ( Asai, T; Kinouchi Shimizu, N; Oku, N; Shimizu, K; Tsukada, H, 2008) |
| "Distant metastasis is a well-recognized predictor of breast cancer-associated mortality, and AIs have shown greater efficacy over tamoxifen in reducing distant metastatic events and improving distant DFS (DDFS)." | ( Tang, SC, 2008) |
| "Tongue cancer metastasis is mainly through blood stream and possibly associated with tumor cell-induced platelet aggregation (TCIPA)." | ( Chan, CP; Chang, MC; Hahn, LJ; Ho, YS; Huang, YL; Jeng, JH; Lee, JJ; Lin, BR; Lin, PS; Wang, YJ; Yeh, HW, 2009) |
| "Tumor cell metastasis is a complex, multi-step process that is a major cause of death and morbidity amongst cancer patients." | ( Bidwell, GL; Credit, K; Davis, A; Flessner, M; Massodi, I; Raucher, D; Tausend, A, 2009) |
| "Tumor metastasis is the primary cause of death of cancer patients." | ( Huang, XY; Yang, S; Zhang, JJ, 2009) |
| "E(2)-induced metastasis is associated with activation of p42/44 MAPK and is completely inhibited by treatment with the MEK1/2 inhibitor, CI-1040." | ( Ariazi, EA; Astrinidis, A; Henske, EP; Hensley, H; Hernandez-Cuebas, L; Jordan, VC; Karbowniczek, M; Morrison, TA; Nicolas, E; Robb, VA; Seeholzer, LF; Walker, CL; Wang, C; Yu, JJ, 2009) |
| "Bone metastasis is the major cause of mortality associated with prostate cancer." | ( Chang, C; Chuang, YC; Hsieh, CY; Huang, HY; Huang, KE; Kang, HY; Li, CF; Shyr, CR; Tsai, MY, 2009) |
| "Metastasis is a highly regulated, multistep process in which cancerous cells shed from the primary tumor and enter the circulatory system, where they interact extensively with host cells before they lodge and colonize the target organ." | ( Konstantopoulos, K; Thomas, SN, 2009) |
| "Metastasis is the leading cause of death from breast cancer." | ( Altenburg, JD; Siddiqui, RA, 2009) |
| "Metastasis is associated with the loss of epithelial features and the acquisition of mesenchymal characteristics and invasive properties by tumor cells, a process known as epithelial to mesenchymal transition (EMT)." | ( Baritaki, S; Bonavida, B; Chapman, A; Palladino, M; Spandidos, DA; Yeung, K, 2009) |
| "Bone metastases are a common cause of skeletal morbidity in patients with advanced cancer." | ( Coleman, RE; Cook, RJ; Lipton, A; Major, PP; Smith, MR; Terpos, E, 2009) |
| "In vivo metastasis is lost immediately after irradiation and regained to a low extent beyond two weeks time for recurrence of cells before injection." | ( Mosch, B; Mueller, K; Pietzsch, J; Steinbach, J, 2009) |
| "Bone metastases are common but underdiagnosed in patients with NSCLC." | ( Hirsh, V; Langer, C, 2010) |
| "Metastasis is the main cause of mortality in NB patients." | ( Dong, K; Liu, J; Wang, Y; Xiao, X; Zheng, J; Zheng, S; Zhu, H, 2010) |
| "Tumor-to-tumor metastasis is a very rare event." | ( Bonneau, C; Duprez, R; Kerdraon, R; Metois, D; Michenet, P; Thimon, S, 2009) |
| "Prevention of metastasis is an important aspect of successful treatment; however, it is known that metastasis can be induced by different treatment modalities." | ( Cemazar, M; Flisar, K; Glavac, D; Mlakar, V; Sersa, G; Todorovic, V, 2011) |
| "Bone metastases are highly frequent complications of breast cancers." | ( Aoki, J; Bendriss-Vermare, N; Bollen, M; Clézardin, P; David, M; Descotes, F; Deux, B; Grès, S; Jansen, S; Peyruchaud, O; Ribeiro, J; Saez, S; Saulnier-Blache, JS; Serre, CM; Wannecq, E, 2010) |
| "Cell expansion and metastasis are considered hallmarks of tumour progression." | ( Danker, K; Reutter, W; Semini, G, 2010) |
| "Tumour metastasis is the primary cause of death of cancer patients." | ( Chen, L; Huang, XY; Jakoncic, J; Yang, S; Zhang, JJ, 2010) |
| "Although metastasis is unequivocally the most lethal aspect of breast cancer and the most prominent feature associated with disease recurrence, the molecular mechanisms whereby EMT mediates the initiation and resolution of breast cancer metastasis remains poorly understood." | ( Parvani, JG; Schiemann, WP; Taylor, MA, 2010) |
| "Ovarian cancer metastasis is characterized by the shedding of malignant cells from the surface of the ovary and their implantation onto the peritoneal surface, which lines the abdominal cavity." | ( Hoffmann, P; Lokman, NA; Oehler, MK; Ricciardelli, C; Rodgers, RJ; Ween, MP, 2011) |
| "Bone metastasis is a serious complication of patients with tumor, and most primary tumors can metastasize to bone." | ( Chen, WS; Wu, YP; Xu, SJ; Zhang, N, 2010) |
| "Tumor metastasis is very complex and this process requires a tumor cell to acquire enhanced motility, invasiveness and anoikis resistance to successfully establish a tumor at a distal site." | ( Islam, M; Kumar, P; Merajver, SD; Pan, Q; Patel, SN; Teknos, TN; Yadav, A, 2010) |
| "The development of metastases is the main reason for cancer-related death in non-small cell lung cancer (NSCLC)." | ( Allgayer, H; Ceppi, P; Kumarswamy, R; Mudduluru, G; Papotti, M; Rapa, I; Scagliotti, GV, 2010) |
| "Cancer metastasis is a primary cause of cancer death." | ( Amagaya, S; Chang, YS; Hou, WC; Hu, ML; Huang, GJ; Huang, SS; Wang, HC; Yang, CM, 2010) |
| "Metastasis is a leading cause of mortality and morbidity in cancer." | ( Erdoğan, A; Gültekin, M; Gümüşlü, S; Sahin, E; Sahin, M, 2010) |
| "Metastases are often resistant to current extirpative therapies and even the newest biological agents cure only a small subset of patients." | ( Chao, YL; Grahovac, J; Lauffenburger, DA; Wells, A; Wu, Q, 2011) |
| "Metastasis is the rapid proliferation of cancer cells (secondary tumour) at a specific place, generally leading to death." | ( Garzón-Alvarado, DA, 2012) |
| "Colon cancer metastasis is often associated with activation of the Wnt/β-catenin signaling pathway and high expression of the metastasis mediator S100A4." | ( Arlt, F; Fichtner, I; Herrmann, P; Lemm, M; Sack, U; Schlag, PM; Shoemaker, RH; Smith, J; Stein, U; Walther, W, 2011) |
| "Tumor metastasis is a main contributor to death in cancer patients." | ( Buchanan, C; Lago Huvelle, MA; Peters, MG, 2011) |
| "Cancer metastasis is the major cause of cancer-related death, and chemoprevention is defined as the use of natural or synthetic substances to prevent cancer formation or cancer progress." | ( Weng, CJ; Yen, GC, 2012) |
| "Tumor growth and metastasis are determined by the complex interplay of factors, including those intrinsic to tumor cells and extrinsic factors associated with the tumor microenvironment." | ( Baker, JH; Freeman, S; Gold, MJ; Gold, MR; Maltby, S; McNagny, KM; Minchinton, AI; Roskelley, CD, 2011) |
| "Potential metastasis is more likely if the tumor size larger than 4 cm." | ( Hong, K; Liao, HY; Lu, J; Ma, LL; Xiao, B; Xiao, CL; Zhang, SD, 2011) |
| "Tumorigenesis and metastasis are associated with metabolic reprogramming, including enhanced glycolysis and glutaminolysis." | ( Dafni, H; Ronen, SM, 2010) |
| "These bone metastases are often accompanied by bone destruction, bone fractures, pain, and hypercalcemia." | ( Buijs, JT; Guise, TA; Juárez, P, 2011) |
| "Tumor metastasis is one of the main causes of death for patients with malignant tumors." | ( Lee, J; Lim, KT, 2011) |
| "Metastasis is a major cause of death in cancer patients." | ( Ahn, YH; Chung, HJ; Hong, JY; Kang, YJ; Lee, SK; Min, HY; Park, EJ; Park, HJ; Pyee, JH; Shin, Y, 2012) |
| "Metastasis is one of the major causes of cancer-associated mortality." | ( Lee, J; Lim, KT, 2012) |
| "Liver metastasis is associated with a proinflammatory microenvironment and up-regulation of cell adhesion molecules expressed by endothelial cells." | ( Bischofs, E; Brodt, P; Bruckner, T; Eichbaum, C; Eichbaum, MH; Meyer, AS; Sohn, C; Steinborn, A; Wang, N, 2011) |
| "Cancer metastasis is a primary cause of cancer death." | ( Chang, LS; Hsieh, CY; Lin, KL; Lin, SR; Tsai, PC, 2011) |
| "Metastasis is a property of malignant cancer cells that requires integrins which with their downstream molecules participate in a number of signaling events in cells with pivotal roles in malignancy, migration and invasion of tumor cells." | ( Azadmanesh, K; Dastpeyman, M; Jahanian-Najafabadi, A; Kia, V; Mostafavi, E; Motamed, N; Shokrgozar, MA, 2012) |
| "Metastasis is a critical event in the progression of head and neck squamous cell carcinoma (HNSCC) and closely correlates with clinical outcome." | ( Kang, JH; Kim, ES; Kyu Woo, J; Lee, HY; Lee, OH; Oh, SH, 2012) |
| "Metastasis is a complex, multistep process that begins with the epithelial-mesenchymal transition (EMT)." | ( Bischoff, FZ; Bottsford-Miller, J; Celestino, J; Deavers, MT; Ellis, LM; Eng, C; Goodman, BW; Jaladurgam, P; Lin, YG; Mayer, JA; Merritt, WM; Mikolajczyk, SD; Nick, AM; Pecot, CV; Pham, T; Pircher, TJ; Roh, JW; Sood, AK; Stone, RL; Wong, KL, 2011) |
| "Bone metastases are associated with an increased risk of skeletal-related events, which can lead to increased morbidity and mortality." | ( Body, JJ, 2012) |
| "Metastasis is the main cause of death for cancer patients." | ( Barbier, M; Clézardin, P; David, M; Descotes, F; Murone, M; Peyruchaud, O; Ribeiro, J; Serre, CM, 2012) |
| "Metastasis is the major cause of morbidity and mortality from breast cancer." | ( Chen, L; Guo, H; Lai, L; Li, H; Liu, Z; Wu, J; Ying, G; Zhang, N, 2012) |
| "Metastasis is seen in 26% of adults and usually involves the liver and then the lymph nodes." | ( Balasundaram, C; Chavalitdhamrong, D; Chow, J; Endres, PJ; Khan, H; Luthra, M, 2012) |
| "Such widespread metastasis is unusual given the small size of the primary tumor." | ( Balasundaram, C; Chavalitdhamrong, D; Chow, J; Endres, PJ; Khan, H; Luthra, M, 2012) |
| "Distant metastasis is the major cause of treatment failure." | ( Bao, YN; Chen, S; Chen, ZY; Kang, TB; Li, XJ; Lu, WH; Peng, LX; Qian, CN; Shao, JY; Teh, BT; Xiang, YQ; Zeng, MS; Zeng, YX; Zhang, JX; Zheng, FJ, 2012) |
| "Nevertheless, metastasis is a complex process and a single-level analysis is not likely to identify its key biological determinants." | ( Flores, RJ; Lau, CC; Lau, SS; Li, Y; Man, TK; Rao, PH; Shen, J; Vannucci, M; Yu, A, 2012) |
| "Because metastasis is the major cause of cancer mortality, we measured cell migration activity and profiled metastasis-related gene expressions in HDACi-treated cancer cells." | ( Chen, CT; Ho, CM; Jou, YS; Lin, KT; Su, WH; Wang, YW, 2012) |
| "Tumor metastasis is responsible for 90% of cancer-associated deaths and highly metastatic cancers are more prone to form metastasis foci and acquire the drug resistance." | ( Cui, J; Dai, W; Lu, J; Wang, J; Wang, X; Wang, Z; Wu, H; Yu, Y; Yuan, L; Zhang, H; Zhang, Q; Zhang, X, 2012) |
| "Breast cancer metastasis is more resistant to chemotherapy and radiotherapy than is cancer of the visceral tissues; therefore, new treatment strategies are urgently needed." | ( Chang, LH; Chang, YL; Chen, CC; Pai, HC; Pan, SL; Peng, CY; Shen, CC; Teng, CM, 2013) |
| "Metastasis is a major cause of death from malignant diseases, and the underlying mechanisms are still largely not known." | ( Chen, H; Du, Z; Han, X; Jia, H; Lin, H; Lu, Y; Tan, X; Wang, Y; Xu, Y; Yu, X; Zhang, J; Zhao, S, 2012) |
| "Peritoneal metastasis is treated more effectively by this regimen than other forms of metastases." | ( Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y, 2013) |
| "Metastasis is a characteristic property of cancer cells, which degrade extracellular matrix containing collagen." | ( Fukuhara, A; Harada, A; Inui, T; Kojima, C; Kono, K; Magata, Y; Nishisaka, E; Ogawa, M; Suehiro, T; Watanabe, K, 2013) |
| "Metastases are the primary cause of human cancer deaths." | ( Byun, S; Heo, YS; Jung, SK; Kang, MJ; Kim, HY; Lee, HJ; Lee, J; Lee, KW; Oh, MH; Son, JE, 2013) |
| "If osseous metastases are detected, a bone scan can detect additional osseous lesions and BMBx may indicate prognostic bone marrow metastases." | ( Hawkins, DS; Jones, RL; Newman, EN, 2013) |
| "Brain metastasis is an increasingly common complication for breast cancer patients; approximately 15- 30% of breast cancer patients develop brain metastasis." | ( Erzinger, SA; Kato, Y; Kiriakova, GM; Liu, H; Palmieri, D; Price, JE; Qian, Y; Steeg, PS, 2012) |
| "Tumor growth and metastasis are associated with angiogenesis and lymphangiogenesis through the production of vascular endothelial growth factor (VEGF) or VEGF-C in tumors, and the phosphorylation of VEGF receptor (VEGFR)-2 or VEGFR-3 in vascular endothelial cells or lymphatic endothelial cells (LECs)." | ( Kimura, Y; Sumiyoshi, M, 2013) |
| "Most commonly these metastases are to the lungs, lymph nodes, neck, skull, scalp, liver, and bones; may be evident on routine follow-up images of the original lesion." | ( Faridi, N; Haroon, S; Mujtaba, SS, 2013) |
| "Early prediction of metastasis is currently impossible due to the lack of specific molecular probes to recognize metastatic HCC cells." | ( Fang, M; Li, Y; Liu, SP; Peng, CW; Rong, Y; Wang, FB; Yuan, JP, 2013) |
| "Hepatic metastasis is responsible for the majority of colorectal cancer (CRC)-related mortalities." | ( Bai, Z; Gong, W; Gu, W; Jian, Z; Li, W; Liang, B; Lin, JE; Tai, Y; Wang, C; Wang, Q; Zhao, Q; Zhen, C; Zhou, T, 2013) |
| "Metastasis is inscribed within the properties of the primitive tumour, as shown by the comparative molecular analysis of the primitive tumour and its own metastases: their similarity is always more important than what could be expected from the general activation of "metastasis genes" or the inhibition of "metastasis suppressor genes"." | ( Robert, J, 2013) |
| "Metastasis is one of the greatest challenges in cancer treatment." | ( Chen, C; Duan, X; Li, Y; Miao, Z; Wang, J; Xiao, J; Yin, Q; Yu, H; Zhang, Z, 2013) |
| "Cancer metastasis is a major cause for cancer-related death and inhibiting cancer metastasis is an alternative way to treat cancer." | ( Hu, X; Liu, Z; Zhang, B, 2013) |
| "Aggressive metastasis is the chief cause of the high morbidity and mortality associated with pancreatic cancer, yet the basis for its aggressive behavior remains elusive." | ( Choi, A; Gerner, EW; Shen, A; Shi, J; Wen, F, 2013) |
| "Tumor metastasis is the main cause of lethality of prostate cancer, because conventional therapies like surgery and hormone treatment rarely work at this stage." | ( Duan, HQ; Guo, W; Jin, M; Kong, D; Ma, SN; Qiu, Y; Wang, R; Zhao, W; Zhou, Q, 2013) |
| "Breast tumor metastasis is a leading cause of cancer-related deaths worldwide." | ( Adkins, C; Gupta, P; Lockman, P; Srivastava, SK, 2013) |
| "Tumor metastasis is the primary cause of death due to cancer, but the mechanisms by which tumor cells metastasize remain incompletely understood." | ( Kahn, ML; Stanger, BZ, 2013) |
| "Metastasis is one of the most threatening features of the oncogenic process and the main cause of cancer-related mortality." | ( Heo, YS; Hwang, MK; Lee, HJ; Lee, KW; Song, NR, 2013) |
| "Once metastasis is established, mutant TP53 together with adipocyte-derived IL-8 upregulates Fatty acid-binding protein 4 (FABP4) expression and then promotes FAs absorption from adipocytes to support rapid tumor growth in adipocyte-rich metastatic environments." | ( Hu, J; Liu, Z; Wang, X, 2013) |
| "Spine metastases are a common and painful complication of cancer." | ( Campos, TP; Dalmázio, I; Donanzam, BA; Valente, ES, 2013) |
| "Metastasis is a complex multistep process that involves the impairment of cell-cell adhesion in the neoplastic epithelium, invasion into adjacent tissues and the dissemination of cancer cells through the lymphatic and haematogenous routes." | ( Ji, K; Jiang, WG; Mason, MD; Ye, L, 2013) |
| "Metastasis is an extremely complex process that is a major problem in the management of cancer." | ( Guruvayoorappan, C; Shathish, K, 2014) |
| "Cancer metastasis is one of the most critical events in cancer patients, and the median overall survival of stage IIIb or IV patients with metastatic lung cancer in the TNM classification is only 8 or 5 months, respectively." | ( Hayakawa, Y; Kaneto, N; Kato, S; Kin, R; Li, F; Saiki, I; Sakurai, H; Tanaka, K; Yokoyama, S, 2013) |
| "Bone metastases are responsible for most of the morbidity associated with metastatic castration-resistant prostate cancer (mCRPC)." | ( Boni, G; Borsò, E; Cianci, C; Federici, F; Francesca, F; Lorenzoni, A; Mariani, G; Mazzarri, S; Orlandini, C; Pastina, I; Ricci, S; Rubello, D; Selli, C, 2014) |
| "Brain metastases are frequently treated with radiation." | ( Allen-Auerbach, M; Chen, W; Czernin, J; DeSalles, AA; Lizarraga, KJ; Phelps, ME; Yong, WH, 2014) |
| "Tumor metastasis is the major cause of treatment failure and poor prognosis of glioma." | ( Cui, G; Lv, L; Wang, Q; Xin, X; Yan, T; Yang, P; Zhang, L; Zhang, N; Zhang, X; Zhang, Y; Zhao, M; Zhu, Y, 2013) |
| "Metastasis is responsible for more than 90% of the mortality observed among patients with breast cancer." | ( Cao, X; Fan, L; Huang, F; Jiang, Y; Li, H; Li, J; Pan, H; Sun, J; Wang, Q; Wang, X, 2014) |
| "Brain metastases are frequent in patients with metastatic melanoma, indicating poor prognosis." | ( Dummer, R; Eggmann, NB; Felderer, L; Goldinger, SM; Hilfiker, PR; Michielin, O; Mitchell, L; Rinderknecht, JD; Turtschi, CP; Veronese, L, 2014) |
| "Skip N2 metastasis is common in patients with c-stage IA NSCLC with high serum SLX, and lobectomy with complete dissection of hilar and mediastinal lymph nodes should remain the standard surgical procedure for these cases." | ( Chung, K; Hanada, S; Inoue, H; Izumi, N; Komatsu, H; Mizuguchi, S; Nishiyama, N; Suehiro, S, 2013) |
| "Cancer cell metastasis is a major cause of cancer death." | ( Han, H; Jiang, J; Li, X; Peng, B; Qian, X; Wang, J; Ying, W; Zhao, X; Zhao, Y; Zhong, R, 2013) |
| "Skeletal metastasis is common in patients with malignancy, but very few patients have acrometastasis, that is, metastasis to the hand or foot." | ( Koizumi, M; Koyama, M, 2014) |
| "Tumour metastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy." | ( Baier, G; Choidas, A; Cronin, SJ; Eickhoff, J; Fededa, JP; Gruber, T; Hinterleitner, R; Ikeda, F; Jamieson, AM; Klebl, BM; Langdon, WY; Loeser, S; Menninger, S; Nitsch, R; Paolino, M; Penninger, JM; Pranjic, B; Schultz-Fademrecht, C; Torka, R; Ullrich, A; Unger, A; Uribesalgo, I; Wallner, S; Wolf, D, 2014) |
| "Melanoma metastasis is a devastating outcome lacking an effective preventative therapeutic." | ( Buss, CG; Merghoub, T; Pencheva, N; Posada, J; Tavazoie, SF, 2014) |
| "The metastasis is one of the greatest challenges for successful cancer therapy." | ( Bao, X; Chen, J; He, X; Li, Y; Niu, B; Yu, H; Zhang, Z; Zhu, J, 2014) |
| "Lymph node metastasis is an important prognostic factor in prostate cancer (PC)." | ( Aillet, G; Campion, L; Kraeber-Bodéré, F; Lacombe, M; Lacoste, J; Le Coguic, G; Mathieu, C; Potiron, E; Rousseau, C; Rousseau, T, 2014) |
| "Bone metastases are a very common problem in prostate cancer." | ( Bajory, Z; Bouzid, M; Cathomas, R; El Ghoneimy, A; Gillessen, S; Goncalves, F; Kacso, G; Kramer, G; Lesniewski-Kmak, K; Milecki, P; Pacik, D; Tantawy, W, 2014) |
| "Cutaneous metastases are more rare than visceral metastases and usually develop later; therefore, cutaneous metastases as initial distant metastases can be easily overlooked." | ( Ni, SM; Wang, SM; Ye, M, 2014) |
| "Metastasis is one of the most important factors related to prostate cancer therapeutic efficacy." | ( Cao, X; Chen, F; Chen, Y; Liu, J; Lv, X; Zheng, L; Zhou, Z, 2014) |
| "Colorectal cancer metastasis is a major cause of mortality worldwide, which may only be controlled with novel methods limiting tumor dissemination and chemoresistance." | ( Chung, MC; Lim, TK; Tan, HT; Tan, XF; Wu, W, 2014) |
| "Cancer metastasis is the spread and growth of tumor cells from the original neoplasm to further organs." | ( Cheng, H; Mollica, M; Re, AT; Wang, L; Wu, S; Zuo, L, 2014) |
| "Bone metastases are often associated with severe morbidity, pain and functional impairment." | ( Froehner, M; Hakenberg, OW; Hölscher, T; Wirth, MP, 2014) |
| "Tumor metastasis is the major obstacle for cancer treatment." | ( Chen, C; Cheng, JK; Chung, CH; Lai, YW; Liu, SC; Peng, CY; Sun, HL; Tang, CH; Wang, PC; Wang, SW; Wu, NL, 2014) |
| "Since metastasis is the major cause of PDA-related death, we therefore investigate the anti-metastasis effect of MART-10 on PDA." | ( Chen, LW; Chen, TC; Chen, WT; Chiang, KC; Hsu, JT; Jan, YY; Juang, HH; Kittaka, A; Kuo, SF; Pang, JH; Takano, M; Yeh, CN; Yeh, TS, 2014) |
| "Tumor metastasis is a prominent cause of treatment failure in cervical carcinoma." | ( Bao, L; Chen, Y; Fu, X; Hao, Q; Liu, W; Wu, H; Zhang, L, 2014) |
| "Metastasis is the most common cause of cancer-related death in patients, and epithelial-to-mesenchymal transition (EMT) is essential for cancer metastasis, which is a multistep complicated process that includes local invasion, intravasation, extravasation, and proliferation at distant sites." | ( Chen, KS; Chen, PN; Chu, SC; Hsu, LS; Su, MY; Yu, CC, 2014) |
| "Cancer metastasis is one of the major causes of death in cancer." | ( Chen, YJ; Liao, MH; Lin, JJ; Su, JH; Tsai, CC; Wu, YJ, 2014) |
| "Metastases are known to be responsible for approximately 90% of breast cancer-related deaths." | ( Abe, S; Aramaki, H; Ikeda, E; Okazaki, H; Takeda, S; Watanabe, K; Yoshioka, Y, 2014) |
| "Metastasis is the main cause of mortality of patients with cancer-related disease." | ( Fan, L; Li, Y; Mei, Q; Meng, J; Sun, Y; Yue, Z; Zhang, D; Zhang, F; Zhang, R; Zhang, X, 2015) |
| "Cancer metastasis is the most dangerous stage of tumorigenesis and evolution, the primary cause of death in cancer patients." | ( Chen, H; Gong, JN; Qu, JL, 2014) |
| "Tumor growth and metastasis are closely associated with the M2 macrophage activation of tumor-associated macrophages (TAMs) in the tumor microenvironment as well as the development of tumor cells." | ( Kimura, Y; Sumiyoshi, M, 2015) |
| "Invasion and metastasis are the major causes of treatment failure in patients with cancer." | ( Chang, CC; Huang, CH; Jayakumar, T; Lu, SH; Sheu, JR; Thomas, PA, 2015) |
| "Metastasis is the main cause of cancer treatment failure and death." | ( Gao, H; He, Q; Liu, Y; Mei, L; Zhang, Q; Zhang, Z, 2014) |
| "Tumor growth and metastasis are not determined by cancer cells alone but also by a variety of stromal cells, and platelet-derived growth factor receptors (PDGF-Rs) are overexpressed by various stromal cell populations." | ( Chayama, K; Kitadai, Y; Onoyama, M; Shinagawa, K; Tanaka, S; Yasui, W; Yuge, R, 2015) |
| "Metastasis is the leading cause of death in lung cancer." | ( Cui, Z; Li, C; Song, G; Wang, E; Zhang, S, 2015) |
| "Bone metastasis is a frequent and fatal complication of cancer that lacks effective clinical treatment." | ( Cai, X; Cheng, Y; Ge, H; Huang, Q; Wang, C; Wang, X; Wang, Y; Xiao, J; Yan, W; Zhang, J; Zhang, Q, 2015) |
| "Bone metastasis is one of the leading causes of death in breast cancer patients." | ( Baatrup, A; Bünger, CE; Chen, M; Dagnaes-Hansen, F; Horsman, MR; Kjems, J; Le, DQ; Sun, M; Wang, M, 2015) |
| "Tumor metastasis is the principle obstacle to the development of efficient treatments for patients with HB." | ( Chen, F; Cui, P; Fu, X; Gong, L; Jiang, L; Xiao, Y; Xu, J; Zhang, D, 2015) |
| "Metastasis is the leading cause of deaths in patients with breast cancer." | ( Dai, C; Guo, J; Ji, W; Song, L; Xu, Y; Zhan, L, 2015) |
| "The outcome of metastasis is determined by the interplay between the specific subpopulation of metastatic cells and host homeostatic factors in specific microenvironments." | ( Bergamo, A; Sava, G, 2015) |
| "Brain metastasis is a major cause of morbidity and mortality in patients with breast cancer." | ( Aldape, KD; Chou, PC; Conrad, CA; Huang, S; Lee, HT; Patterson, C; Priebe, W; Sawaya, R; Xie, K; Xue, J; Yang, P; Zhou, A, 2015) |
| "Tumor metastasis is the main cause of cancer-related patient death." | ( Lao, Y; Li, X; Sun, M; Tan, H; Wang, H; Wang, X; Wu, M; Xi, Z; Xu, H; Xu, N, 2015) |
| "Metastasis is responsible for most cancer-related deaths, and, among common tumor types, melanoma is one with great potential to metastasize." | ( Berrocal, A; Botella-Estrada, R; Carmona, FJ; Elez, E; Esteller, M; Fernandez-Figueras, MT; Ferreira, HJ; Flaherty, KT; Frederick, DT; Gallagher, WM; Girotti, MR; Guil, S; Heyn, H; Liz, J; Lopez-Serra, P; Lorigan, P; Manzano, JL; Marais, R; Martínez-Cardús, A; Martinez-Iniesta, M; McDermott, U; Moran, S; Moutinho, C; Muñoz-Couselo, E; Oord, Jv; Pontén, F; Portela, A; Vidal, A; Villanueva, A; Vizoso, M, 2015) |
| "Metastasis is the major cause of death in cancer patients." | ( Allison, SE; Mackenzie, PI; Murray, M; Petrovic, N, 2015) |
| "Metastasis is the leading cause of mortality in malignant diseases." | ( Bendas, G; Dreckmann, T; Haasis, S; Jantscheff, P; Massing, U; Raynor, A; Ross, T; Schlesinger, M; Wilde, M, 2015) |
| "Invasion and metastasis are responsible for 90% of cancer-related mortality." | ( Bracke, ME; De Ryck, T; Katritzky, AR; Patronov, A; Roman, BI; Slavov, SH; Stevens, CV; Vanhoecke, BW, 2015) |
| "Invasion and metastasis are controlled by the invadopodia, which delivers matrix-degrading enzymes to the invasion interface permitting cancer cell penetration and spread into healthy tissue." | ( Ingley, E; Kendrick, TS; Kucera, N; Le, C; Louw, A; McCarthy, DJ; Phillips, M; Satiaputra, J; Tie, SR, 2016) |
| "Immune escape and metastasis are the hallmarks of several types of cancer including bladder cancer." | ( Brito, RB; Dellê, H; Ferreira, JM; França, CM; Malta, CS; Matheus, LH; Matos, YS; Nunes, VS; Silva, CS; Souza, DM, 2015) |
| "Since metastasis is the important cause of ATC-related death, our results strongly encourage the further in vivo study of MART-10 application against ATC." | ( Chen, CH; Chen, LW; Chen, TC; Chiang, KC; Juang, HH; Kittaka, A; Kuo, SF; Lin, JD; Lin, SF; Ng, S; Pang, JH; Takano, M; Yeh, CN, 2015) |
| "Metastasis is the main cause of cancer-related deaths and remains the most significant challenge to management of the disease." | ( Caterino, TD; Ditzel, HJ; Jensen, ON; Leth-Larsen, R; Lund, RR; Lænkholm, AV; Nissen, J; Terp, MG, 2015) |
| "Metastasis is one of the most important factors involved in patients with melanoma." | ( Kang, YJ; Lee, SG; Nam, JO, 2015) |
| "Melanoma cell metastasis is the primary cause of patient death." | ( Chen, PN; Chu, SC; Hsieh, YH; Hsieh, YS; Hung, CH; Yang, SF; Yang, SH, 2015) |
| "Tumorigenesis and metastasis are frequently associated with altered structure and expression of oligosaccharides on cell surface glycoproteins and glycolipids." | ( Begum, R; Patel, KR; Patel, PS; Vajaria, BN, 2016) |
| "Cancer metastasis is the main cause for the high mortality in breast cancer patients." | ( Bao, X; Cao, H; He, X; Li, Y; Yin, Q; Yu, H; Zhang, Z, 2016) |
| "Metastasis is the main cause of mortality in cancer patients." | ( Choi, SI; Kim, EK; Lee, B; Lee, R; Maeng, YS, 2016) |
| "Early metastasis is still the most recalcitrant factor in the treatment of lung cancer patients." | ( Gan, T; Peng, S; Wang, Y; Wu, J; Yang, J; Zhao, M, 2016) |
| "Metastasis is still a severe challenge in osteosarcoma treatment." | ( Lin, HQ; Mao, JP; Ren, HY; Wang, SD; Xie, T; Ye, ZM; Zhu, T, 2016) |
| "Metastasis is a critical factor contributing to poor prognosis in cancer, but the underlying mechanisms of metastasis are still poorly understood." | ( Fujiwara, N; Imoto, S; Inazawa, J; Kawano, T; Kozaki, KI; Miyano, S; Morishita, M; Muramatsu, T; Tsuda, H; Yamaguchi, R, 2016) |
| "Bone metastasis is a major cause of prostate cancer (PCa) morbidity and mortality." | ( Chen, Z; Gera, L; Kucuk, O; Li, X; Mamouni, K; Wu, D; Zhang, S, 2016) |
| "Distant metastasis is the early event during the progression in rectal cancer." | ( Chi, P; Huang, S; Huang, Y; Lin, H; Lu, X; Sun, Y; Wang, X; Xu, Z; Ye, D, 2016) |
| "Relapse and metastasis are two key risk factors of hepatocellular carcinoma (HCC) prognosis; thus, it is emergent to develop an early and accurate detection method for prognostic evaluation of HCC after surgery." | ( Chen, H; Guan, Q; Tu, JC; Wang, FB; Yang, YF; Yin, CQ; Yuan, CH, 2016) |
| "The pattern of metastases is likely regulated through interactions between chemokine receptors and chemokines, and perturbations in these signaling cascades responsible for cytoskeletal organization and directional migration have the potential to alter metastatic cell trafficking behaviors." | ( Byrum, ML; Fan, TM; Fredrickson, RL; Pondenis, HC; Wycislo, KL, 2016) |
| "Metastasis is the major cause of cancer-associated death in humans, and its early diagnosis will help clinicians to develop suitable therapeutic strategies which may save life of cancer patients." | ( Chandra, P; Noh, HB; Pallela, R; Shim, YB, 2016) |
| "Metastasis is the leading lethal factor severely restraining the effectiveness of clinical treatment." | ( Chen, X; Chen, Y; Guo, Y; Kan, X; Li, Q; Li, Y; Liu, X; Wang, X; Wang, Y; Wang, Z; Weng, X; Xiao, H; Yang, Q; Zhang, G; Zhou, B; Zhu, X, 2016) |
| "Metastasis is the leading cause of cancer-related death in humans." | ( Albarrán-Juárez, J; Han, K; Müller, UC; Offermanns, S; Pasparakis, M; Strilic, B; Wachsmuth, L; Yang, L, 2016) |
| "Metastasis is the reason for most cancer death, and a crucial primary step for cancer metastasis is invasion of the surrounding tissue, which may be initiated by some rare tumor cells that escape the heterogeneous primary tumor." | ( Chen, X; Deng, Q; Feng, J; Guo, C; Huang, H; Ma, S; Shen, B; Wu, K; Wu, Z; Xia, B; Zhang, J; Zhang, K; Zhang, S; Zhu, L, 2016) |
| "Cancer metastasis is a multistep process associated with the induction of an epithelial-mesenchymal transition (EMT) and cancer stem cells (CSCs)." | ( Cackowski, FC; Decker, AM; Franceschi, RT; Jung, Y; Lee, E; Li, Y; Pienta, KJ; Taichman, RS; Wang, J; Yumoto, K, 2016) |
| "Tumor metastasis is a major cause leading to the deaths of cancer patients." | ( Duan, J; Fan, S; Li, X; Li, Y; Pan, X; Pan, Y; Shi, Y; Tie, L; Wang, X; Xiaokaiti, Y, 2016) |
| "Bone metastasis is a deadly consequence of cancers, in which osteoclast forms a vicious cycle with tumor cells." | ( Cheng, WY; Gallegos, ZR; Jin, Z; Krzeszinski, JY; Saghatelian, A; Schwaid, AG; Wan, Y, 2017) |
| "Metastasis is the leading cause of death for cancer patients." | ( Adams, DJ; Arends, MJ; Bald, T; Cambridge, EL; Campbell, AD; Clare, S; Galli, A; Gleeson, D; Griggs, N; Karp, NA; Macaulay, IC; Ryder, E; Sansom, OJ; Speak, AO; Spiegel, S; Tuck, E; Tüting, T; van der Weyden, L; Velasco-Herrera, MD; Voet, T; Wardle-Jones, H; Wong, K, 2017) |
| "Tumor metastasis is a complex process in which cells detach from the primary tumor and colonize a distant organ." | ( Giralt, E; Lo Re, D, 2017) |
| "Metastasis is the main cause of death in breast cancer patients." | ( Anissian, A; Enderami, SE; Fattahi, M; Hassannia, H; Hosseini, F; Jadidi-Niaragh, F; Kokhaei, P; Mahdian-Shakib, A; Mirshafiey, A, 2017) |
| "Metastasis is the principal event leading to breast cancer death." | ( Deng, H; Dong, A; Li, Y; Qin, Z; Song, K; Wang, F; Zhang, J; Zhao, X, 2017) |
| "Metastasis is the main cause of these deaths." | ( Bruzzone, A; Entschladen, F; Gargiulo, L; Lüthy, IA; Piñero, CP; Rivero, EM; Zänker, K, 2017) |
| "Metastasis is the main problem in successful treatment of many types of cancer such as melanoma." | ( Akbari, V; Nurani, M; Taheri, A, 2017) |
| "Metastasis is the key phase of cancer progression that characterizes a more advanced stage and a poorer prognosis." | ( Chen, H; Fan, L; Jia, L; Jiang, K; Liu, J; Shao, J; Shen, Z; Zheng, G, 2017) |
| "Metastases are discovered in 3-36% of patients at the time of diagnosis." | ( Bullova, P; Caisova, V; Gupta, G; Pacak, K; Pang, Y; Schovanek, J; Semenza, GL; Wang, H; Wolf, KI; Yang, C; Zhuang, Z, 2017) |
| "Metastasis is the main cause of death of PCa patients, yet the molecular mechanisms of this process are poorly understood." | ( Chen, Y; Duan, X; Liao, Z; Liu, C; Liu, W; Liu, Z; Pan, X; Tao, Z; Wang, X; Wang, Y; Yao, H; Yin, B; Yu, P; Zhang, Y, 2017) |
| "Tumor metastasis is the leading cause of death in cancer patients, and epithelial-mesenchymal transition (EMT) is an essential step in tumor metastasis." | ( Cheng, SX; Fan, JX; Hong, S; Li, C; Rong, L; Xu, ZS; Zhang, XZ; Zheng, DW; Zhu, JY, 2017) |
| "Metastasis is responsible for most cancer-related deaths, but the current clinical treatments are not effective." | ( Ali, MRK; Chen, K; El-Sayed, MA; Fang, N; Han, T; Tang, Y; Wu, R; Wu, Y; Xiao, H, 2017) |
| "Research on metastasis is gaining momentum for effective cancer management." | ( Kumar Sahoo, S; Parhi, P; Suklabaidya, S, 2017) |
| "Metastasis is the main cause of cancer-related death and requires the development of effective treatments with reduced toxicity and effective anticancer activity." | ( Cordova, CAS; Creczynski-Pasa, TB; Jasper, R; Locatelli, C; Mascarello, A; Nunes, RJ; Silva, AH; Winter, E; Yunes, RA; Zanetti-Ramos, BG, 2017) |
| "Choroidal metastasis is rare in cancer patients and it may cause visual disturbances that reduce their quality of life." | ( Ariyasu, R; Funazo, T; Hwang, MH; Ikegami, N; Konishi, C; Morita, K; Nakagawa, K; Nakao, S; Nishizaka, Y; Taki, M; Wakayama, T; Yoshimura, C, 2017) |
| "Invasion and metastasis are the primary causes of mortality from hepatocellular carcinoma (HCC)." | ( Duan, J; He, Y; Huang, X; Li, M; Liao, W; Lu, C; Yang, Y; Zhang, J; Zhong, C; Zhu, R, 2017) |
| "Distant metastasis is strongly associated with poor prognosis of breast cancer." | ( He, Y; Huang, Y; Liu, C; Peng, L; Wu, K; Zheng, S, 2017) |
| "Tumor metastasis is an important factor of poor prognosis in patients with HCC." | ( Feng, B; Li, C; Su, Z; Sun, C; Tang, L; Zheng, G; Zhu, Y, 2018) |
| "Metastasis is the major hindrance in the treatment of all cancers, including laryngeal squamous cell carcinoma." | ( Balasubramanian, S; Hoda, M; Rajagopalan, R; Shakya, G, 2018) |
| "Peritoneal metastasis is a major cause of recurrence of gastric cancer and integrins are key molecules involved in gastric cancer cells attachment to the peritoneum." | ( Cohen-Jonathan-Moyal, E; Kowalski-Chauvel, A; Seva, C; Teissier, G; Toulas, C, 2018) |
| "Cancer metastasis is a dynamic process during which cancer cells separate from a primary tumor, migrate through the vessel wall into the bloodstream, and extravasate at distant sites to form secondary colonies." | ( McCarty, OJT; Mitrugno, A; Rigg, RA; Shatzel, JJ; Sylman, JL; Tassi Yunga, S; Williams, CD, 2018) |
| "Interestingly, metastasis is a result of stroma-coordinated hallmarks such as invasion and migration of the tumor cells from the primary niche, regrowth of the invading tumor cells in the distant organs, proliferation, vascularization, and immune suppression." | ( Achyut, BR; Angara, K; Arbab, AS; Borin, TF; Rashid, MH, 2017) |
| "Because bone metastases are associated with increased morbidity in patients with RCC, bone-related outcomes were analyzed in METEOR." | ( Appleman, LJ; Arén Frontera, O; Bracarda, S; Castellano, D; Choueiri, TK; Drabkin, H; Escudier, B; Lougheed, JC; Milwee, S; Motzer, RJ; Olencki, T; Oudard, S; Powles, T; Rolland, F; Tomczak, P; Vaena, D; Youkstetter, J, 2018) |
| "Metastasis is one of the major obstacles for successful therapy of breast tumor." | ( Hong, Y; Hu, F; Huang, X; Liu, X; Meng, T; Tan, Y; Yang, X; Yuan, H; Zhao, Y; Zhu, Y, 2018) |
| "Metastasis is a major cause of mortality in cancer." | ( He, Y; Negandhi, AA; Parfrey, PS; Penney, ME; Savas, S; Yilmaz, YE, 2018) |
| "Tumor metastasis is the primary obstacle in cancer treatment and is always the leading cause of human death." | ( Cao, D; Ci, T; Ke, X; Liu, H; Sun, H; Wu, H, 2018) |
| "Metastasis is responsible for the majority of cancer-related deaths and prevention of metastasis remains a big challenge for cancer therapy." | ( Chen, XP; Lu, JJ; Luo, WW; Wang, YT; Zhao, WW, 2018) |
| "Metastasis is the main cause of death in people with cancer." | ( Li, YJ; Yan, XP; Yang, CX, 2018) |
| "Metastasis is the primary cause of death in prostate cancer (PCa) patients." | ( Antognelli, C; Cecchetti, R; Peirce, MJ; Riuzzi, F; Talesa, VN, 2018) |
| "Tumour metastasis is the major cause of breast cancer mortality." | ( Cao, J; Ci, Y; Gao, J; Han, M; Huang, Z; Li, H; Liu, Y; Lu, S; Zhang, J; Zhang, Y; Zhu, X, 2018) |
| "Metastasis is the major cause of cancer-specific death in patients with prostate cancer (PCa)." | ( Gao, X; Li, K; Li, LY; Liu, W; Mao, YH; Pang, J; Xiao, C, 2018) |
| "Tumor metastasis is the leading cause of cancer death; due to the progress made in the elucidation of the mechanism of cancer cell metastasis, there is hope for patients with severe stages of cancer." | ( Chen, T; Dai, D; Han, L; Tao, Z; Wang, H; Wang, L; Wu, L; Yang, Z; Yuan, Z; Zhu, Z, 2018) |
| "Presence of metastasis is not necessary to establish the diagnosis." | ( Ali, U; Kazi, F; Mahmood, H; Tajammul, SS, 2018) |
| "Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy, and palliative therapy." | ( Febbraro, A; Giordano, G; Pedersini, R; Quaquarini, E; Raffaele, M; Rossello, R; Turletti, A; Villa, F, 2018) |
| "Metastasis is commonly seen in advanced stage of cancers, and matrix metalloproteinases (MMPs) are commonly up-regulated and have been identified as critical regulators." | ( Chang, CN; Chang, PC; Chen, JH; Lu, DY; Tsai, CF; Wang, SL; Yeh, WL, 2018) |
| "Metastasis is the major cause of mortality in prostate cancer patients." | ( Astone, M; Beigh, FH; Deng, Y; Ferrari, MG; Ganaie, AA; Hoeppner, LH; Hussain, T; Konety, BR; Koochekpour, S; Maqbool, R; Morrissey, C; Murugan, P; Parray, AS; Saleem, M; Siddique, HR; Umbreen, S, 2018) |
| "Tumor metastasis is a high risk in thyroid cancer." | ( Gong, Y; Li, Z; Liu, F; Liu, Y; Su, A; Wu, W; Zhao, W; Zhou, Q; Zhu, J, 2018) |
| "Peritoneal metastasis is a primary metastatic route for gastric cancers, and the mechanisms underlying this process are still unclear." | ( He, Z; Huang, X; Li, B; Li, Q; Li, Z; Wang, L; Wang, W; Wei, S; Xia, Y; Xu, Z; Yang, L; Zhang, D, 2018) |
| "Metastasis is the main cause of cancer mortality." | ( Chai, CY; Chiang, CM; Chiou, SS; Hsu, SH; Huang, SK; Liu, KY; Wang, LT; Wang, SN; Yokoyama, KK, 2019) |
| "Metastasis is responsible for the great majority of deaths in cancer patients." | ( Hwang, GS; Jeon, Y; Kang, KS; Kim, HY; Kim, YJ; Lee, J; Park, DH; Park, JY; Shin, MS; Yamabe, N, 2018) |
| "Tumor metastasis is the main cause of death in advanced colorectal cancer." | ( Huang, S; Jin, M; Lin, Z; Ma, H; Shen, Q; Wu, G; Zhang, D; Zhang, T; Zhao, L; Zhou, P, 2019) |
| "Metastasis is the leading cause of breast cancer-related deaths." | ( Fu, L; Hou, Y; Liu, M; Qin, Y; Sun, K; Teng, Y; Wen, S; Xi, L; Yang, D; Zhao, M, 2019) |
| "Progression to bone metastases is associated with significant morbidity and high cost." | ( Borno, HT; Small, EJ, 2019) |
| "Metastasis is the process through which the primary cancer cells spread beyond the primary tumor and disseminate to other organs." | ( Di, LJ; Gardner, K; Hao, D; Li, J; Li, P; Meng, Y; Wang, L; Wang, Y; Zhang, C; Zhao, Z; Zhou, H, 2019) |
| "Breast tumor metastasis is a leading cause of cancer-related deaths worldwide." | ( Awasthi, S; Chikara, S; Horne, D; Salgia, R; Singhal, J; Singhal, SS, 2019) |
| "Metastasis is the leading cause of cancer mortality and cancer cell migration is an essential stage of metastasis." | ( Chi, SW; Choi, J; Han, DC; Han, YM; Kang, JS; Kwon, BM; Lee, CW; Lee, S; Lee, SK; Lee, YJ; Moon, JH; Yoon, YJ; Yun, J, 2019) |
| "Metastasis is one of the main causes of mortality in cancer patients." | ( Chao, W; Deng, JS; Huang, GJ; Kuo, YH; Li, PY, 2019) |
| "Metastasis is the major cause of cancer-death." | ( Chen, WR; Doughty, A; Li, X; Li, Y; Nordquist, RE; Wang, L; West, C; Zhou, F, 2019) |
| "Because metastasis is associated with the majority of cancer-related deaths, its prevention is a clinical aspiration." | ( Allen, PD; Armstrong, PC; Cerutti, C; Gil-Bernabé, AM; Gomes, AL; Lucotti, S; Markelc, B; Mitchell, JA; Muschel, RJ; Ridley, AJ; Smart, S; Soyer, M; Warner, TD; Watson, K, 2019) |
| "Metastasis is the major cause of high mortality in cancer patients; thus, blocking the metastatic process is of critical importance for cancer treatments." | ( Chen, J; Chen, L; Chen, Y; Gao, X; Gu, X; Huang, Y; Jiang, T; Liang, K; Liu, S; Lu, H; Ma, F; Pei, Y; Song, Q; Wang, J; Xu, M; Zhou, S, 2019) |
| "Metastasis is the leading cause of tumor-related death from lung cancer." | ( Cheng, W; Hoffman, RM; Jeong, LS; Jia, L; Jiang, Y; Li, L; Liang, Y; Qi, H; Yang, X; Yu, J; Zheng, P; Zhou, L, 2019) |
| "Chemoresistance and metastasis are the main cause of treatment failure." | ( Rongrong, S; Sun, S; Xiaowu, L; Yangmei, Z; Youwei, Z; Yuan, Y, 2019) |
| "Tumor metastasis is the predominant cause of lethality in cancer." | ( Fu, W; Lao, Y; Wang, J; Wu, M; Xu, H; Xu, N; Zhang, J; Zhang, L; Zhao, Z; Zheng, Z, 2019) |
| "Recurrence and metastasis are the leading causes of tumour-related death in patients with oesophageal squamous cell carcinoma (ESCC)." | ( Dai, TY; Deng, X; Gao, FX; Han, F; He, XM; Hu, Z; Long, Y; Qin, M; Ren, DL; Wang, C; Wu, J; Xu, T, 2019) |
| "Peritoneal metastasis is common in advanced gastric cancer patients and is typically associated with a worse prognosis." | ( Che, X; Chen, Y; Deng, M; Hu, X; Liu, B; Liu, Y; Qu, X; Song, H; Xu, X; Yu, R; Zhang, Y, 2019) |
| "Metastasis is a multistep biological process regulated by multiple signaling pathways." | ( Fu, Y; Gong, T; Hu, D; Huang, Y; Li, H; Luo, J; Zhang, P; Zhang, ZR, 2019) |
| "Metastasis is a major dilemma of cancer therapy." | ( Feng, X; Huang, M; Liu, Q; Xie, L; Zhang, K, 2019) |
| "As tumor metastasis is the leading cause of death in patients with CRC, it is important to elucidate the molecular mechanisms that drive CRC metastasis." | ( Chen, M; Jiang, X; Jin, T; Wang, T; Wang, Z; Wu, Y; Yang, M; Zhang, H; Zhu, Q, 2019) |
| "Metastasis is one of the main contributors to the poor prognosis of hepatocellular carcinoma (HCC)." | ( Chen, X; Huang, J; Lan, T; Li, J; Li, X; Liao, M; Wu, H; Xie, K; Xu, L; Yuan, K; Zeng, Y, 2020) |
| "Tumor metastasis is the most dangerous stage in tumorigenesis and its evolution, which causes about 80% clinical death." | ( Du, YZ; Jiang, MS; Li, X; Luo, LH; Qin, B; Xuan, SY; Yang, J; Yin, H; Yin, XY; You, J; Yuan, XL; Zhu, C, 2019) |
| "Metastasis is the most prevalent cause of treatment failure in patients with colon cancer." | ( Chen, PN; Chu, SC; Hsieh, YS; Hsu, LS; Huang, SF; Tu, YC, 2019) |
| "Tumor metastasis is a primary source of morbidity and mortality in cancer." | ( Cui, N; Dai, K; Ichikawa-Shindo, Y; Kakihara, S; Kamiyoshi, A; Kawate, H; Matsui, S; Sakurai, T; Shindo, T; Tanaka, M; Wei, Y, 2020) |
| "Cancer metastasis is the primary reason for cancer-related deaths, yet there is no technique capable of detecting it due to cancer pathogenesis." | ( Dharmalingam, P; Tan, B; Venkatakrishnan, K, 2020) |
| "Tumor growth and metastasis are multistep processes regulated by multiple signaling pathways." | ( He, Q; Li, M; Long, Y; Ren, K; Wang, Y; Xiang, B; Yang, Y; Zhang, Z, 2020) |
| "Preventing cancer metastasis is one of the remaining challenges in cancer therapy." | ( Gu, W; Liu, J; Movahedi, F; Wu, Y; Xu, T; Xu, ZP, 2020) |
| "Metastasis is one of the main reasons causing death in cancer patients." | ( Hu, FQ; Li, Y; Liu, X; Shang, XW; Wang, L; Yuan, H; Zhou, XQ, 2020) |
| "Metastasis is the leading cause of cancer mortality and is a major hurdle for lung cancer treatment." | ( Dong, M; Liu, D; Wang, Y; Zhu, X, 2020) |
| "Surgery-accelerated metastasis is mediated in part through tumor supportive alterations in macrophage phenotype." | ( Blank, B; Kallis, MP; Maloney, C; Soffer, SZ; Steinberg, BM; Symons, M, 2020) |
| "Cancer invasion and metastasis are the leading causes of death." | ( Fu, Q; Liu, H; Liu, Z; Lu, Y; Sun, X; Yu, P; Zhang, W, 2020) |
| "Acrometastasis is infrequent and generally indicates a wider spread of metastasis with poor prognosis." | ( Diaz, E; Gallardo-Alvarado, L; Leon, DC; Perez-Montiel, D; Ramirez-Morales, R; Ramos, AA, 2020) |
| "Metastases are the cause of the vast majority of cancer deaths." | ( Beckett, MA; Bryan, DS; Cichoń, U; Khodarev, NN; Krysztofiak, K; Pearson, AT; Poli, EC; Posner, MC; Robinson, DN; Rock, RS; Schiffhauer, ES; Stack, M; Surcel, A; Thomas, DG; Weichselbaum, RR; Xue, L, 2020) |
| "Metastasis is the most significant cause of morbidity and mortality in breast cancer patients." | ( Hermawan, A; Putri, H, 2020) |
| "Tumor tropism metastasis is a multi-step process that involves interactions between tumor cells and the microenvironment." | ( Chen, X; Lin, D; Lin, J; Lin, Z; Liu, D; Liu, Y, 2021) |
| "Breast cancer metastasis is a complex process that depends not only on intrinsic characteristics of metastatic stem cells, but also on the particular microenvironment that supports their growth and modulates the plasticity of the system." | ( Fico, F; Santamaria-Martínez, A, 2020) |
| "Metastases are the leading cause of breast cancer-related deaths." | ( Brown, EB; Desa, DE; Hill, RL; Martens, JWM; Smid, M; Strawderman, RL; Turner, BM; Wu, W, 2020) |
| "Invasion and metastasis are the major causes leading to the high mortality of colon cancer." | ( Geng, C; Guo, Y; Li, T; Li, X; Li, Y; Liu, W; Wang, C, 2021) |
| "Metastasis is the most prevalent cause of cancer-associated deaths amongst patients with cervical cancer." | ( Chen, PN; Chu, SC; Hsieh, YS; Huang, SC; Kao, SH; Lin, MS, 2021) |
| "Metastasis is the leading cause of death in retinoblastoma (Rb) patients." | ( Chen, Y; Wang, K; Zhou, F; Zhu, X; Zou, W, 2021) |
| "Distant organ metastasis is the main cause of death in breast cancer patients." | ( Huang, Y; Li, Q; Lin, X; Xiang, Y; Xie, D; Yang, J; Zhou, M; Zhou, R; Zhou, Z, 2021) |
| "Metastasis is the leading cause of mortalities in cancer patients due to the spreading of cancer cells to various organs." | ( Gao, X; Pu, Y; Smith, J; Wang, C; Wu, B; Xue, J, 2021) |
| "Metastasis is the fundamental cause of cancer mortality, but there are still very few anti-metastatic drugs available." | ( Chen, C; Cho, WC; He, Y; Le, MTN; Lu, Y; Wang, D; Wang, R; Wei, W; Yang, M; Ye, Z; Yu, J; Yue, J; Zhang, H; Zhang, L, 2021) |
| "Metastasis is the major cause of death in patients with CRC." | ( Dai, F; Feng, Y; Gao, L; Ge, C; Li, X; Wang, C; Wang, S; Xie, S; Xu, X; Zhang, K, 2021) |
| "Metastasis is the main cause of breast cancer mortality." | ( Chen, M; Hou, Y; Jin, W; Liu, Q; Liu, Y; Sun, H; Yang, X; Zhao, Y, 2021) |
| "Peritoneal metastasis is a common form of metastasis among advanced gastric cancer patients." | ( Chiu, PWY; Deng, J; Kang, W; Kang, X; Li, W; Liang, H; Liu, W; Ng, EKW; To, KF; Wang, G; Wong, CC; Yu, J; Zhao, S, 2021) |
| "Metastasis is the major reason for the high mortality of colorectal cancer (CRC) patients and its molecular mechanism remains unclear." | ( Chen, J; Fan, D; Feng, W; Huang, W; Ji, X; Liu, D; Qiao, C; Sun, M; Wang, Y; Wu, K; Xia, L; Xie, M; Zhang, T, 2021) |
| "Metastasis is a complex process that is divided into several steps, including separation of tumor cells from the primary tumor, invasion, cell migration, intravasation, vasculature survival, extravasation, and colonization of the secondary site." | ( Arik, D; Aykanat, NEB; Badak, B; Canaz, F; Kacar, S; Sahinturk, V, 2021) |
| "Brain metastasis is one of the common distant metastases of lung cancer." | ( Li, B; Li, J; Sun, L; Wang, B, 2022) |
| "Metastasis is the leading cause of colorectal cancer (CRC)-induced death." | ( Hua, Q; Lin, Z; Ren, J; Wang, H; Wang, L; Xu, G; Yu, D; Zhang, B; Zhang, D; Zhang, T; Zhao, L, 2021) |
| "Relapse and metastasis are important factors endangering the life of breast cancer patients, but the mechanism is still unclear." | ( Feng, T; Gu, R; Guo, Y; Li, K; Li, Q; Li, S; Lin, P; Ou, D; Yuan, H; Zhang, J; Zhao, G, 2021) |
| "Tumor metastasis is the leading cause of cancer mortality, often characterized by abnormal cell growth and invasion to distant organs." | ( Ambatipudi, K; Bisht, VS; Giri, K; Kumar, D, 2021) |
| "Metastasis is one of most lethal causes that confer a poor prognosis of patients with esophageal squamous cell carcinoma (ESCC), whereas there is no available target drug for metastatic ESCC currently." | ( Chen, L; Fang, D; Song, Y; Wang, C; Xie, S; Yang, H; Zeng, H; Zhao, Z, 2021) |
| "Metastasis is the major cause of TNBC mortality." | ( Al Bayati, A; Blonska, M; Carroll, SF; Cho, HM; Das, R; Elledge, C; Gil-Henn, H; Pimentel, A; Ramakrishnan, S; Rosenblatt, JD; Sankar, AP; Shin, SU; Zhang, Y, 2021) |
| "Metastasis is a major contributor of death in cancer patients, and there is an urgent need for effective treatments of metastatic malignancies." | ( Chen, Y; Cui, J; Han, J; Li, L; Li, Z; Liu, M; Liu, Z; Wang, Q; Wang, Z; Zhang, N, 2021) |
| "Metastasis is responsible for approximately 90% of cancer-associated mortality but few models exist that allow for rapid and effective screening of anti-metastasis drugs." | ( Goh, BC; Gong, Z; Li, Y; Makinoshima, H; Nakayama, J; Tan, L; Wang, S, 2021) |
| "Brain metastases are a leading cause of death in patients with breast cancer." | ( Ahmed, AU; Balyasnikova, IV; Burga, R; Castro, B; Cordero, A; Fares, J; Kanojia, D; Lee-Chang, C; Lesniak, MS; Miska, J; Petrosyan, E; Ramsey, MD; Rashidi, A; Schwartz, CW; Xiao, T; Zhang, P, 2022) |
| "Cancer metastasis is the cause of the majority of cancer-related deaths." | ( Adhav, R; An, T; Chan, UI; Deng, CX; Lei, JH; Li, J; Liu, J; Miao, K; Mo, L; Shu, X; Su, SM; Wang, Y; Xu, J; Xu, X; Zhang, X, 2022) |
| "Tumor metastasis is a hallmark of cancer." | ( Chen, JH; Fan, J; Han, JH; He, TC; Jia, HL; Lin, J; Lu, L; Wang, XY; Zhang, C; Zhang, JB; Zhang, P; Zhang, R; Zhu, WW, 2022) |
| "Bone metastasis is closely related to tumor death in prostate cancer (PC)." | ( Bao, Y; Cao, Z; Hu, K; Hu, Y; Hu, Z; Liao, J; Wu, Q; Xi, X; Zhang, Z; Zhong, X; Zhou, J, 2022) |
| "Bone metastasis is a common impairment associated with advanced breast cancer." | ( Hamilton, G; Lang, C; Moser, D; Neumayer, C; Plangger, A; Radtke, C; Rath, B; Staud, C; Teufelsbauer, M, 2022) |
| "Metastasis is a major cause of CRC recurrence and mortality." | ( Lan, J; Liu, H; Mao, Y; Pan, K; Wu, D; Wu, X; Xu, Y; Yang, J; Yang, L; Zhang, T, 2022) |
| "Bone metastases are often difficult to manage as they can be symptomatic and skeletal-related events (SREs) can contribute to significant morbidity and declines in performance status." | ( Choy, E; Cote, GM; Fidias, PM; Gainor, JF; Heist, RS; Michaelson, MD; Muzikansky, A; Sequist, LV; Shaw, A; Sullivan, RJ; Wirth, L, 2022) |
| "Brain metastasis is a devastating clinical condition globally as one of the most common central nervous system malignancies." | ( Dong, C; Pan, B; Sun, Z; Wang, C; Ye, Z; Yue, X; Zhu, L, 2022) |
| "Metastasis is the primary cause of cancer-related mortality." | ( Gao, R; Li, M; Yang, X; Zhang, G; Zhang, W; Zhou, D, 2022) |
| "Metastasis is the leading cause of mortality in most patients with cancer." | ( Lee, KE, 2023) |
| "Metastasis is the leading cause of mortality in most patients with cancer." | ( Lee, KE, 2023) |
| "Metastasis is the leading cause of mortality in most patients with cancer." | ( Lee, KE, 2023) |
| "Metastasis is the hallmark of failed tumor treatment and is typically associated with death due to cancer." | ( Bai, S; Chen, L; Chen, Y; Du, J; Liu, R; Luo, Y; Ma, W; Wang, M; Wei, Y, 2023) |
| "Metastasis is the hallmark of failed tumor treatment and is typically associated with death due to cancer." | ( Bai, S; Chen, L; Chen, Y; Du, J; Liu, R; Luo, Y; Ma, W; Wang, M; Wei, Y, 2023) |
| "Distant metastasis is the main cause of death of TNBC patients." | ( Gomez-Puerto, MC; Gu, Y; Hagenaars, SC; Kuipers, TB; Liu, S; Mei, H; Mesker, WE; Ten Dijke, P; van Dinther, M, 2023) |
| "Adrenal metastasis is the most common adrenal malignancy and can be bilateral in up to 43% of patients." | ( Bancos, I; Hallemeier, C; Herndon, J; Jethwa, K; Shariff, A, 2023) |
| "Bone metastasis is one of the main complications of lung cancer and most important factors that lead to poor life quality and low survival rate in lung cancer patients." | ( Gu, Y; Guo, QM; Liu, MF; Lou, JT; Qian, WL; Qiao, LH; Ren, YZ; Sun, Z; Wang, L; Wang, XQ; Wu, F; Wu, L; Xu, WX; Yang, T; Zhang, LF; Zhang, XZ; Zhao, MN, 2023) |
| "Metastasis is a leading cause of mortality in patients with lung adenocarcinoma." | ( Cao, Y; Duan, S; Fu, W; Meng, M; Tang, L; Wang, D; Wang, X; Yang, Y; Zhang, Z, 2023) |
| "Metastasis is the leading cause of cancer-related death, where TGFβ-induced epithelial-mesenchymal transition (EMT) process confers on cancer cells increased metastatic potential." | ( Chen, S; Fu, X; Guo, J; Li, K; Liu, W; Ma, H; Ming, Y; Peng, Y; Wang, J; Zhang, T, 2023) |
| Excerpt | Reference |
|---|
| "Eight patients with symptomatic liver metastasis from different primary tumours received palliative radiation therapy." | ( Turek, M, 1975) |
| "12 patients with extensive metastases of malignant testicular tumors and 5 other patients with other rapidly growing metastasizing tumors were treated." | ( Jonas, U; Körner, F; Lund, S, 1975) |
| "Sixty two patients with metastases of testicular teratoblastoma were subjected to combination chemotherapy." | ( Orel, NF, 1979) |
| "Detection of early asymptomatic bony metastases will provide a better planning of treatment with rational approach." | ( Beckman, KW; Blom, O; Hahn, P; Rydman, H; Vikterlöf, KJ, 1979) |
| "Thirteen metastatic fractures and metastasis of upper extremity of the femur have been treated by Enders' blind nailing in the Orthopaedic Surgery Department of Strasbourg University Hospital." | ( Babin, S; Calmes, E; Jacquemaire, B; Katzner, M; Schvingt, E, 1976) |
| "Hepatic metastasis is usually quite resistant to conventional systemic chemotherapy." | ( Lee, YT, 1978) |
| "Forty-eight patients with liver metastases were treated at Rhode ISland Hospital in a nonrandomized sequential manner between January 1972 and June 1977." | ( Glicksman, AS; Leone, LA; Rege, VB; Soderberg, CH; Webber, BM, 1978) |
| "One patient died with widespread metastases despite intensive chemotherapy with actinomycin D and triple therapy." | ( Goldstein, DP; Osathanondh, R; Pastorfide, GB, 1975) |
| "In the treatment of lung metastases the combination of whole-lung irradiation and maintained chemotherapy with AMD + VCR proved excessively toxic: in 5 of 11 patients acute diffuse pneumonitis developed, and it was fatal in 3." | ( Jeffs, RD; Jenkin, RD; Sonley, MJ; Stephens, CA, 1976) |
| "Pulmonary metastases were most commonly responsive to chemotherapy." | ( Burgess, MA; Byers, R; Rentschler, R, 1977) |
| "Although distant metastases develop rather frequently no satisfactory form of therapy has been reported." | ( Pinedo, HM; Vermeer, RJ, 1979) |
| "Recently the resection of pulmonary metastases combined with chemotherapy has increased the survival rate." | ( Jenkin, RD, 1977) |
| "Microscopic metastases of some patients were eradicated by this adjuvant chemotherapy." | ( Hustu, O; Kumar, AP; Pratt, C; Rivera, G; Shanks, E; Smith, J, 1977) |
| "The occurrence of pulmonary metastases in patients suffering from primary classic osteogenic sarcoma is compared among two groups of patients treated according to different protocols at Groote Schuur Hospital." | ( Mills, EE, 1978) |
| "In four patients, delayed onset of metastasis was observed at 18--43 months from initiation of treatment." | ( Etcubanas, E; Wilbur, JR, 1978) |
| "Tumor growth and lung metastases were significantly suppressed, when tumor cells were mixed with BCG and inoculated subcutaneously into vitamin A-treated animals." | ( Kurata, T; Micksche, M, 1978) |
| "Primary mammary tumors and metastases in regional lymph nodes proved to be mostly susceptible to the conducted therapy." | ( Borisov, AI, 1978) |
| "Previous treatment of metastases, dominant site of metastases and performance condition were similar in the patients." | ( Arwidi, A; Lindholm, CE; Mattsson, W; von Eyben, F, 1979) |
| "We treat patients free from metastases with a 60Co-source (right and left lateral 120-degree arc rotational therapy with 5000 rads over 5 weeks) combined with hormonal therapy." | ( Guddat, HM; Lenk, S; Schnorr, D, 1977) |
| "15 patients with distant metastases of hypernephroid carcinoma were treated with medroxyprogesterone acetate (usually 300 mg daily by mouth)." | ( Hahn, D; von Lieven, H, 1977) |
| "Fifteen patients with sarcoma metastases in the soft tissue were treated with karminomycin in combnation with methotrexate and cyclophosphane." | ( Assekritova, IV; Gorbunova, VA; Lichinitser, MR, 1977) |
| "Eight patients had extensive metastases at the beginning of treatment: they at first received only chemotherapy, followed by radiotherapy or operation, as indicated." | ( Höffken, K; Holfeld, H; Scherer, E; Schmidt, CG; Schmitt, G; Seeber, S; Siemers, E, 1979) |
| "The meningeal metastasis was treated by surgery and irradiation with orbital penetration; the lymph nodes were irradiated, and COPP polychemotherapy was given to treat the rest of the metastatic localizations." | ( Caballero, O; Martínez, J; Marty, ML; Mayans, J; Sanz, MA, 1979) |
| "Quantitative radiology of metastases is compared with other pretreatment characteristics in ability to predict survival in 102 patients with advanced Stage IV prostatic carcinoma." | ( Byar, DP; Hovsepian, JA, 1979) |
| "3 melanoma patients suffering from skin metastases were treated by epifocal DNCB-application." | ( Djawari, D; Weidner, F, 1979) |
| "Disseminated peritoneal metastases were more frequently found in BCG-treated animals." | ( Justrabo, E; Lagneau, A; Martin, F; Martin, MS; Michel, MF, 1977) |
| "Three patients developed CNS metastasis while on treatment." | ( Blumenschein, GR; Burgess, MA; Buzdar, AU; Hortobagyi, GN; Tashima, CK; Waterfield, WC, 1978) |
| "Weight of the tumor and lymphogenous metastases tended to increase, but the number of metastatic foci in the lungs was unchanged by the administration of urokinase." | ( Kodama, Y; Tanaka, K, 1978) |
| "If there are additional metastases those to the choroid do not require primary radiotherapy, as the treatment resulted with the remission in six of eight of the patients (mean duration of 12 months) and a rise in visual acuity in five of the six indicated." | ( Stolzenbach, G; von Domarus, D, 1978) |
| "The mortality rate and the incidence of metastases were both markedly lower than in a comparable previous series treated by radiotherapy alone, or by operation plus radiotherapy, but all without chemotherapy." | ( Bacci, G; Campanacci, M; Pagani, PA, 1978) |
| "The case of a 43-year-old man who had a metastasis of an anaplastic bronchus carcinoma in the iris and died of metastases 3 months after the appearance of the iris tumor, despite adequate chemotherapy, is reported." | ( Barishak, YR; Baruh, E; Lazar, M, 1978) |
| "This case emphasizes that cardiac metastases must be considered in the differential diagnosis of heart failure in patients treated with Adriamycin." | ( Brown, JA; Oster, MW; Raafat, J, 1978) |
| "A difference was found in the rate of metastases between the patients who did and did not receive chemotherapy; the overall survival of about 80% in both groups was better than anticipated." | ( Albo, V; D'Angio, GJ; Evans, AE; Finklestein, JZ; Hammond, GD; Leiken, S; Santulli, T; Weiner, J, 1976) |
| "In patients who have distant metastases at the time of therapy, there is no evidence of improved overall survival rates by the use of irradiation, either preoperatively or postoperatively." | ( Montague, ED; Romsdahl, MM, 1976) |
| "35 of the 40 patients developed metastases in spite of estrogen therapy and/or orchidectomy." | ( Kölln, CP; Nagel, R, 1976) |
| "Nine instances of hepatic metastases were unaffected by therapy but 68% of the skin and nodal patients responded." | ( Cohen, SM; Greenspan, EM; Ratner, LH; Weiner, MJ, 1977) |
| "However, the incidence of pulmonary metastasis was unaffected by the chemotherapy, being 42% in controls and 37% in PAF-treated mice." | ( Anderson, JC; Fugmann, RA; Martin, DS; Stolfi, RL, 1977) |
| "Skin, lymph node, and soft tissue metastases more frequently responded to therapy, while hepatic, peritoneal, and osseous metastases responded with an intermediate frequency." | ( Klahr, C; Presant, CA; Van Amburg, A, 1977) |
| "We report observations on the spread by metastasis and infiltration of a transplantable tumour in rats treated by 60Co gamma-irradiation of the primary, irradiation plus parenteral cyclophosphamide, or parenteral cyclophosphamide alone." | ( Dixon, B; Moore, JV, 1977) |
| "Tumor growth and lung metastases were significantly suppressed, when tumor cells were mixed with BCG and inoculated subcutaneously into vitamin A-treated animals." | ( Kurata, T; Micksche, M, 1977) |
| "Patients with demonstrable metastases should receive the same chemotherapy until either all tumor has regressed or all immature elements have reverted to mature tissue." | ( Barlow, JJ; Piver, MS; Sinks, L; Tsukada, Y, 1976) |
| "Nine patients had no visible metastases at diagnosis: two died following the development of pulmonary metastases and the rest have been free of disease for periods varying from 4 months to 4 1/2 years following completion of treatment." | ( Cassady, JR; Jaffe, N; Paed, D; Salian, S; Traggis, D, 1976) |
| "Four patients suffering from brain metastases were studied by brain scintigraphy carotid angiography and rCBF measurement, before and after one week of treatment with dexamethasone." | ( Baleriaux, D; Capon, A; Fruhling, J; Hildebrand, J; Verbist, A, 1976) |
| "Osteoblastic bony metastases were observed in a case of medulloblastoma three years after surgery and radiation treatment." | ( DeLand, FH; Ho, EP; Lieber, A; Maruyama, Y, 1976) |
| "The number of pulmonary metastases may be decreased with adjunctive immunotherapy following excision of the primary tumor." | ( DeBlasi, RF; Fisher, SJ; Miller, CW, 1976) |
| "The 2 patients whose pulmonary metastases responded to combined therapy developed pulmonary fibrosis and pneumonitis in the treated areas 3 months after radiation therapy (RT) (1400 and 1600 rads respectively)." | ( Cham, W; Martinez, A; Murphy, ML; Rosen, G; Tefft, M, 1975) |
| "Enhancement of tumor metastasis, as induced by hydrocortisone pretreatment, was not reproduced by the administration of 6-mercaptopurine, testosterone, or estradiol." | ( Kodama, M; Kodama, T, 1975) |
| "The initial response of the metastases to 131I ablative therapy was excellent." | ( McConnon, JK; Mitchell, RI; von Westarp, C, 1975) |
| "78 women with breast cancer metastases were divided into 5 groups as to type of therapy and observed." | ( Arutiunian, DE; Barkhudarian, LKh; Gazarian, ES; Movsesian, MA; Ovsepian, LKh, 1975) |
| "These are presumed to be due to occult metastasis present at the time of the initial treatment." | ( Hickey, RC; McBride, CM; Sugarbaker, EV, 1975) |
| "With regard to the frequency of metastases and to the survival rate, treatment with Phenprocoumon alone showed significantly better results as sole radiation treatment." | ( Doench, K; Frischkorn, R; Rath, W, 1976) |
| "Cytostatic treatment of metastasising testicular cancers has only been of limited value." | ( Höffken, K; Schmidt, CG; Seeber, S; Tingelhoff, J, 1976) |
| "was more effective in inhibiting metastases in animals started on treatment 7 to 13 days after tumor inoculation than in animals in which levanization was started earlier." | ( Leibovici, J; Sinai, Y; Wolman, M, 1976) |
| "If these results are applicable to metastases in these two organs, they indicate potential diffusion-mediated resistance to chemotherapy, and potential hypoxia-mediated resistance to radiotherapy of both metastases and micrometastases." | ( Aliño, SF; Alvarez, FJ; Hilario, E; Rodeño, E; Simón, J, 1992) |
| "In contrast, no suppression of metastases was observed when the cells were pretreated with 8-bromo-cAMP, forskolin, or cholera toxin." | ( Amsterdam, A; Eisenbach, L; Suh, BS, 1992) |
| "Spontaneous metastasis incidence was low for both controls and treated cells; however, almost all animals (15/16) injected i." | ( Albini, A; Carlone, S; Colacci, A; De Giovanni, C; Grilli, S; Lollini, PL; Melchiori, A; Parodi, S, 1992) |
| "Three patients with isolated liver metastases and one patient with local recurrence of rectal carcinoma received regional therapy with higher 5-FU doses." | ( Preiss, J, 1992) |
| "To treat established lung metastasis, mice bearing 15-day C3L5 transplants were given CIbT or CIT alone or in combination with two 4-day rounds (days 20-23, 31-34) of IL-2 (15,000 Cetus units, i." | ( Chan, FP; Khoo, NK; Lala, PK; Saarloos, MN, 1992) |
| "SPG also inhibited the pulmonary metastasis of NR-S1 tumor after radiotherapy." | ( Amemiya, K; Arika, T; Nomoto, K, 1992) |
| "Those with metastases in the liver or a lymphangitic pattern on chest x-ray were allowed either a single prior regimen for advanced disease or no therapy for metastatic disease if less than 1 year had elapsed since the completion of adjuvant chemotherapy." | ( Akman, SA; Blevins, C; Doroshow, JH; Leong, LA; Margolin, KA; Morgan, RJ; Raschko, JW; Somlo, G, 1992) |
| "All dogs developed metastasis at a median time of 202 days (range, 41-444 days) after initiation of treatment." | ( Dodge, RK; Forrest, LJ; Heidner, GL; McEntee, MC; Novotney, CA; Page, RL; Thrall, DE, 1992) |
| "Four patients had metastases at the time of treatment." | ( Albano, M; Contesso, G; Durand, S; Flamant, F; Genin, J; Gerbaulet, A; Habrand, JL; Haie, C; Pejovic, MH; Schwaab, G, 1991) |
| "In the case of multi-site metastases, outside of trials, the decision to employ chemotherapy must be taken on an individual basis." | ( Schalhorn, A, 1991) |
| "In an experimental murine metastasis model host pretreatment protocol (HPP) was tested to abrogate lung colonization of tumor cells." | ( Ladányi, A; Lapis, K; Paku, S; Pápay, J; Szende, B; Timár, J, 1990) |
| "The formation of lung metastases was prevented by 70 to 100%, depending on the treatment." | ( Grauffel, C; Jones, R; Knödgen, B; Moulinoux, JP; Sarhan, S; Seiler, N, 1990) |
| "Treatment of micrometastases of HX34 human melanoma grown as xenografts in nude mice represents an advanced stage of preclinical investigations concerning targeted radiotherapy of this neoplasm using 3,7-(dimethylamino)phenazathionium chloride [methylene blue (MTB) labeled with astatine-211 (211At) (alpha-particle emitter)." | ( Carpenter, RN; Link, EM, 1990) |
| "At the discovery of metastasis in treated patients, they were above this value in 12/17 (71%) of patients." | ( Krebs, BP; Namer, M; Pons-Anicet, D; Ramaioli, A, 1988) |
| "Surgery was the main therapy." | ( Contesso, G; Friedman, S; Mouriesse, H; Spielmann, M; Terrier, P; Terrier-Lacombe, MJ, 1989) |
| "For seventy two patients with liver metastasis, radical surgery with removal of liver metastatic lesions post removed intra arterial infusion therapy (5FU,MMC) was carried out and the resulting 5-year survival rate was 40% for patients with H1 liver metastasis." | ( Hojo, K, 1989) |
| "In the experimental lung metastasis model, intravenous administration of rIFN gamma followed by intravenous or intranasal administration of GLA-60 showed potent inhibition of lung metastases of B16-BL6 melanoma, whereas the reverse sequence of administration (GLA-60/rIFN gamma) or administration of a mixture of rIFN gamma and GLA-60, which cannot induce the production of TNF, caused no inhibition of lung metastases." | ( Azuma, I; Hasegawa, A; Kiso, M; Maeda, H; Murata, J; Saiki, I; Yamamoto, N, 1989) |
| "Thirty-seven men with symptomatic bone metastases from prostate cancer that had progressed following earlier treatment with estrogens and/or orchidectomy were treated with low-dose prednisone (7." | ( Gospodarowicz, M; Meakin, W; Panzarella, T; Rider, W; Stewart, L; Tannock, I, 1989) |
| "Using the experimental metastases assay, we investigated the organ colonization properties of RA-treated and -untreated populations of F9 cells." | ( Pacenti, L; Rusciano, D; Terrana, B, 1987) |
| "She died from general metastasis seven months after the radical mastectomy in spite of adjuvant immunochemotherapy." | ( Hanamura, N; Iida, F; Kasuga, Y; Katsuyama, T; Oota, H; Senga, O; Tsuchiya, S, 1986) |
| "All but 2 of the patients with distant metastases had high Tg levels during suppression therapy; 1 of these 2 patients exhibited high Tg levels after T3 withdrawal." | ( Amerio, R; Betterle, C; Busnardo, B; Casara, D; Girelli, ME; Piccolo, M, 1986) |
| "Twelve patients (2 with only bone metastases, 3 with only soft tissues metastases and 7 with bone and soft tissues metastases) were treated with 131-I-MIBG (specific activity: 20 mCi/mg), 100 to 200 mCi every 3-6 months." | ( Brendel, AJ; Charbonnel, B; Chatal, JF; Lanehche, B; Lumbroso, J; Marchandise, X; Mornex, R; Schlumberger, M; Wemeau, JL, 1988) |
| "These results probably reflect that metastases in different anatomical locations differ with respect to sensitivity to antineoplastic treatments." | ( Andersen, J; Birkler, NE; Ejlertsen, B; Kamby, C; Rose, C; Rytter, L; Zedeler, K, 1988) |
| "A substantial decrease in lung metastasis number was observed as a result of treatment with all of the three oligopeptides." | ( Denes, L; Kisfaludy, L; Lapis, K; Pal, K; Sipos, L; Szende, B, 1987) |
| "The incidence of lung metastases was increased in TAM-treated pts (P = 0." | ( Andersen, J; Andersen, KW; Birkler, NE; Ejlertsen, B; Kamby, C; Rose, C; Rytter, L; Zedeler, K, 1988) |
| "In contrast, growth of metastases of B16-melanoma and R-3230 adenocarcinoma could not significantly be influenced by any of those treatments." | ( Bengelsdorff, KH; Hagmayer, G; Sedlacek, HH; Seiler, FR, 1987) |
| "First appearance of local metastases was prolonged in only the intraarterial magnetically localized doxorubicin-treated group of animals." | ( Berman, ML; DiSaia, PJ; Rettenmaier, MA; Senyei, A; Stratton, JA; White, DB; Widder, K, 1987) |
| "Two patients with metastases after primary surgery to remove a dysgerminoma were successfully treated by chemotherapy." | ( Brökelmann, J; Hartlapp, JH, 1987) |
| "The number of lymph-node and visceral metastases was greatly increased by the treatment with hydrocortisone unrelated to the doses and sexes." | ( Kubota, K; Kubota, R; Matsuzawa, T; Takeda, S, 1987) |
| "While metastasis plays a pivotal role in the ultimate success of failure of therapy, it is in fact a result of a more insidious malignant process termed tumor progression." | ( Fidler, IJ; Frost, P, 1986) |
| "However, the inhibitory effect on metastasis was abrogated by the in vitro treatment of the peritoneal adherent cells with silica." | ( Mashiba, H; Matsunaga, K, 1986) |
| "Patients with regional metastases of malignant melanoma (75 with Stage IIIA soft tissue metastases, 124 with Stage IIIB nodal metastases and 75 with Stage IIIAB soft tissue and nodal metastases) treated by regional perfusion between 1957 and 1982 were retrospectively studied to identify prognostic factors relating to survival." | ( Krementz, ET; Mather, FJ; Sutherland, CM, 1987) |
| "Pulmonary disease and lymph node metastases were particularly sensitive to this therapy." | ( Allan, SG; Carmichael, J; Chisholm, GD; Cornbleet, MA; Duncan, W; MacDougall, RH; Smyth, JF, 1985) |
| "The effectiveness of the treatment on metastasis was also shown by the prolongation of mean survival time in groups of mice which showed no local recurrence of tumors." | ( Hosokawa, M; Kobayashi, H; Mizukoshi, T; Sugawara, M, 1985) |
| "After treatment, the incidence of lung metastasis was analyzed in LLC-inoculated mice, and the presence or absence of metastasis in affiliated lymph nodes was determined in mouse ascites hepatoma 134-inoculated mice." | ( Koga, S; Maeta, M; Oda, M, 1985) |
| "Transperitoneal and lymph node metastases were the major causes of treatment failure." | ( Douglass, HO, 1985) |
| "Tumor metastasis was decreased in all parenterally fed mice, a phenomenon related to the route of administration and apparently independent of energy substrate." | ( Baumgartner, TG; Copeland, EM; Economides, E; Mahaffey, SM; Sitren, HS; Talbert, JL, 1985) |
| "Preferably metastases of the soft parts respond to the therapy." | ( Dobberstein, N; Köhler, A; Noss, W; Pohl, J; Stoltmann, R, 1986) |
| "Patients with metastases showed a significantly decreased response to DNCB compared to the results obtained before radiotherapy." | ( Csere, T; Kuhn, E; Stefanits, K, 1985) |
| "Six of them had tumor metastasis with in 6 months after the initial treatment(s)." | ( Matsumoto, S; Oi, S; Raimondi, AJ, 1985) |
| "Cerebral metastases were the sole or major cause of death in 8/9 patients who relapsed following control with DTIC for nine months or longer, and one patient developed a carcinoma of the breast following therapy with DTIC and BCNU." | ( Berris, R; Hill, GJ; Parkin, P; Philpott, GW; Ruess, R, 1974) |
| "2 of these patients had multiple lung metastases which were unsuccessfully managed by actinomycin D therapy." | ( Bloom, HJ; Hendry, WF, 1973) |
| "A patient on Depo-Provera with lung metastases had recurrence after 62 months when treatment was reduced to every other week but when Colprone was then given, regression again occurred and has continued for almost 10 years." | ( Rozier, JC; Underwood, PB, 1974) |
| "Bony metastases were unaffected by the drug and were treated by local radiotherapy." | ( Ellis, F; Paine, CH; Wright, FW, 1970) |
| "Median survival from onset of metastasis was much longer in patients who had responded to previous endocrine therapy than those who had failed (53 versus 23 months; P less than 0." | ( Manni, A; Pearson, OH; Trujillo, JE, 1980) |
| "None of the patients with distant metastases when initially evaluated survived more than four years following the initiation of radiotherapy and chemotherapy." | ( Hsu, MM; Tu, SM, 1983) |
| "Bone metastases seem to respond best to this therapy." | ( Blossey, HC; Nagel, GA; Wander, HE, 1982) |
| "However, distant osseous metastases occurred in both cases, during and after the PGE1 administration." | ( Imashuku, S; Nakajima, F; Todo, S, 1983) |
| "Distant metastases are more important as cause of death than loco-regional relapses, it is why adjuvant chemotherapy is necessary, especially in young patients and in those with extensive disease." | ( Auclerc, G; Auclerc, MF; Baillet, F; Blondon, J; Facchini, T; Jacquillat, C; Lefranc, JP; Weil, M, 1984) |
| "Castration or diabetes prevents metastasis formation, but treatment with estrogen or insulin restores the metastasizing capacity." | ( Liotta, LA; Shafie, SM, 1980) |
| "Partial suppression of distant metastasis by adjuvant chemotherapy was apparent in the overall study, in the extremity tumor category, and in the subgroup of patients who had received limb-sparing surgery; however, no survival advantage for chemotherapy-treated patients was demonstrated." | ( Ahmann, DL; Burgert, EO; Edmonson, JH; Fleming, TR; Ivins, JC; O'Connell, MJ; Sim, FH; Soule, EH, 1984) |
| "However, distant osseous metastases were developed in both cases, during and after the PGE1 administration." | ( Esumi, N; Imashuku, S; Nakajima, F; Todo, S, 1984) |
| "Distant metastases and chemotherapy in malignant thymoma are reviewed." | ( Ichino, Y; Ishikawa, T; Obuchi, M; Suko, K, 1983) |
| "5 patients with lymph node metastases had been operated radically and were treated postoperatively." | ( Jensen, G; Medenwaldt, B; Meigel, WN; Meissner, K; Mensing, H; Voigt, H, 1982) |
| "In the case of small and circumscribed metastases which could be eliminated by surgical treatment, the excretion of 5-S-Cysteinyldopa remained normal." | ( Graef, V; Paul, E; Ruppel, R, 1980) |
| "In 12 patients, the metastases appeared after the end of chemotherapy." | ( Bacci, G; Campanacci, M; Giunti, A; Pagani, P, 1980) |
| "Seventeen of them had clinically metastases and had had no previous therapy." | ( Andersson, L; Edsmyr, F; Esposti, PL, 1980) |
| "Five patients had metastases prior to receiving chemotherapy, and 11 of the remaining 20 nonmetastatic patients received preoperative or preirradiation chemotherapy." | ( Evans, AE; Gregg, JR; Kramer, S; Lange, B; Toledano, S; Wimmer, R, 1982) |
| "In patients without metastases median survival was 48 weeks in the treated group and 12 weeks in controls." | ( Cocking, JB; Cwynarski, MT; Diffey, BL; Fox, CA; Hanley, J; Jackson, GA; Mallinson, CN; Rake, MO; Wass, VJ, 1980) |
| "However, the high incidence of metastasis indicated the need for more effective systemic chemotherapy for further improvement of treatment results." | ( Burgert, EO; Gehan, EA; Kissane, J; Nesbit, ME; Perez, CA; Pritchard, DJ; Tefft, M; Vietti, TJ, 1981) |
| "The operative treatment of metastasis improves the prognosis especially of small intestine carcinoids." | ( Burow, B; Heymann, H; Jung, D; Meffert, O; Putzki, H, 1982) |
| "Forty-two of the 106 patients with metastasis had experienced local treatment failures, suggesting that such patients may be at greater risk of metastasis." | ( Ames, FC; Hickey, RC, 1982) |
| "Patients without lymph node metastases were not treated." | ( Albrecht, M; Jepsen, G; Thomsen, K; Trams, G, 1981) |
| "A spontaneous metastases model in mice is being used to test the efficiency of various treatments in eliminating metastases." | ( Chu, AM; Down, JD; Fowler, JF; Reinartz, G; Travis, EL, 1981) |
| "A significant decrease in the number of metastases was observed in the triple drug therapy, administered for three cycles, BCNU only, and BCNU and adriamycin." | ( Drago, JR; Worgul, TJ, 1981) |
| "Central nervous system metastases developed in 16 (19%) of the 83 patients unresponsive to hormoinal therapy and this was significantly higher than the 6% rate (3 of 53) observed among the hormone-responsive patients (P = 0." | ( Blumenschein, GR; Buzdar, AU; Hortobagyi, GN; Legha, SS; Smith, TL; Swenerton, KD, 1980) |
| "One patient, presenting with pleural metastasis three years after undergoing incomplete resection of thymoma, failed to respond to treatment." | ( Evans, WK; Feld, R; Phillips, MJ; Simpson, WJ; Thompson, DM, 1980) |
| "The number of metastases in estrogen-treated mice was higher than in the other groups." | ( Gaydos, D; Mastromatteo, W; Proctor, JW; Yamamura, Y, 1981) |
| "In a spontaneous lung metastasis model using B16-BL6 melanoma, multiple administrations of this polypeptide, before or after surgical excision of the primary tumor, resulted in significant inhibition of tumor metastasis." | ( Murata, J; Saiki, I, 1995) |
| "Because distant visceral metastases still remain a major site of failure after this HDC regimen, a more effective systemic therapy is needed." | ( Ghalie, R; Hartsell, WF; Kaizer, H; Shah, AB, 1995) |
| "Experimental metastasis assays, in which B16F1 melanoma cells (controls vs eristostatin-treated, 25 micrograms/ml) were injected via mesenteric veins of anesthetized C57BL/6 mice, showed that eristostatin reduced (P < 0." | ( Chambers, AF; Grattan, M; Groom, AC; Khokha, R; Koop, S; MacDonald, IC; McLane, MA; Morris, VL; Niewiarowski, S; Schmidt, EE, 1995) |
| "The study included 14 patients with metastasis who did not respond (n = 3) to therapy with TMX alone or progressed after initial stable disease (SD) (n = 11)." | ( Barni, S; Cazzaniga, M; Esposti, D; Fossati, V; Lissoni, P; Meregalli, S; Tancini, G, 1995) |
| "Their role in tumor cell metastasis, the ultimate challenge for the treatment of cancer patients, are however not well-documented." | ( Butovich, IA; Gao, X; Hagmann, W; Honn, KV; Liu, B; Tang, DG; Timar, J, 1994) |
| "The proportion of mice with metastasis decreases for an increasing number of transplant generations of treatment, and after 10 transplant generations of treatment metastatic capacity is completely lost in immunocompetent mice." | ( Giraldi, T; Pacor, S; Perissin, L; Rapozzi, V; Zorzet, S, 1995) |
| "Chemoimmunotherapy of pulmonary metastases was investigated in a protocol of combined anti-tumour agents and interferon-beta and/or interleukin-2." | ( Iigo, M; Moriyama, M; Tsuda, H, 1994) |
| "Patients without haematogenous metastases at the beginning of the therapy and continuous local tumor control reached a median survival rate of 42." | ( Renner, H; van Kampen, M, 1994) |
| "Initiating treatment for metastases with endocrine therapy does not compromise survival, even when such therapy is given to women who have receptor-negative malignancy." | ( Muss, HB, 1994) |
| "173 patients with regional lymphatic metastases (n = 139) or distant disease (n = 34) were prospectively randomised, following resection of all clinically detectable tumour, to observation (n = 88) or adjuvant chemotherapy (n = 85)." | ( Blumenson, L; Karakousis, C, 1993) |
| "Pulmonary metastasis of B16/F10 cells in mice was inhibited by pretreatment of the cells with 1,6-epi-cyclophellitol in culture." | ( Atsumi, S; Iinuma, H; Nosaka, C; Ochi, Y; Umezawa, K, 1993) |
| "A 58-year-old woman with multiple organ metastases from breast cancer who had undergone radical mastectomy three years ago, was treated with oral 5'-DFUR 600 mg/day." | ( Dohi, K; Gotoh, T; Kataoka, T; Nishiki, M; Okamoto, T; Sadamoto, S, 1993) |
| "Inhibition of experimental tumor metastasis was dose-dependent and was observed when animals were treated the day before or the day after tumor-cell injection." | ( Algarra, I; Gaforio, JJ; Garrido, F; Höglund, P; Ljunggren, HG; Pérez, M, 1993) |
| "Enhancement of spontaneous lymph node metastasis of B16F10/L5 cells was also evident in TNF-alpha- but not in F4168-treated mice." | ( Kato, M; Kuroda, K; Mitsuishi, Y; Miyata, K; Nishimura, K; Sakae, N; Shikama, H, 1995) |
| "In spontaneous metastasis assays, limited treatment with batimastat (commencing when s." | ( Bone, EA; Box, GM; Brown, PD; Court, WJ; Eccles, SA; Thomas, W, 1996) |
| "Large vaginal metastasis was the only identifiable factor significantly associated with failure of initial single-agent chemotherapy (p = 0." | ( Lurain, JR; Roberts, JP, 1996) |
| "Microscopic analysis of metastases revealed a decrease in the average size of lesions in the groups treated with IL-2." | ( Esteban, JM; Hartmann, D; Mazumder, A; Verma, UM; Verma, UN; Wakefield, L; Wojtowicz-Praga, S, 1996) |
| "Up to 30% to 40% of metastases from hormone receptor-positive primary breast cancer do not respond to endocrine therapy." | ( Helin, H; Holli, K; Isola, J; Kononen, J; Kuukasjärvi, T, 1996) |
| "Peritoneal metastasis has been clinically considered to be a terminal stage, so aggressive therapy has not been performed." | ( Chung, YS; Nishimura, S; Sowa, M; Yashiro, M, 1996) |
| "In a spontaneous lung metastasis model using B-16-BL6 melanoma, multiple administrations of this polypeptide, before or after surgical excision of the primary tumor, resulted in significant inhibition of tumor metastasis without affecting the growth of the primary tumor." | ( Azuma, I; Saiki, I, 1994) |
| "Patients with localized and symptomatic metastases are best treated with radiotherapy." | ( Baert, L; Brady, LW; Goethuys, H; Lieskovsky, G; Petrovich, Z; Van Poppel, H, 1997) |
| "All 16 metastases from untreated patients were positive for TNF-alpha." | ( Bergenwald, C; Gustafsson, B; Håkansson, A; Håkansson, L; Krysander, L; Sander, B, 1997) |
| "Pulmonary metastasis of B16 BL6 cells in mice was remarkably inhibited by pretreatment of the cells with these compounds in culture." | ( Adachi, H; Azetaka, M; Fukuyasu, H; Iizuka, Y; Kondo, S; Nishimura, Y; Satoh, T; Takeuchi, T, 1997) |
| "Lung metastases developed in only 1 of 12 mice in the treated group, while they developed in 6 of mice of the control group." | ( Gao, DM; Sun, FX; Tang, ZY; Xia, JL; Xue, Q; Yang, BH, 1997) |
| "Pulmonary metastases were not inhibited by the treatment with AHCC plus UFT, whereas metastases to axillary lymph nodes (LN) were obviously inhibited." | ( Hosokawa, M; Kobayashi, M; Kuramitsu, Y; Li, YQ; Matsushita, K; Obara, M; Ohiro, Y, 1998) |
| "Distant metastasis is a more common pattern of failure than locoregional recurrence after adequate radiotherapy in patients with nasopharyngeal carcinoma (NPC)." | ( Hsu, CY; Jan, JS; Lin, JC, 1998) |
| "In spontaneous metastasis model, multiple administration of both apo-bLf and Lfcin-B significantly inhibited lung metastasis of B16-BL6 cells, however it was only apo-bLf that exhibited the inhibitory effect of tumor growth at the time of primary tumor amputation (on day 21) after tumor inoculation." | ( Azuma, I; Hata, K; Shimazaki, K; Watanabe, R; Watanabe, S; Yoo, YC, 1998) |
| "Most patients with metastases from uveal melanoma receive treatments that were established for stage IV cutaneous melanoma." | ( Becker, JC; Bröcker, EB; Kämpgen, E; Rünger, TM; Terheyden, P, 1998) |
| "The median number of lung metastases in the control groups was 12; after treatment with 5 or 10 mg of rutin, the number of lung colonies increased to 19 and 27, respectively." | ( Drewa, G; Grzanka, A; Pałgan, K; Schachtschabel, DO; Sujkowska, R, 1998) |
| "In cases of brain metastases (n = 12) radiation therapy was added." | ( Fuchs, T; Keilholz, U; Proebstle, TM; Scheibenbogen, C; Sterry, W, 1998) |
| "In both spontaneous and experimental metastasis models of tumor-bearing mice, treatment with 1alpha,25(OH)2D3 inhibited pulmonary metastasis." | ( Kimura, T; Matsuno, H; Yudoh, K, 1999) |
| "Distant metastases and multidrug resistance are critical problems in the therapy of human small cell lung cancer (SCLC)." | ( Matsushima, K; Mukaida, N; Nishioka, Y; Nokihara, H; Sone, S; Tsuruo, T; Yano, S, 1999) |
| "The potential for site of metastasis as a predictive variable for response to chemotherapy and survival was examined, in addition to other clinical parameters." | ( Assersohn, L; Benepal, T; Cunningham, D; Norman, A; Oates, J; Ross, PJ, 1999) |
| "A new therapeutic strategy for treating metastasis in hepatocellular carcinoma (HCC) has entailed the use of antiangiogenic agents such as suramin, BB-94 (Batimastat), TNP-470, and carboxyamido-triazole (CAI, a synthetic inhibitor of non-excitable calcium channels that reversibly inhibits angiogenesis)." | ( Bu, W; Li, XM; Qin, LX; Tang, ZY; Xia, JL, 1999) |
| "Animal models for breast cancer metastasis are valuable tools for studying mechanisms of metastasis and for preclinical testing of anti-metastatic therapy regimens." | ( Engebraaten, O; Fodstad, O, 1999) |
| "Inhibitors of tumor angiogenesis and metastasis are rapidly emerging as important new drug candidates for cancer therapy." | ( Brown, KJ; Cowden, WB; Francis, DJ; Freeman, C; Parish, CR, 1999) |
| "The present metastasis experiment clearly indicates that the administration of rh SOD enhances the antimetastatic effect of ADR." | ( Hagiwara, S; Kogawa, K; Koike, K; Kuribayashi, K; Muramatsu, H; Nakamura, K; Niitsu, Y; Nishihori, Y; Sakamaki, S; Tanaka, M, 1999) |
| "As the outcome of patients with brain metastases from malignant melanoma is generally poor, this combined chemo- and radiation therapy may provide improved care for such patients." | ( Gademann, G; Gollnick, H; Ulrich, J, 1999) |
| "Cases with lymph node and liver metastases, as well as primary lesions, showed excellent response to the therapy with positive response rates of 54." | ( Gamoh, M; Ishibashi, S; Ishioka, C; Kanamaru, R; Kato, S; Murakawa, Y; Shibata, H; Shimodaira, H; Shineha, R; Suzuki, T; Yoshioka, T, 1999) |
| "Lung metastasis in mice bearing subcutaneous tumors was significantly inhibited by HCFU at doses of 100-150 mg kg(-1) day(-1) without severe toxic side-effects, when orally administered three times per week either from week 4 or week 6 to 9 weeks after implantation." | ( Abe, A; Inada, K; Nakanishi, H; Tatematsu, M; Tsukamoto, T; Yasui, K, 1999) |
| "Liver metastases were present in 50% of the controls, 30% of the gemcitabine-treated animals, and 20% of C225-treated animals." | ( Abbruzzese, JL; Bruns, CJ; Davis, DW; Evans, DB; Harbison, MT; Hicklin, DJ; McConkey, DJ; Portera, CA; Radinsky, R; Tsan, R, 2000) |
| "Both effects on tumour growth and metastases were augmented by treating simultaneously nude mice with 7." | ( Barbanti-Brodano, G; Bompadre, S; Campioni, D; Caputo, A; Ciomei, M; Corallini, A; Ferrante, L; Leone, L; Montesi, M; Possati, L; Rocchetti, R; Sola, F; Talevi, S; Trabanelli, C, 1999) |
| "The lung metastasis rate of the control and treated group was 80%(8/10) and 30%(3/10), respectively (P = 0." | ( Xia, J; Yang, B, 1997) |
| "Forty-two patients with measurable metastases of colorectal cancer were treated with 5-FU in daily doses of 600 mg/m2 given in a 6-hour intravenous (i." | ( Cizej, TE; Markovic, A; Plesnicar, A; Stabuc, B, 2000) |
| "We discovered metastases in 6 patients (6%) after preoperative therapy." | ( Gretschel, S; Rau, B; Riess, H; Schlag, PM; Wust, P, 2000) |
| "Tumor lung metastasis was inhibited by treatment with either TX-1877 or KIN-806 without irradiation at a dose of 0." | ( Hori, H; Inayama, S; Inomata, T; Kasai, S; Kuwasaka, H; Masui, M; Nagasawa, H; Oka, S; Oshodani, T; Uto, Y; Yamashita, M, 2001) |
| "The number and size of spontaneous metastases were also decreased in animals inoculated with AZT-treated cells." | ( Alonso, DF; Gomez, DE; Olivero, OA; Tejera, AM, 2001) |
| "Fifty-nine cancer patients with bone metastases were enrolled sequentially into one of 8 treatment groups in the core protocol." | ( Berenson, JR; Givant, E; Harvey, H; Hupkes, M; Lipton, A; Rosen, LS; Savage, A; Swift, R; Vescio, RA; VonTeichert, JM; Woo, M, 2001) |
| "Development of distant metastases and acquired multidrug resistance (MDR) are major problems in therapy for human small cell lung cancer (SCLC)." | ( Hanibuchi, M; Higasida, T; Nishioka, Y; Nokihara, H; Sone, S; Tsuruo, T; Yano, S, 2001) |
| "The rate of metastasis in the cervical lymph node was significantly decreased in the groups treated with the cisplatin or peplomycin on day 7 after implantation." | ( Kawashiri, S; Kojima, K; Kumagai, S; Nakagawa, K; Yamamoto, E, 2001) |
| "Resistance to metastasis was assessed under baseline conditions and following the administration of a beta-adrenergic agonist, metaproterenol (MP)." | ( Ben-Eliyahu, S; Hong-Fen, L; Maimon, Y; Rosenne, E; Shakhar, K; Waisman, T, 2001) |
| "Distant metastases remain the main cause of treatment failure in NPC." | ( Allam, A; El-Badawi, S; El-Serafi, M; El-Weshi, A; Ibrahim, E; Khafaga, Y; Mosseri, V, 2001) |
| "Distant metastasis (DM) is the most common mode of recurrence among patients with advanced head and neck carcinoma treated with intra-arterial cisplatin and radiotherapy (RADPLAT)." | ( Doweck, I; Robbins, KT; Vieira, F, 2001) |
| "The rates of distant metastasis were 10% for chemotherapy group and 32% for control group (P=0." | ( Ho, CM; Ho, WK; Lam, P; Wei, WI; Yuen, AP, 2001) |
| "On the protection of bone metastasis of colon 26 PMF-15 implanted to mouse calvaria, CLIK-148 treatment significantly inhibited calvaria bone absorption (direct metastasis)." | ( Asao, T; Fukushima, M; Katunuma, N; Nukatsuka, M; Tsuge, H, 2002) |
| "Distant metastases are the most common cause of treatment failure." | ( Adelstein, DJ; Carroll, MA; Esclamado, RM; Lavertu, P; Rybicki, LA; Saxton, JP; Strome, M; Wood, BG, 2002) |
| "Furthermore, growth and metastasis of subcutaneous tumours after administration of the cyclic RGD-peptide was significantly delayed in comparison to controls (P<0." | ( Buerkle, MA; Dellian, M; Jonczyk, A; Messmer, K; Pahernik, SA; Sutter, A, 2002) |
| "However, the number and size of lung metastases were reduced in treated animals when examined at the time of sacrifice." | ( Bergerat, JP; Cazenave, JP; Céraline, J; Chenard, MP; Deplanque, G; Klein-Soyer, C; Mah-Becherel, MC, 2002) |
| "The rates of metastases in the groin and the lungs were at least 12-fold lower in the photodynamically treated animals compared with untreated or surgery-treated groups." | ( Brandis, A; Gross, S; Harmelin, A; Rosenbach-Belkin, V; Salomon, Y; Scherz, A; Schreiber, S, 2002) |
| "The failure to reduce distant metastasis and improve survival may have related in part to the more advanced disease stage in our patients and the relatively low compliance rate of adjuvant chemotherapy." | ( Au, GK; Choy, D; Chua, DT; Sham, JS, 2002) |
| "Since metastases to the liver, left adrenal gland, and Douglas' pouch were detected in addition to ascites and bilateral hydronephrosis, the tumor was judged unresectable and systemic chemotherapy with TS-1 was begun." | ( Araki, S; Asakura, R; Itou, A; Kobayashi, K; Naganuma, J; Teruya, M; Yanagida, O, 2002) |
| "Presence of metastases and pretreatment extent of disease system grouping at diagnosis had an adverse influence on overall survival in multivariate analysis." | ( Aronson, D; Brown, J; Chapchap, P; Czauderna, P; Keeling, J; Mackinlay, G; Otte, JB; Perilongo, G; Plaschkes, J; Pritchard, J; Shafford, E, 2002) |
| "In a hepatic metastasis model, mice treated with an intravenous administration of both AdCD (2 x 10(8) pfu) and an intermediate dose of AdmIL-2 (1 x 10(6) pfu) demonstrated the most significant reduction of metastatic foci and the longest survival following a 5-FC administration." | ( Hamada, H; Iwahashi, M; Nakamori, M; Terasawa, H; Tsunoda, T; Ueda, K; Yamaue, H, 2002) |
| "Osteolytic bone metastasis is a frequent problem in the treatment of cancer." | ( Akedo, H; Iwasaki, T; Mukai, M; Nakamura, H; Tatsuta, M; Terada, N; Tsujimura, T, 2002) |
| "Many patients who develop metastases are offered systemic chemotherapy to try to extend survival and maintain or improve quality of life." | ( , 2002) |
| "The therapy prevented metastasis, eradicated established metastases in some mice, and prolonged the survival of tumor-bearing mice." | ( Dong, Z; Lu, W; Zhang, F, 2002) |
| "11 (44%) patients showed cerebral metastases prior to therapy with temozolomide." | ( Christophers, E; Frick, S; Haacke, TC; Hauschild, A; Lischner, S; Rosien, F; Schäfer, F, 2002) |
| "Analysis of pulmonary metastases revealed that combined therapy also had a more potent antimetastatic effect than each modality alone." | ( Gorelik, E; Huang, X; Laird, AD; Watkins, S; Wolf, SF; Wong, MK; Yi, H, 2002) |
| "Solitary brain metastases were to be resected before chemotherapy." | ( Bains, MS; Bilsky, M; Downey, RJ; Ginsberg, R; Heelan, R; Kris, MG; Miller, VA; Ng, KK; Rusch, VW, 2002) |
| "Primary tumor growth and pulmonary metastases were measured to evaluate the effects of treatment with AS alone, CPA alone or the combination of CPA and AS." | ( Beckett, MA; Gupta, VK; Koons, A; Kufe, DW; Lee, JY; Manan, A; Mauceri, HJ; Montag, AG; Park, JO; Schumm, LP; Seetharam, S; Weichselbaum, RR, 2002) |
| "The drug-resistance and metastasis in early stages of human malignant ovarian neoplasm have significant effect on chemotherapy of human ovarian carcinoma." | ( Huang, SG; Jiang, S; Kong, BH; Ma, YY, 2002) |
| "Patients with unresectable distant metastasis are not suitable candidates for surgical resection and intraoperative radiation therapy, whereas those with resectable metastasis are potential candidates." | ( Hashiguchi, Y; Kato, S; Kazumoto, T; Nishimura, Y; Sakamoto, H; Sakura, M; Sekine, T; Tanaka, Y, 2003) |
| "The number of lung metastases of B16 melanoma could be decreased by the daily administration of 1 mg kg(-1) TT-232 or 60 mg kg(-1), but not of 30 mg kg(-1) DTIC." | ( Bökönyi, G; Horváth, A; Kéri, G; Szende, B, 2003) |
| "The incidence of spontaneous lymph node metastasis was inhibited completely by the combination therapy (P < 0." | ( Chikazawa, M; Fukata, S; Inoue, K; Shuin, T; Yoshikawa, C, 2003) |
| "Subsequent distant metastases after PALN treatment developed in 58% (7/12)." | ( Cho, MJ; Kim, JS; Kim, Ki; Kim, SY, 2003) |
| "Finally, in an experimental metastasis model, we show that treatment of tumor cells with the disaccharide markedly reduced their lung colonization potential after injection into severe combined immunodeficient mice." | ( Brown, JR; Esko, JD; Fuster, MM; Wang, L, 2003) |
| "Improved methods of detecting micrometastases may provide a basis for improved planning of postoperative therapy for patients already at risk for tumor recurrence." | ( Barrera, JE; Campana, JP; Jafek, BW; Miller, ME; Said, S; Shroyer, KR, 2003) |
| "In 3 patients, CNS metastases were detected during NEF therapy those who had a partial response in their visceral metastases." | ( Blomqvist, C; Elomaa, I; Joensuu, H, 2003) |
| "Rapid tumor growth and widespread metastases developed in untreated mice within 2 weeks, leading to a median survival of 21 days." | ( Bouvet, M; Hoffman, RM; Katz, MH; Moossa, AR; Spivack, D; Takimoto, S, 2003) |
| "To assess the effect on metastasis, XV454 was administered intravenous or orally 10 minutes and 3 hrs before tumor cell injection, respectively." | ( Amaya, M; Amirkhosravi, A; Blaydes, S; Desai, H; Francis, JL; Meyer, T; Mousa, SA, 2003) |
| "Before chemotherapy, liver metastases were present in 78 (60%) patients and elevated transaminase in 25 (19%)." | ( Bonsignori, M; Delprete, S; La Cesa, A; Marcucci, F; Massacesi, C; Rocchi, MB; Santini, D; Tonini, G; Vincenzi, B, 2003) |
| "27 patients had no metastases at diagnosis; 26 of these were treated with primary chemotherapy combining epirubicin and cisplatin." | ( Bouaziz, M; Daoud, J; Drira, MM; Frikha, M; Ghorbel, A; Jlidi, R; Toumi, N, 2003) |
| "Cytoreductive surgery or radiation of metastases seems beneficial in well-selected patients, especially as immunotherapy is available." | ( Heinzer, H; Huland, E, 2003) |
| "Liver metastases were significantly diminished by the splenic injection of 5-FU, particularly in comparison with the portal injection or systemic administration." | ( Asao, T; Kanoh, K; Kuwano, H; Nomoto, K; Shimura, T; Suzuki, H, 2004) |
| "Ketamine increased metastasis most potently, and this effect was markedly reduced in rats pretreated with a beta-adrenergic antagonist (nadolol) or with chronic small doses of an immunostimulator (polyriboinosinic:polyribocytidylic acid)." | ( Bar-Yosef, S; Ben-Eliyahu, S; Melamed, R; Shakhar, G; Shakhar, K, 2003) |
| "Patients with measurable liver metastases of colorectal cancer with World Health Organization performance status (WHO PS) <2 were treated with a 5-day continuous infusion of hepatic arterial irinotecan every 3 weeks at a dose of 20 mg/m(2)/day." | ( de Greve, J; Giaccone, G; Gruia, G; Pinedo, HM; van Groeningen, CJ; van Riel, JM, 2004) |
| "In patients with or without visceral metastases, second-line treatment with anastrozole resulted in a CB rate of 31." | ( Howell, A; Robertson, JF; Vergote, I, 2003) |
| "As long as metastasis is confined to one organ system and is removable, surgery remains the treatment of first choice." | ( Eigentler, TK; Garbe, C, 2004) |
| "The total number of lung metastases was 19 in control group and 10 in vitamin C and K(3)-treated mice." | ( Calderon, PB; Gilloteaux, J; Jamison, JM; Summers, JL; Taper, HS, 2004) |
| "In alkylglycerol-treated mice, metastasis dissemination was reduced by 64 +/- 8%, whereas SLO effect was 30 +/- 9% below control." | ( Le Lan, J; Leduc, C; Legrand, AB; Legrand, P; Martin, B; Moulinoux, JP; Pedrono, F; Saïag, B, 2004) |
| "Bone metastases were reduced by the ZOL treatment." | ( Hiraga, T; Tamura, D; Ueda, A; Williams, PJ; Yoneda, T, 2004) |
| "Mice carrying brain metastases of the human, highly angiogenic melanoma cell line Mel57-VEGF-A were either or not treated with different dosages of ZD6474, a vascular endothelial growth factor (VEGF) receptor 2 tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor." | ( de Waal, R; Heerschap, A; Küsters, B; Leenders, WP; Maass, C; Ruiter, D; Ryan, A; Verrijp, K; Wesseling, P, 2004) |
| "Placebo-treated Mel57-VEGF-A brain metastases evoked an angiogenic response and were highlighted in CE-MRI." | ( de Waal, R; Heerschap, A; Küsters, B; Leenders, WP; Maass, C; Ruiter, D; Ryan, A; Verrijp, K; Wesseling, P, 2004) |
| "Visible metastases were observed in the lungs of animals from control and cisplatin-treated groups but not in animals from the alpha-TEA- or alpha-TEA + cisplatin-treated groups." | ( Anderson, K; Kline, K; Lawson, KA; Sanders, BG; Simmons-Menchaca, M; Sun, L, 2004) |
| "In a mouse model of liver metastasis, we administered B717/LIC-101 by bolus intravenous injection, adjusting the rate and volume of administration to what is feasible in human therapy." | ( Hirabayashi, K; Irimura, T; Ishiyama, K; Kashimori, I; Kitagawa, H; Naito, H; Nakagawa, S; Nogawa, M; Ohgi, T; Yamaguchi, T; Yano, J, 2004) |
| "To assess the role of SDF-1/CXCR4 in metastasis, bone metastases were established by administering CaP cells into the left cardiac ventricle of nude animals in the presence or absence of neutralizing CXCR4 antibody." | ( Cook, K; Dai, J; Jung, Y; Keller, ET; Koh-Paige, AJ; McCauley, LK; Osman, NI; Pienta, KJ; Schneider, A; Shim, H; Sun, YX; Taichman, RS; Wang, J, 2005) |
| "A phase II study evaluating the metastasis complete response rate after induction chemotherapy was conducted in patients who had positive metastatic sites on MIBG scans at diagnosis." | ( Bergeron, C; Bernard, F; Boneu, A; Bouzy, J; Chastagner, P; Coze, C; Hartmann, O; Michon, J; Perel, Y; Plantaz, D; Rodary, C; Rubie, H; Valteau-Couanet, D, 2005) |
| "The 5-year distant metastasis-free survival rate, with and without adjuvant chemotherapy, was 97% and 96%, respectively." | ( Chan, KY; Cheng, SH; Chong, V; Chu, NM; Feng, AC; Hong, CF; Hsieh, CY; Huang, AT; Jian, JJ; Lin, CY; Lin, YC; Tan, TD; Tsai, SY; Yen, KL, 2005) |
| "Melanoma patients having liver metastases were treated with IL-2 with or without HDC within a randomized, multicenter, phase III trial." | ( Asemissen, AM; Gehlsen, K; Hellstrand, K; Keilholz, U; Letsch, A; Scheibenbogen, C; Schmittel, A; Thiel, E; Thorén, F, 2005) |
| "In vivo, metastasis to the liver was significantly inhibited by pretreatment of the cells with MIF siRNA." | ( Kondo, M; Nishihira, J; Sasaki, F; Sato, Y; Sun, B; Todo, S; Yoshiki, T, 2005) |
| "Given the early steps of metastasis in which tumour cells interact with endothelial cells of blood vessels, and, given the independent prognostic value in breast cancer of both the quantification of tumour vascularisation and the detection of micrometastases in the bone marrow, the aim of this study was to determine the relationship between vascularisation, measured by Chalkley morphometry, and the bone marrow content of cytokeratin-19 (CK-19) mRNA, quantified by real-time reverse transcriptase polymerase chain reaction, in a series of 68 patients with localised untreated breast cancer." | ( Benoy, IH; Dirix, LY; Elst, H; Salgado, R; Scharpé, S; Van Dam, P; Van Marck, E; Vermeulen, PB; Weyler, J, 2005) |
| "Because of systemic metastases, only palliative treatment, consisting of an excision of the lesion for local hygiene, could be offered." | ( Beustes-Stefanelli, M; Cornu, H; Hoefler, P; Merle, M; Porte, B, 2005) |
| "Five patients with unresectable liver metastases who had failed multiple prior chemotherapy regimens received seven 90Y microsphere treatments to a single liver lobe." | ( Amesur, N; Avril, N; Bienert, M; Carr, BI; Geller, DA; McCook, B; Sheetz, M; Tutor, C, 2005) |
| "The SUVs in the 30 treated liver metastases decreased from 6." | ( Amesur, N; Avril, N; Bienert, M; Carr, BI; Geller, DA; McCook, B; Sheetz, M; Tutor, C, 2005) |
| "Sizeable metastases positively stained for PSA and limited air gaps were found in lungs of untreated mice." | ( Blank-Porat, D; Cutts, SM; Entin-Meer, M; Levovich, I; Malik, Z; Nudelman, A; Phillips, DR; Rephaeli, A; Tarasenko, N, 2005) |
| "Lung metastasis incidence was reduced (16-70%) by all treatments, significantly in the FS and SDG + FO groups." | ( Chen, J; Thompson, LU; Wang, L, 2005) |
| "Patients with skeletal metastases from hormone-refractory prostate cancer have shown variable responses to high-activity therapy with (186)Re-HEDP and peripheral stem cell support." | ( Binnie, D; Dearnaley, D; Divoli, A; Flux, G; McCready, VR, 2005) |
| "Tumor growth and incidence of metastases were significantly reduced in all treated mice." | ( Adrian, TE; Bell, RH; Ding, XZ; Hennig, R; Iwamura, T; Jovanovic, BD; Rao, SM; Segersvard, R; Talamonti, MS; Ventura, J; Ward, E, 2005) |
| "Liver metastases were completely inhibited (0/10) in the pre-AS treatment, while they occurred in 4 out of 10 and 5 out of 10 mice in the post-AS treatment and the control groups, respectively (p<0." | ( Mai, M; Takahashi, Y, 2005) |
| "While in control mice metastases in lung, liver and in intestine were prevailing, liposomal treatment resulted in a new localization of metastases in muscles." | ( Fichtner, I; Keil, C; Zeisig, R, 2005) |
| "In the metastasis model with A549 cells, the lung weight in the M475271 (50 mg/kg)-treated group was less than that of the control group, despite no difference in the number of metastatic nodules." | ( Matsumori, Y; Muguruma, H; Nakataki, E; Sone, S; Yano, S; Yoshizumi, M; Zheng, R, 2005) |
| "Lung metastasis is the most crucial event affecting the treatment of osteosarcoma and is dependent on tumor angiogenesis." | ( Hioki, Y; Kusuzaki, K; Matsumine, A; Seto, M; Sonoda, J; Tomoda, R; Uchida, A, 2005) |
| "In the experimental lung metastasis xenograft models, treatment with bexarotene inhibited the development of the lung tumour nodule formation compared to control." | ( Corpuz, MR; Lamph, WW; Negro-Vilar, A; Prudente, RY; Yen, WC, 2006) |
| "Treatment options for metastases of differentiated thyroid carcinoma (DTC) are limited due to decreased uptake of radioiodide (I-131)." | ( Corssmit, EP; Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP, 2006) |
| "Twelve patients with metastases of DTC, with insufficient uptake of I-131, received 6 weeks of treatment with 300 mg bexarotene/day." | ( Corssmit, EP; Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP, 2006) |
| "To improve the detectability of lung metastases, an experimental blood-borne lung metastases model in mice was established using intravenously administered HSV1-tk-expressing NG4TL4 fibrosarcoma cells (NG4TL4-TK) and simulated the clinical application of HSV1-tk plus ganciclovir (GCV) prodrug activation gene therapy." | ( Deng, WP; Fu, YK; Gelovani, JG; Hwang, JJ; Lee, CC; Liu, RS; Wang, HE; Wei, HJ; Wu, CC; Wu, CW; Yang, DM; Yang, WK, 2006) |
| "Since modern treatment of liver metastases includes serial hepatectomies and portal vein obstruction, we investigated the effects of portal vein ligation (PVL) and partial hepatectomy (PH) on tumor growth." | ( Clavien, PA; Graf, R; Heinrich, S; Jochum, W, 2006) |
| "The number of lung metastases detected by a computerized image analyzer was reduced, compared to untreated animals, by about 69% in NG-treated mice and by about 36% in HP-treated mice." | ( Beninati, S; Forni, C; Lentini, A; Provenzano, B, 2007) |
| "Radiotherapy of metastasis yielded to long-term survival." | ( Daoud, J; Drira, MM; Frikha, M; Ghorbel, A; Karray, H; Khanfir, A, 2006) |
| "Distant metastasis is one of the main causes of treatment failure in nasopharyngeal carcinoma (NPC)." | ( Han, F; Hou, X; Huang, PY; Li, S; Lu, LX; Shao, JY; Zhang, L; Zhao, C, 2006) |
| "It has a tendency to metastasise to regional or distant sites after incomplete treatment." | ( Chen, CT; Lou, PJ; Wang, CP; Yang, TH, 2007) |
| "Inhibitors of tumor angiogenesis and metastasis are increasingly emerging as promising agents for cancer therapy." | ( Chen, Y; Ding, J; Geng, M; Hou, Y; Li, J; Liu, H; Xie, C; Xin, X; Zhang, X; Zhang, Z; Zhao, H, 2006) |
| "Under the diagnosis of multiple lung metastases, the patient was hospitalized and received intensive chemotherapy with docetaxel 40 mg/week (day 1), 5-fluorouracil 500 mg/day (days 1-5), cisplatin 10 mg/day (days 1-5)." | ( Honda, J; Miyoshi, T; Seike, J; Tangoku, A; Umemoto, A; Yoshida, T, 2006) |
| "Due to ongoing osseous metastases, in November/December 1992 a radiotherapy of the right hip (50 Gy) was performed." | ( Adams, S; Baum, RP; Breidert-Backes, I; Hör, G, 1997) |
| "Intracranial metastasis in GTN is a curable disease that carries compromised survival because of difficulty in implementing the treatment regimen, patient noncompliance and late diagnosis." | ( Cagayan, MS; Lu-Lasala, LR, 2006) |
| "TF-Ag is important in adhesion and metastasis and as a potential immunotherapy target." | ( Glinskii, OV; Glinsky, VV; Heimburg, J; Huxley, VH; Klick, R; Morey, S; Rittenhouse-Olson, K; Roy, R; Wild, L; Yan, J, 2006) |
| "DFMO did not affect pulmonary metastasis when primary tumors of control and DFMO-treated mice were matched for size." | ( Bruggeman, R; Demers, LM; Griffith, JW; Jun, JY; Manni, A; Verderame, MF; Washington, S, 2007) |
| "In the in vivo metastasis models, parthenolide treatment suppressed lung metastasis when treatment was initiated concurrently with s." | ( Kishida, Y; Myoui, A; Yoshikawa, H, 2007) |
| "Allodynia induced by bone metastasis was attenuated by treatment with (186)Re-MAG3-HBP or (186)Re-HEDP, but (186)Re-MAG3-HBP tended to be more effective." | ( Asano, D; Hashimoto, K; Kawashima, H; Kinuya, S; Mori, H; Mukai, T; Ogawa, K; Saji, H; Shiba, K, 2007) |
| "In this experiment, the lung metastasis model of murine colon adenocarcinoma (C26) was established in 6- to 8- weeks of age female BALB/c mice, and then treated with 0." | ( Cai, BW; Chen, J; Hui, XH; Li, H; Wang, W; Zhu, B, 2007) |
| "Significant inhibition of migration, metastasis, vasculogenicity, and angiogenesis was recorded after treatment of Ewing's sarcoma cells with NVP-AEW541." | ( García-Echeverría, C; Hofmann, F; Landuzzi, L; Lollini, PL; Manara, MC; Nanni, C; Nanni, P; Nicoletti, G; Picci, P; Scotlandi, K; Zambelli, D, 2007) |
| "DFMO did not affect pulmonary metastasis when primary tumors of control and DFMO-treated mice were matched for size." | ( Bruggeman, R; Demers, LM; Griffith, JW; Jun, JY; Manni, A; Verderame, MF; Washington, S, 2008) |
| "Lymph node metastasis was significantly reduced in both the ZD6474 alone and combined treatment groups, with 3/10 and 1/5 animals developing metastases, compared with 10/10 and 9/9 in the control and gemcitabine groups (P<0." | ( Barge, A; Bruns, CJ; Conrad, C; Geissler, EK; Guba, M; Ischenko, I; Jauch, KW; Köhl, G; Ryan, AJ; Wedge, SR; Wiegand, U; Yezhelyev, M, 2007) |
| "We report a case of hepatic metastasis from an unknown primary, where treatment with Y-90 microspheres was the only available option due to inoperability and low tolerance to chemotherapy." | ( AL-Nahhas, A; Canelo, R; Gishen, P; Stamp, G; Tait, P; Tehranipour, N; Woo, K, 2007) |
| "Identification of regional node metastasis is important for accurate staging and optimal treatment of early melanoma." | ( Essner, R; Huynh, Y; Lee, JH; Morton, DL; Scheri, RP; Torisu-Itakura, H; Ye, X, 2007) |
| "GC therapy had a better impact on metastases in the lung and lymph nodes than on metastases in the liver and bone." | ( Aoki, K; Ikeda, T; Kikugawa, T; Ochi, T; Ozawa, A; Shimamoto, K; Tanji, N; Toshino, A; Yamaguchi, A; Yanagihara, Y; Yokoyama, M, 2007) |
| "Because both types of metastases can occur in breast cancer, bone scintigraphy and FDG-PET should be considered as complementary and can currently be regarded as standard of care for staging in breast cancer patients, whereas the decision to use F-18 fluoride PET should be made individually for each patient, depending on the expected change of therapy management." | ( Schirrmeister, H, 2007) |
| "Treatment of 'metastasis', in retrospect, usually involves minimal residual disease and therapy naïve tumors." | ( Kerbel, RS; Man, S; Munoz, R, 2007) |
| "Detection of micrometastasis in peripheral blood may possess a prognostic significance after definitive chemo-radiation therapy." | ( Chen, TF; Fu, XL; Jiang, GL; Qian, H; Wang, LJ; Wu, KL; Zhang, YQ; Zhao, S, 2007) |
| "After 8 cycles, all metastases responded, and this therapy is now being continued (19 cycles) on an outpatient basis." | ( Furukawa, K; Iida, S; Iwasaki, R; Naito, Z; Noguchi, T; Sugisaki, Y; Tajiri, T; Tsuchiya, S; Yanagihara, K; Yokoyama, T, 2007) |
| "alphaPlGF inhibited growth and metastasis of various tumors, including those resistant to VEGF(R) inhibitors (VEGF(R)Is), and enhanced the efficacy of chemotherapy and VEGF(R)Is." | ( Autiero, M; Carmeliet, P; Chorianopoulos, E; Collen, D; De Mol, M; Dewerchin, M; Fischer, C; Giacca, M; Jonckx, B; Koch, M; Liesenborghs, L; Loges, S; Mazzone, M; Moons, L; Pattarini, L; Plaisance, S; Stassen, JM; van Rooijen, N; Wyns, S; Zacchigna, S, 2007) |
| "Eight patients with metastases of DTC, with insufficient uptake of I-131 who showed increased uptake of radioiodine after previous treatment with bexarotene were treated with radioiodine (7400 MBq), preceded by 6 weeks of treatment with bexarotene 300 mg/day." | ( Liu, YY; Morreau, HA; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP, 2008) |
| "It reduced metastasis formation in mice by approximately 90% when administered by a repetitive once daily dosing regimen of 50 mg/kg via oral or intraperitoneal routes and was nontoxic up to 500 mg/kg, following intraperitoneal administration daily for two weeks." | ( Bhusare, SR; Breuer, E; Frant, J; Hadar, R; Hoffman, A; Katz, Y; Qadri, B; Reich, R, 2008) |
| "Of the 539 patients with bone metastases treated in our department from June 2002 to December 2006 with i." | ( Amadori, D; Barbanti, F; Giorgio-Marrano, G; Ibrahim, T; Mercatali, L; Ronconi, S; Vicini, C, 2008) |
| "Survival after metastasis was reduced among NQO1(*)2 homozygotes, further implicating NQO1 deficiency in cancer progression and treatment resistance." | ( Aaltonen, K; Aittomäki, K; Bartek, J; Bartkova, J; Blomqvist, C; Eskelinen, M; Fagerholm, R; Heikkilä, P; Hofstetter, B; Holli, K; Kallioniemi, A; Kataja, V; Kilpivaara, O; Kosma, VM; Lukas, J; Mannermaa, A; Nevanlinna, H; Syrjäkoski, K; Tommiska, J; Uusitupa, M; von Smitten, K; Vrtel, R, 2008) |
| "Tumor invasion into adjacent organs and metastasis were not observed in the DMAPT/celecoxib treatment groups." | ( Crooks, PA; Holcomb, B; Neelakantan, S; Njoku, V; Ralstin, M; Schmidt, CM; Sweeney, CJ; Wu, H; Yip-Schneider, MT, 2008) |
| "Tumour volume and the incidence of metastasis in nude mice injected with UM-UC-3R cells was significantly greater than those of nude mice injected with UM-UC-3P cells; however, systemic administration of OGX-011 plus a low dose of gemcitabine significantly suppressed tumour volume and the incidence of metastasis in both groups." | ( Fujisawa, M; Gleave, ME; Hayashi, N; Miyake, H; Muramaki, M; So, A; Sowery, R, 2009) |
| "When the hepatic metastases disappeared after 13 courses, the primary MCN was removed surgically after 16 courses of GEMOX treatment." | ( Hamada, K; Horiuchi, R; Igarashi, R; Obayashi, K; Ohwada, S; Sunose, Y; Takeyoshi, I; Yamamoto, K, 2008) |
| "Formation of lung and extrapulmonary metastases after intravenous administration of MT3 breast cancer cells was significantly reduced when mice were treated with a single intravenous dose of DIP/OPP-L containing 100nmol lipid 6h before tumour cell inoculation." | ( Fichtner, I; Wenzel, J; Zeisig, R, 2009) |
| "/ Against metastases to orbital foramen, chest wall and bone, the oral treatment with S-1 was started at 80 mg/day everyday for 4 weeks, followed by a 2-week rest interval as 1 cycle, and ZOL was injected at 4 mg every 4 weeks." | ( Arita, K; Hiranuma, S; Kuramochi, J; Kurokawa, T; Matsumoto, A; Sanada, K; Takiguchi, N; Tanaka, Y; Usui, S, 2009) |
| "E(2)-induced metastasis is associated with activation of p42/44 MAPK and is completely inhibited by treatment with the MEK1/2 inhibitor, CI-1040." | ( Ariazi, EA; Astrinidis, A; Henske, EP; Hensley, H; Hernandez-Cuebas, L; Jordan, VC; Karbowniczek, M; Morrison, TA; Nicolas, E; Robb, VA; Seeholzer, LF; Walker, CL; Wang, C; Yu, JJ, 2009) |
| "Brain metastasis has become an increasing cause of morbidity and mortality in cancer patients as the treatment of systemic disease has improved." | ( JuanYin, J; Kelly, K; Koretsky, A; Munasinghe, J; Shapiro, E; Tracy, K; Zhang, L, 2009) |
| "The experimental metastasis was shown to develop differently in mice with opposing social experience: saline-treated winners had significantly less metastases in the lung than the saline-treated losers." | ( Avgustinovich, DF; Il'nitskaia, SI; Kaledin, VI; Kudriavtseva, NN; Nikolin, VP; Popova, NA, 2009) |
| "Tumor growth and metastasis were checked after the 4-week treatment." | ( Ge, YS; Jia, WD; Li, JS; Ma, JL; Wang, W; Wang, ZH; Xu, GL, 2009) |
| "Although the treatment of extrahepatic metastases from primary liver tumors is essentially palliative, a solitary metastasis from such tumors offers a possibility of cure by surgical resection." | ( Cuervas-Mons, V; Gimenez, L; González, J; Jimenéz, M; Lucena, JL; Martinez Arrieta, F; Rubio, E; Turrión, VS, 2009) |
| "Seventeen patients (77%) had liver metastases and an equal number had received prior chemotherapy and/or interferon-alfa for recurrent disease." | ( Kellokumpu-Lehtinen, P; Skyttä, T; Tyynelä, K; Vihinen, P; Vuoristo, MS, 2009) |
| "In addition, an in vivo experimental metastasis model also showed that treatment with the drugs resulted in a significantly lower number of metastatic pulmonary nodules relative to control mice." | ( Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Liu, WM; Meyer, B, 2009) |
| "Furthermore, decreased metastasis was observed with double suicide gene treatment." | ( Cheng, XD; Hao, X; Hu, XB; Su, MQ; Yang, L; Yin, Y; Yue, QH; Zhou, TC, 2009) |
| "She developed distant metastases immediately after completing adjuvant chemotherapy following surgery, which were detected by an [18F] 2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan." | ( Hama, Y; Nakagawa, K, 2013) |
| "Two patients with brain metastasis from NSCLC developed brain hemorrhage after gefitinib therapy." | ( Liao, XB; Liu, JQ; Sun, XL; Wang, YX; Yan, DF; Yan, SX; Yang, JS, 2010) |
| "The ability to study spontaneous micrometastases in the absence of a primary tumor is important since this is the manner in which most patients are treated clinically." | ( Duval, DL; Ehrhart, EJ; Sottnik, JL; Thamm, DH, 2010) |
| "Prevention of metastasis is an important aspect of successful treatment; however, it is known that metastasis can be induced by different treatment modalities." | ( Cemazar, M; Flisar, K; Glavac, D; Mlakar, V; Sersa, G; Todorovic, V, 2011) |
| "In light of the pro-metastasis function, many strategies are currently being explored to antagonise the TGF-beta pathway as a treatment for metastatic cancers." | ( Kang, Y; Korpal, M, 2010) |
| "Complete macroscopic resections of metastases in liver, lung or other abdominopelvic sites were performed following tumor downstaging by the treatment regimen in 11 patients (21%), 8 of whom being alive at 3 years." | ( Adam, R; Bouchahda, M; Giacchetti, S; Gorden, L; Guettier, C; Hauteville, D; Innominato, PF; Karaboué, A; Lévi, F; Saffroy, R, 2011) |
| "Doxorubicin treatment alone enhanced metastasis to lung in the human breast cancer MDA-MB-231 orthotopic xenograft model and metastasis to bone in the 4T1 orthotopic xenograft model, which was significantly blocked when TbetaR1-KI was administered in combination with doxorubicin." | ( Agyin, J; Bandyopadhyay, A; De, K; Lin, S; Sun, LZ; Tang, Y; Wang, L; Yeh, IT, 2010) |
| "Therapy was stopped mainly due to metastasectomy or tumour progression (7 patients each)." | ( Cathomas, R; Köberle, D; Lanz, D; Popescu, R; Roth, A; Ruhstaller, T; Simcock, M; Uhlmann, C; von Moos, R; Widmer, L, 2010) |
| "Fibrosarcomas without metastasis were the only tumours observed in the MCA-treated quail, while quail treated with JM16 and MCA developed undifferentiated tumours, fibrosarcomas, lymphosarcomas or combinations with or without metastasis." | ( Blackmore, C; Mondal, SP; O'Connell, P; Schat, KA; Wakenell, PS, 2010) |
| "Median survival of patients with brain metastases from nonsmall cell lung cancer (NSCLC) is poor and more effective treatments are urgently needed." | ( Catot, S; Colomer, R; de Castro, J; Guillem, V; Gúrpide, A; Isla, D; Lianes, P; Massutí, B; Mayo, C; Paz-Ares, L; Polo, E; Porta, R; Pradas, A; Puig, T; Queralt, C; Reguart, N; Rosell, R; Salinas, P; Sánchez-Torres, JM; Tarón, M, 2011) |
| "Treatment and prevention of bone metastases is a major problem in patients with cancer." | ( Lipton, A, 2010) |
| "Understanding the biology of bone metastases has uncovered many new potential therapies for the treatment and prevention of bone metastases." | ( Lipton, A, 2010) |
| "To investigate the incidence of scalp metastases in high-risk breast cancer patients in order to assess whether caution is warranted with scalp cooling during adjuvant therapy." | ( Breed, WP; Nortier, JW; van de Sande, MA; van den Hurk, CJ, 2010) |
| "Since metastases, the prevailing deadliest pathologic feature of cancer in clinics, have been the main obstacle in cancer therapy, antimetastatic effects and mechanisms of Biz compounds are interesting and significant topics of all time for researchers undergoing the investigations of metastases biology, treatments and patho-physiology." | ( Lu, DY; Lu, TR, 2010) |
| "It increases liver metastasectomies rate and can be safely administered." | ( Antonucci, A; Baldi, PL; Bruera, G; Cannita, K; De Galitiis, F; Ficorella, C; Mancini, M; Marchetti, P; Ricevuto, E; Santomaggio, A; Tudini, M, 2010) |
| "RECK functions as a metastasis suppressor in CCA; upregulation of RECK expression could provide a potential therapy to improve the prognosis of this type of cancer." | ( Khuntikeo, N; Loilome, W; Namwat, N; Puapairoj, A; Puetkasichonpasutha, J; Sripa, B; Tassaneeyakul, W; Techasen, A; Wongkham, S; Yongvanit, P, 2011) |
| "A new metastasis during the treatment is considered a sign of drug failure and alternative therapeutic methods should be tried." | ( Board, R; Hawkins, R; O'Dwyer, J; Shablak, A, 2011) |
| "To seek therapies targeting metastasis for cancer treatment, we developed a novel ST inhibitor, Lith-O-Asp, and investigated its antimetastatic and antiangiogenic effects and mechanisms." | ( Balraj, G; Chang, TT; Chen, JY; Cheng, HC; Huang, SM; Juan, HF; Li, WS; Sun, YC; Tang, YA; Wang, SC; Wang, YC; Wu, KW; Wu, LW, 2011) |
| "Survival following diagnosis of liver metastasis remains poor and improved treatment strategies to combat liver metastases are needed." | ( Chambers, AF; Dales, DW; Foster, PJ; Hedley, BD; Liby, KT; Macdonald, IC; Mackenzie, L; Sporn, MB; Townson, JL, 2011) |
| "Multiorgan metastasis of drug-resistant 4T1 breast tumors was totally resistant to doxorubicin treatment." | ( Bao, L; Dash, S; Haque, A; Hazari, S; Jackson, K; Jetly, R; Moroz, K, 2011) |
| "She developed lung metastases 2 years thereafter, but survived free of relapse for 8 years following chemotherapy and pulmonary lobectomy." | ( Morioka, T; Niikura, N; Okamura, T; Saito, Y; Suzuki, Y; Terada, M; Terao, M; Tokuda, Y; Tsuda, B, 2010) |
| "The potential for metastasis makes recognition of CHRCC cells in cytologic preparations important for patient surveillance, management, and treatment." | ( Davion, S; Kulesza, P; Nayar, R; Rohan, S, 2012) |
| "Understanding drivers for metastasis in human cancer is important for potential development of therapies to treat metastases." | ( Brattain, LE; Brattain, MG; Chowdhury, A; Chowdhury, S; Howell, GM; Rajput, A; Teggart, CA; Weber, HR, 2011) |
| "Therefore, the inhibition of metastasis in human osteosarcoma cells by treatment with this novel agent, LJJ-10 may be a useful chemotherapeutic approach." | ( Chen, KT; Chiu, YJ; Chuang, YH; Chung, JG; Hour, MJ; Kuo, SC; Lu, CC; Tsai, SC; Yang, JS, 2011) |
| "After resection of CRC and synchronous metastases, 53 (84%) out of 63 patients without chemotherapy, and 38 (83%) out of 46 that received 5-fluorouracil (5-FU) alone or with leucovorin (LV) developed recurrent tumors." | ( Kanazawa, T; Kawai, K; Kazama, S; Kitayama, J; Mori, K; Nagawa, H; Nozawa, H; Saito, S; Sunami, E; Yazawa, K, 2011) |
| "This may provide a novel approach for metastasis therapy of lung cancer by dietary isothiocyanates and possibly other types of cancer." | ( Li, Y; Liu, B; Wu, H; Wu, X; Xu, K; Yan, H; Zhou, Q; Zhu, Y, 2011) |
| "Patients with progression of metastases after pretreatment have short survival and are unlikely to benefit from CN." | ( Bex, A; Blank, C; Haanen, J; Horenblas, S; Meinhardt, W; van Tinteren, H, 2011) |
| "Inhibition of bone metastasis gene was displayed to some extent in all the tested groups treated with CFPC, showing an increased level of OPG mRNA expression (It was 60." | ( Chen, XF; Sheng, L; Wu, CY, 2011) |
| "Anti-metastasis therapy based on RNA interference (RNAi) is emerging as one of promising strategies in tumor therapy." | ( Ji, Y; Kong, H; Li, X; Meng, J; Wu, X; Xu, H; Zhang, W, 2011) |
| "In vivo, rHuEPO increased lung metastases in immunocompromised mice injected with MDA-MB-231 or MDA-MB-435 cells and treated with chemotherapy relative to mice treated with chemotherapy alone (P < 0." | ( Allan, AL; Beausoleil, MS; Boasie, A; Chu, JE; Hedley, BD; Ormond, DG; Xenocostas, A, 2011) |
| "In in vivo spontaneous pulmonary metastasis model employing intravenously injected CT26 mouse colon cancer cells in Balb/c mice, pinosylvin (10 mg/kg body weight, intraperitoneal administration) significantly inhibited the formation of tumor nodules and tumor weight in lung tissues." | ( Ahn, YH; Chung, HJ; Hong, JY; Kang, YJ; Lee, SK; Min, HY; Park, EJ; Park, HJ; Pyee, JH; Shin, Y, 2012) |
| "Multidrug resistance and cancer metastases are two obstacles to a successful chemotherapy and metastases are closely associated with drug resistance." | ( Ju, RJ; Li, N; Li, RJ; Lu, WL; Wang, XX; Wang, ZH; Yao, HJ; Yu, Y; Zhang, L; Zhang, Y; Zhou, J, 2012) |
| "The inability to diagnose small volume metastases early has limited effective treatment of stage 4 breast cancer." | ( Arami, H; Disis, ML; Ellenbogen, RG; Kievit, FM; Lai, VP; Park, JO; Stephen, ZR; Veiseh, O; Wang, T; Zhang, M, 2012) |
| "Three patients with metastasising squamous-cell carcinoma of the cervix are presented who entered long-term complete remission after treatment with cisplatinum and etoposide." | ( Bouvy, JJ; Braun, JJ; Ruit, JB, 2011) |
| "Here we present a man with pancreatic metastases from PTC, report our experience with sorafenib therapy, and discuss the role of endoscopic ultrasound (EUS)-guided biopsy in its diagnosis." | ( Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS, 2012) |
| "Time from metastasis to first-line chemotherapy was longer in the capecitabine group (52 vs." | ( Anderson, R; Balkrishnan, R; Camacho, F; Kamal, AH; Kimmick, G; Wei, W, 2012) |
| "Eight had previously treated brain metastases." | ( Gooding, WE; Kirkwood, JM; Leng, S; Lin, Y; Moschos, SJ; Sander, C; Tarhini, AA; Yin, Y, 2012) |
| "Moreover, T(3)-enhanced metastasis in vivo was repressed by the treatment of TRAIL-blocking antibody." | ( Chen, CY; Chen, SL; Chen, WJ; Chi, HC; Chung, IH; Huang, YH; Liao, CH; Liao, CJ; Lin, KH; Lin, YH; Tsai, CY; Tsai, MM; Tseng, YH; Wu, SM; Yeh, CT, 2012) |
| "Distant metastasis is the major cause of treatment failure." | ( Bao, YN; Chen, S; Chen, ZY; Kang, TB; Li, XJ; Lu, WH; Peng, LX; Qian, CN; Shao, JY; Teh, BT; Xiang, YQ; Zeng, MS; Zeng, YX; Zhang, JX; Zheng, FJ, 2012) |
| "Because metastasis is the major cause of cancer mortality, we measured cell migration activity and profiled metastasis-related gene expressions in HDACi-treated cancer cells." | ( Chen, CT; Ho, CM; Jou, YS; Lin, KT; Su, WH; Wang, YW, 2012) |
| "Tumor metastasis was also enhanced in HDACi-treated mice." | ( Chen, CT; Ho, CM; Jou, YS; Lin, KT; Su, WH; Wang, YW, 2012) |
| "However, increased metastasis occurred only upon administration of a very high sunitinib dose, but not when lower, clinically relevant doses were used." | ( Bird, D; Erler, JT; Foo, S; Foster, J; Frentzas, S; Gourlaouen, M; Mather, SJ; Pili, R; Powles, T; Preece, N; Reynolds, AR; Robertson, D; Sharpe, K; Soffe, J; Springer, CJ; van Weverwijk, A; Welti, JC, 2012) |
| "Dose-dependent anti-metastasis activity and blockage of vascular endothelial growth factor receptor 1 (VEGFR1) binding following treatment with BVOE were confirmed by cell migration assays and immunoblots to detect decreased expression of matrix metalloproteinases (MMP-9)." | ( Chidambara Murthy, KN; Jayaprakasha, GK; Patil, BS, 2012) |
| "Breast cancer metastasis is more resistant to chemotherapy and radiotherapy than is cancer of the visceral tissues; therefore, new treatment strategies are urgently needed." | ( Chang, LH; Chang, YL; Chen, CC; Pai, HC; Pan, SL; Peng, CY; Shen, CC; Teng, CM, 2013) |
| "Peritoneal metastasis is treated more effectively by this regimen than other forms of metastases." | ( Chen, Y; Cui, Y; Feng, Y; Li, Q; Liu, T; Wang, Y; Yu, Y, 2013) |
| "The presence of bone metastases in patients with metastatic renal cell carcinoma treated with oral tyrosine kinase inhibitors (TKIs) is associated with poorer outcome as compared with patients without bone involvement." | ( Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P, 2012) |
| "Unexpectedly, tumor metastasis was observed in 77% of the subjects treated with RAD001, either alone or as part of the combination treatment." | ( Bison, S; de Jong, M; Koelewijn, SJ; Krenning, EP; Melis, M; Pool, SE; van der Graaf, LM, 2013) |
| "To further characterize the reduced metastasis observed upon PMIP treatment, we conducted motility assays and observed that PMIP inhibits cell motility of breast cancer cells." | ( Bitler, BG; Broka, DM; Horm, TM; Louderbough, JM; Schroeder, JA, 2012) |
| "Studies suggest that patients with metastases limited in number and destination organ benefit from metastasis-directed therapy." | ( Appelbaum, D; Chmura, SJ; Farrey, K; Salama, JK; Solanki, AA; Weichselbaum, RR; Yenice, KM, 2012) |
| "Systemic Neuro2A metastases or human LS174T colon carcinoma metastases in liver were also successfully treated with this combined approach." | ( Anton, M; Cengizeroglu, A; Ellwart, JW; Farkasova, K; Haase, R; Ogris, M; Su, B; Viola, JR; Wagner, E, 2013) |
| "In fact, the metastasis of LLC to mouse lungs is drastically inhibited by preadministration of CS-E or a phage display antibody specific for CS-E." | ( Mizumoto, S; Sugahara, K, 2013) |
| "In breast cancer the development of metastasis is a major turning point in the treatment and outcome of the disease." | ( Chowdry, J; Corfe, BM; Evans, CA; Mackinder, MA; Staton, CA, 2012) |
| "Five distant metastases in 3 patients occurred after the initiation of chemoradiotherapy." | ( Hoshikawa, H; Kishino, T; Mori, N; Mori, T; Nishiyama, Y; Yamamoto, Y, 2013) |
| "Cancer metastasis and immune suppression are critical issues in cancer therapy." | ( Ahmed, H; Bandyopadhyaya, G; Davila, E; Guha, P; Kaczanowska, S; Kalvakolanu, DV; Kaptan, E; Martin, SS; Thompson, K; Vasta, GR, 2013) |
| "Here, we aim to understand how omental metastases differ from primary tumors and how these differences may influence chemotherapy." | ( Brard, L; Brodsky, AS; Collins, C; Comisar, L; Douglass, E; Fischer, A; MacLaughlan, S; Miller, DH; Smith, PJ; Steinhoff, M; Vang, S; Wu, HT, 2013) |
| "In patients with a high risk of distant metastases and suitable for systemic salvage therapy, a positive lesion must be obviously visualized with one of the currently available imaging techniques." | ( Borghesi, M; Brunocilla, E; Castellucci, P; Ceci, F; Fanti, S; Gacci, M; Martorana, G; Nanni, C; Schiavina, R; Vagnoni, V, 2013) |
| "Forty-six patients with oligometastases, defined as five or fewer clinical detectable metastases from any primary site, were treated on a phase I/II trial from February 2007 to September 2010." | ( Chen, CT; Chen, SH; Kao, J; Packer, SH; Schwartz, M; Sung, MW; Tong, CC, 2014) |
| "Several key metastasis-related mediators, such as vascular endothelial growth factor-A, vascular endothelial growth factor-C, and matrix metalloproteinase-9, were inhibited in the presence of etodolac as compared to untreated M2 macrophages." | ( Na, YR; Seok, SH; Son, DI; Yoon, YN, 2013) |
| "Cancer metastasis is a major cause for cancer-related death and inhibiting cancer metastasis is an alternative way to treat cancer." | ( Hu, X; Liu, Z; Zhang, B, 2013) |
| "Tumor metastasis is the main cause of lethality of prostate cancer, because conventional therapies like surgery and hormone treatment rarely work at this stage." | ( Duan, HQ; Guo, W; Jin, M; Kong, D; Ma, SN; Qiu, Y; Wang, R; Zhao, W; Zhou, Q, 2013) |
| "Brain metastases from germ cell tumors (GCT) are rare and treatment has not yet been standardized." | ( Boyle, HJ; Droz, JP; Fléchon, A; Jouanneau, E, 2013) |
| "The clinical data of men with brain metastases from GCT treated in a single cancer hospital from January 1993 to September 2007 were reviewed." | ( Boyle, HJ; Droz, JP; Fléchon, A; Jouanneau, E, 2013) |
| "Treatment for patients with brain metastases at relapse is still not optimal." | ( Boyle, HJ; Droz, JP; Fléchon, A; Jouanneau, E, 2013) |
| "For management of bone pain due to metastasis, she had also undergone stereotaxic radiation therapy of the neck one and a half years earlier and unsealed internal radiation therapy with (89)Sr injection five months prior to the current presentation, Subsequently, myelosuppression progressively worsened and she finally required a blood transfusion." | ( Aotsuka, N; Masuda, S; Matsuura, Y; Utsu, Y; Wakita, H, 2013) |
| "Tumor size and metastasis were monitored to assess the effect of different treatment regimens." | ( He, X; Li, X; Qi, F; Qiu, Y; Zhao, N; Zhu, L, 2013) |
| "Brain metastases are frequently treated with radiation." | ( Allen-Auerbach, M; Chen, W; Czernin, J; DeSalles, AA; Lizarraga, KJ; Phelps, ME; Yong, WH, 2014) |
| "According to treatment, ORR, metastasectomies, PFS and OS were significantly favourable in triplet CT plus targeted agent compared to triplet, respectively: 80%, 40%, 13 months, not reached; 28%, 6%, 8 months, 11 months." | ( Bruera, G; Cannita, K; Ficorella, C; Giordano, AV; Ricevuto, E; Vicentini, R, 2014) |
| "Tumor metastasis is the major cause of treatment failure and poor prognosis of glioma." | ( Cui, G; Lv, L; Wang, Q; Xin, X; Yan, T; Yang, P; Zhang, L; Zhang, N; Zhang, X; Zhang, Y; Zhao, M; Zhu, Y, 2013) |
| "The inhibition of cancer cell metastasis by graphene and graphene oxide might provide new insights into specific cancer treatment." | ( Chen, C; Gao, X; Jia, Y; Wei, T; Yu, M; Zhang, B; Zhao, K; Zheng, J; Zhou, H; Zhou, T, 2014) |
| "The response rate of skin metastasis to eribulin treatment was coherent with systemic responses." | ( Addamo, G; Barbieri, E; Borgonovo, K; Botta, M; Ciccarese, M; Cretella, E; Dazzani, MC; Di Maio, M; Farina, G; Gamucci, T; Girelli, S; La Verde, N; Mentuccia, L; Moretti, A; Pavese, I; Pellegrino, A; Piva, S; Rispoli, AI; Saladino, T; Salesi, N; Traverso, ES; Varese, P; Zuradelli, M, 2013) |
| "The 3-year local recurrence and distant metastasis rates in the adjuvant chemotherapy group were 4." | ( Chang, H; Chen, L; Du, XJ; Gao, YH; Liu, MZ; Peng, HH; Wen, BX; Xiao, L; You, KY; Zeng, ZF; Zhou, GQ, 2013) |
| "An increasing number of treatments of metastases rely on diagnostics and imaging these days." | ( Choi, K; Jeong, SY; Jun, E; Kim, BS; Kim, IS; Kim, K; Ko, HK; Kwon, IC; Na, JH; Park, JH; Park, S; Ryu, JH; Seo, DH; Yeom, HJ; You, DG, 2014) |
| "Histopathology revealed no metastasis in the liver, small intestine and large intestine in any of the animals in the experimental groups; however this process was evident in the lungs and kidneys, being inhibited by melatonin administration." | ( Alves, LC; Batista, AP; da Silva, TG; de Medeiros, PL; dos Santos, FA; Teixeira, ÁA; Teixeira, VW, 2013) |
| "Liver and intrapelvic metastases were found upon examination 6 months after surgery during adjuvant chemotherapy with XELOX plus bevacizumab." | ( Kita, I; Mukubo, H; Nakanuma, S; Sato, N; Takanaka, T; Yasui, T, 2013) |
| "Ki-67 index and liver metastases were the significant prognostic factors for predicting PFS of subsequent lapatinib therapy in the univariate analysis and the multivariate analysis." | ( Bian, L; Du, G; Guo, YF; Jiang, ZF; Li, W; Song, ST; Wang, T; Wu, SK; Zhang, HQ; Zhang, SH, 2014) |
| "Fifty-nine BRAF(V600)-mutant melanoma metastases from patients treated with dabrafenib or vemurafenib were analyzed." | ( Becker, TM; Boyd, SC; Carlino, MS; Fung, C; Haydu, LE; Howle, J; Hyman, J; Kefford, RF; Long, GV; Menzies, AM; Mijatov, B; Pupo, GM; Rizos, H; Saw, R; Scolyer, RA; Thompson, JF, 2014) |
| "Overall, distant-metastasis-free-survival 5 years after treatment was 73%." | ( Dörr, W; Franckena, M; Georg, P; Kirchheiner, K; Pötter, R; Schmid, MP; Sturdza, A, 2014) |
| "Tumour metastasis is the primary cause of mortality in cancer patients and remains the key challenge for cancer therapy." | ( Baier, G; Choidas, A; Cronin, SJ; Eickhoff, J; Fededa, JP; Gruber, T; Hinterleitner, R; Ikeda, F; Jamieson, AM; Klebl, BM; Langdon, WY; Loeser, S; Menninger, S; Nitsch, R; Paolino, M; Penninger, JM; Pranjic, B; Schultz-Fademrecht, C; Torka, R; Ullrich, A; Unger, A; Uribesalgo, I; Wallner, S; Wolf, D, 2014) |
| "Finally, an experimental lung metastasis model was utilised to gauge the metastatic activity of eribulin-treated TNBC in the in vivo setting." | ( Agoulnik, S; Funahashi, Y; Kimura, T; Kuznetsov, G; Matsui, J; Ozawa, Y; Sato, Y; Taylor, N; Uesugi, M; Xu, S; Yoshida, T, 2014) |
| "Imaging spontaneous cancer cell metastasis or heterogeneous tumor responses to drug treatment in vivo is difficult to achieve." | ( Blower, PJ; Diocou, S; Fruhwirth, GO; Mullen, GE; Ng, T, 2014) |
| "Most patients with brain metastases have active extracranial disease, which limits survival unless effective systemic therapy can be administered." | ( Aandahl, G; Dalhaug, A; Haukland, E; Marienhagen, K; Nieder, C; Pawinski, A, 2014) |
| "Thus, interfering with metastasis has been regarded as a promising strategy to improve the current cancer treatments." | ( Fu, YY; Huang, P; Li, BH; Shi, JN; Xin, CW; Yang, XL; Ying, Y; Zhang, ML; Zheng, ZQ, 2014) |
| "Twenty-two patients with CNS metastasis received vemurafenib (male : female=13 : 9; median age 49); 12 had received no previous local therapy to the brain (group A), six had undergone previous surgery and/or radiotherapy with residual disease (group B; n=6) and four patients had received previous local therapy to the brain but with evidence of progression in the CNS before the start of vemurafenib and were included in group A (n=12+4=16)." | ( Atkinson, VG; Dzienis, MR, 2014) |
| "Patients with inoperable tumors due to metastasis at the time of diagnosis who were treated with oxaliplatin or irinotecan as the first-line treatment were included in this study." | ( Choi, PR; Kim, JH; Kim, SE; Lee, GW; Moon, W; Park, MI; Park, SJ, 2014) |
| "The results showed that the lung metastasis was significantly inhibited by PNS treatment in both spontaneous and experimental metastasis models." | ( Chen, Y; Cui, J; Du, X; Jia, C; Li, L; Wang, P; Wang, W; Xiong, M; Yang, Q; Yu, X; Zhang, T, 2014) |
| "Patients with a diagnosis of metastases before, at the time of, or within 3 months from the diagnosis of renal cell carcinoma (RCC) and first-line treatment with sunitinib were included." | ( Anastasiou, I; Bamia, C; Bamias, A; Beuselinck, B; Chrisofos, M; Constantinides, C; Deliveliotis, C; Dimopoulos, MA; Elaidi, TR; Escudier, B; Liontos, M; Mitropoulos, D; Oudard, S; Papatsoris, A; Stravodimos, K; Tzannis, K, 2014) |
| "Patients without metastases but with a high WBC had inferior event-free survival and local control rates and may require more aggressive therapy." | ( Bakhshi, S; Biswas, B; Khan, SA; Mohanti, BK; Mridha, AR; Rastogi, S; Sharma, DN; Sharma, MC, 2014) |
| "Chemotherapy can be used in metastasis case." | ( Chassagne, JF; De Runz, A; Eluecque, H; Gauchotte, G; Gisquet, H; Mansuy, L; Simon, E; Sorin, T, 2015) |
| "Distant metastasis was the main pattern of treatment failure." | ( Hu, C; Shi, Q; Yang, Z; Zhang, Y, 2014) |
| "Tumor metastasis is the major obstacle for cancer treatment." | ( Chen, C; Cheng, JK; Chung, CH; Lai, YW; Liu, SC; Peng, CY; Sun, HL; Tang, CH; Wang, PC; Wang, SW; Wu, NL, 2014) |
| "Tumor metastasis is a prominent cause of treatment failure in cervical carcinoma." | ( Bao, L; Chen, Y; Fu, X; Hao, Q; Liu, W; Wu, H; Zhang, L, 2014) |
| "Patients with possible liver metastases on pretreatment PET and patients with confirmed metastatic disease at the time of surgery do not benefit from resection." | ( Berry, MF; D'Amico, TA; Englum, BR; Erhunmwunsee, L; Onaitis, MW, 2015) |
| "Effective treatment for remote metastases has not been recognized." | ( Iguchi, F; Kusano, J; Murai, N; Takahashi, Y; Taniguchi, Z, 2014) |
| "In a systemic metastasis model, following intracardiac injection of PCb2 cells, 80% (8/10) of controls, 10% (1/10) Selinexor- and 20% (2/10) KPT-251-treated animals developed radiographic evidence of lytic bone lesions." | ( Addis, A; Di Cesare, E; Festuccia, C; Gravina, GL; Kauffman, M; Landesman, Y; Lenzi, A; Mancini, A; McCauley, D; Shacham, S; Tortoreto, M; Zaffaroni, N, 2014) |
| "Tumor size, existence of metastasis, and histopathologic classification remain incapable in terms of treatment decision and prognosis estimation." | ( Adalet, I; Aykan, F; Has Simsek, D; Kuyumcu, S; Sanlı, Y; Turkmen, C; Unal, S, 2014) |
| "Targeting the process of metastasis has been proposed as a potential strategy in cancer treatment." | ( Fan, L; Li, Y; Mei, Q; Meng, J; Sun, Y; Yue, Z; Zhang, D; Zhang, F; Zhang, R; Zhang, X, 2015) |
| "Treating metastasis has been challenging due to tumors complexity and heterogeneity." | ( Abu-Kaoud, N; Ghiabi, P; Jiang, J; Maleki, M; Pasquier, J; Rafii, A; Rafii, S, 2014) |
| "Patients with liver metastases from colorectal carcinoma who were scheduled for local ablation by radiotherapy (image-guided high-dose-rate interstitial brachytherapy) were prospectively randomized to receive PTX, UDCA and LMWH for 8 weeks (treatment) or no medication (control)." | ( Damm, R; Gademann, G; Hass, P; Kropf, S; Mohnike, K; Pech, M; Ricke, J; Sangro, B; Seidensticker, M; Seidensticker, R; Wust, P, 2014) |
| "A mouse model of MPE caused by pleural metastasis of lung cancer was first established, and As2O3 was then intraperitoneally injected to treat the MPE." | ( Chen, K; Huang, H; Li, B; Xie, SL; Yang, MH; Zang, YS; Zhao, XW, 2015) |
| "Invasion and metastasis are the major causes of treatment failure in patients with cancer." | ( Chang, CC; Huang, CH; Jayakumar, T; Lu, SH; Sheu, JR; Thomas, PA, 2015) |
| "Among them, 3 patients with bladder metastasis received intravesical chemotherapy of fluorouracil." | ( Feng, F; Ren, T; Wan, X; Wang, D; Xiang, Y; Yang, J, 2014) |
| "Brain metastases (BM) are highly prevalent among anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC) patients; yet little is known about their real-world treatment patterns and clinical and economic burdens." | ( Culver, KW; Dea, K; Guérin, A; Nitulescu, R; Sasane, M; Wu, EQ; Zhang, J, 2015) |
| "Bone metastasis is a frequent and fatal complication of cancer that lacks effective clinical treatment." | ( Cai, X; Cheng, Y; Ge, H; Huang, Q; Wang, C; Wang, X; Wang, Y; Xiao, J; Yan, W; Zhang, J; Zhang, Q, 2015) |
| "Tumor metastasis is the principle obstacle to the development of efficient treatments for patients with HB." | ( Chen, F; Cui, P; Fu, X; Gong, L; Jiang, L; Xiao, Y; Xu, J; Zhang, D, 2015) |
| "Invasion, metastasis, and recurrence are the most common causes of death in patients with hepatocellular carcinoma (HCC) and are therefore critical factors for both therapy and prognosis." | ( Jiang, WG; Li, YJ; Liu, JB; Liu, XJ; Wang, B; Zhang, M, 2015) |
| "Pretreatment screening on distant metastases is particularly useful in head and neck squamous cell carcinoma (HNSCC) patients with high risk factors." | ( Boellaard, R; de Bree, R; Hoekstra, OS; Leemans, CR; Meeuwis, J; Witte, BI, 2015) |
| "CCT129254 inhibits melanoma metastasis when administered 2 days after orthotopic intradermal injection of the cells, or when treatment starts after metastases have arisen." | ( Caldwell, J; Collins, I; Garrett, MD; Hooper, S; Kuemper, S; Mardakheh, FK; Marshall, CJ; McCarthy, A; Sadok, A; Sahai, E; Yeo, M, 2015) |
| "Maximum efficacy of inhibition of bone metastasis was achieved when GLPG0187 was combined with the standard-of-care metastatic breast cancer treatments." | ( Clément-Lacroix, P; Drabsch, Y; Li, Y; Pujuguet, P; Ren, J; Ten Dijke, P; van Dam, H; van Laar, T; Zhang, L, 2015) |
| "Before treatment, the LS174T metastases (n=7) were more heterogeneous than SW1222 metastases (n=12) (uniformity, P=0." | ( Boxer, G; Cook, GJ; Goh, V; Pedley, RB; Rajkumar, V; Robson, M; Siddique, M, 2015) |
| "Patients with metastasis often show reduced Lysophosphatidylcholine (LysoPC) plasma levels and treatment of metastatic tumour cells with saturated LysoPC species reduced their metastatic potential in vivo in mouse experiments." | ( Bendas, G; Dreckmann, T; Haasis, S; Jantscheff, P; Massing, U; Raynor, A; Ross, T; Schlesinger, M; Wilde, M, 2015) |
| "Experimental metastasis studies in mice were performed after pretreatment of B16." | ( Bendas, G; Dreckmann, T; Haasis, S; Jantscheff, P; Massing, U; Raynor, A; Ross, T; Schlesinger, M; Wilde, M, 2015) |
| "Forty women with IDC who had distant metastasis at the time of initial diagnosis and who underwent FDG PET/CT before receiving treatment were enrolled in the study." | ( Ahn, BC; Chae, YS; Jeong, SY; Lee, J; Lee, SW; Son, SH; Song, BI, 2015) |
| "The presence of distant metastases is an indication for primary palliative hormone therapy." | ( Benoist, GE; Gerritsen, WR; Kramers, C; Mulders, PF; Schers, HJ; van Erp, PH; Westdorp, H, 2015) |
| "After chemotherapy, metastases may disappear on cross-sectional imaging but residual metastatic disease may still exist." | ( Andersson, RG; Keussen, I; Lindell, G; Nilsson, J; Sturesson, C, 2015) |
| "change from metastasectomy to systemic therapy) or "minor" (e." | ( Eigentler, TK; Garbe, C; la Fougère, C; Nikolaou, K; Pfannenberg, C; Schüle, SC, 2016) |
| "In a mouse model of metastasis, the arrest of HCT116 cancer cells in the liver was reduced after treatment with CID16020046 or cannabidiol." | ( Andersen, L; El-Heliebi, A; Fauland, A; Feuersinger, D; Hasenöhrl, C; Haybaeck, J; Heinemann, A; Kargl, J; Lax, S; Magnes, C; Schicho, R; Stančić, A; Uranitsch, S, 2016) |
| "The pathogenesis of bone metastasis is unclear, and much focus in metastatic biology and therapy relays on epigenetic alterations." | ( Bendinelli, P; Desiderio, MA; Disanza, A; Maroni, P; Matteucci, E, 2016) |
| "12 patients with unresectable liver metastases from colorectal cancer were enrolled and received neoadjuvant FOLFIRI (5-fluorouracil, leucovorin, irinotecan) plus bevacizumab therapy." | ( Amato, DM; Avallone, A; Catalano, O; Filice, S; Fusco, R; Granata, V; Izzo, F; Nasti, G; Petrillo, A, 2015) |
| "Patients diagnosed with melanoma brain metastases have few treatment options and poor prognosis, and improved treatment strategies for these patients require detailed understanding of the underlying pathobiology." | ( Gaustad, JV; Rofstad, EK; Simonsen, TG, 2015) |
| "Furthermore, metastases in treated animals have a less invasive morphology." | ( Al-Abed, Y; Behr, CA; Edelman, MC; Glick, RD; Hesketh, AJ; Maloney, C; Soffer, SZ; Steinberg, BM; Symons, M, 2015) |
| "PTEN statusand liver metastasis couldpredict theclinical efficacyof subsequent lapatinib therapy." | ( Bian, L; Du, G; Guo, Y; Jiang, Z; Song, S; Wang, T; Xu, X; Zhang, S; Zhuo, J, 2015) |
| "Tumor metastasis would seriously impair the efficacy of chemotherapy." | ( Cun, X; Gao, H; He, Q; Lu, L; Wang, Y; Xia, T; Yang, Y; Yu, Q; Zhang, L; Zhang, Q; Zhang, Z, 2016) |
| "Chemotherapy-naïve patients with liver metastases plus or minus limited extrahepatic metastases were randomly assigned to receive either modified FOLFOX (mFOLFOX6; control) or mFOLFOX6 plus SIRT (SIRT) plus or minus bevacizumab." | ( Boucher, E; Bower, G; Cade, DN; Eliadis, P; Ferguson, T; Findlay, MP; Ganju, V; Gebski, V; Gibbs, P; Heinemann, V; Isaacs, R; Kröning, H; Moeslein, F; Peeters, M; Perez, D; Powell, A; Price, D; Ricke, J; Robinson, BA; Rodríguez, J; Shacham-Shmueli, E; Sharma, NK; Strickland, AH; Taieb, J; Thurston, K; Tichler, T; Van Buskirk, M; van Hazel, GA; Walpole, E; Wolf, I, 2016) |
| "Recurrence and metastasis after curative resection remain critical obstacles in HCC treatment." | ( Bai, D; Jiang, G; Wang, X; Zhang, C; Zhang, L; Zhu, Q, 2016) |
| "Early metastasis is still the most recalcitrant factor in the treatment of lung cancer patients." | ( Gan, T; Peng, S; Wang, Y; Wu, J; Yang, J; Zhao, M, 2016) |
| "Distant metastases were the most common form of treatment failure and occurred in 31 (34 %) patients (PORT, n = 17; POCRT, n = 14)." | ( Chang, JT; Fan, KH; Fang, KH; Hsieh, CE; Lee, LY; Liao, CT; Lin, CY; Tsang, YM; Wang, CC; Wang, HM; Yang, LY; Yen, TC, 2016) |
| "Patients with bone and visceral metastases were more likely to use everolimus versus endocrine-monotherapy." | ( Fang, A; Guérin, A; Hao, Y; Kageleiry, A; Koo, V; Li, N; Peeples, M; Tang, D; Wu, EQ, 2016) |
| "Distant metastasis was the primary cause of treatment failure, which was significantly higher in N2-3 patients than in N0-1." | ( He, XY; Hu, CS; Wu, MY, 2016) |
| "Patients who underwent metastasectomy or those with Eastern Cooperative Oncology Group performance status (ECOG-PS) ≤1 had longer PFS and OS independent of the type of chemotherapy regimen." | ( Artaç, M; Avcı, N; Çabuk, D; Coşkun, HŞ; Dane, F; Doruk, H; Faruk Aykan, N; Karaağaç, M; Karabulut, B; Karabulut, S; Korkmaz, L; Turhal, NS, 2016) |
| "Optical in vivo imaging of cancer metastasis showed that 3,6-DHF administration suppresses the lung metastasis of BC cells in vivo." | ( Chang, H; Chen, J; Gu, Y; Mi, M; Peng, X; Yi, L; Zhang, Q; Zhu, J, 2016) |
| "Moreover, the inhibition of the metastasis of the 5-azacytidine-treated EC9706 cells was impaired following transfection with siRNA targeting CDH1 (CDH1 siRNA), and the inhibition of cell proliferation was attenuated following the downregulation of SOX17 by siRNA targeting SOX17 (SOX17 siRNA)." | ( He, H; He, Y; Jiang, D; Li, W; Ma, H; Niu, Z; Wu, D; Xie, X; Zuo, X, 2016) |
| "Furthermore, the metastasis of tumor cells derived from ventrally transplanted mammary tumor grafts is suppressed by the coadministration of FNIII14 and doxorubicin." | ( Akari, S; Fujita, M; Fukai, F; Hayashi, R; Itagaki, K; Iyoda, T; Kodama, H; Nagamine, Y; Nakane, Y; Orita, H; Otsuka, K; Owaki, T; Taira, J; Takizawa, Y; Tokita, Y, 2016) |
| "Thus, there is an urgent need for anti-metastasis therapy." | ( Ekpenyong, AE; Gross, E; Guck, J; Mimlitz, M; Nichols, M; Ning, J; Prathivadhi-Bhayankaram, SV; Taylor, C, 2016) |
| "Tumor growth and metastasis in the lung, liver, and peritoneum were significantly more enhanced in CRC cells treated with EA than those treated with the cis form of EA, oleic acid (OA), or vehicle." | ( Fujii, K; Fujiwara, R; Kadochi, Y; Kishi, S; Kuniyasu, H; Mori, S; Nishiguchi, Y; Ohmori, H; Sasaki, T, 2017) |
| "Abnormal tumor vessels promote metastasis and impair chemotherapy." | ( Bifari, F; Boeckx, B; Brajic, A; Cantelmo, AR; Carmeliet, P; Chaturvedi, P; Conradi, LC; Cruys, B; De Bock, K; Decimo, I; Dewerchin, M; Eelen, G; Finotto, L; Ghesquière, B; Goveia, J; Haraldsen, G; Hol, J; Kalucka, J; Kampen, K; Kuchnio, A; Lambrechts, D; Malik, AB; Pircher, A; Rabelink, T; Rehman, J; Schoonjans, L; Schoors, S; Stapor, P; Stav-Noraas, TE; Teuwen, LA; Thienpont, B; Treps, L; Veys, K; Vriens, J, 2016) |
| "At present, there is no specific anti-metastasis drug in HCC treatment." | ( Chai, L; Chen, L; Chen, X; Fu, A; Hu, J; Luo, H; Pei, H; Peng, A; Qiu, Q; Shao, X; Wan, L; Wang, C; Wei, Y; Wu, W; Yang, H; Yang, J; Yang, L; Ye, H; Zhao, C, 2017) |
| "Lunasin treatment inhibited metastasis of breast cancer cells, partially through modestly inhibiting production of the angiogenesis-mediator vascular endothelial growth factor (VEGF) and significantly by inhibiting secretion in the Ad-CM condition." | ( Hsieh, CC; Huang, YS; Wang, CH, 2016) |
| "Bioluminescent imaging of tumor metastases to the liver, lungs, and spleen revealed that sunitinib administration enhances metastasis, but only in tumors displaying innate resistance to therapy." | ( Bicknell, R; Heath, VL; Wragg, JW, 2017) |
| "The results suggest that liver oligometastasis of gastrointestinal stromal tumor may not be controllable by surgery alone and require concomitant imatinib therapy." | ( Hata, Y; Hirai, T; Ikawa, O; Ishikawa, T; Kagimura, T; Kanda, T; Masuzawa, T; Mochizuki, I; Nishida, T; Ojima, H; Sodeyama, H; Takagane, A, 2017) |
| "However, the genetics of metastases largely reflects that of the primary tumor in untreated patients, and PDAC driver mutations are shared by all subclones." | ( Carrer, A; Feinberg, AP; Iacobuzio-Donahue, CA; Li, X; Locasale, JW; Makohon-Moore, A; McDonald, OG; Mentch, SJ; Natsume, S; Salz, TH; Saunders, T; Stauffer, KM; Tryggvadottir, R; Warmoes, MO; Wellen, KE; Word, AE; Wu, H; Zhong, Y, 2017) |
| "Locoregional treatment of metastasis should always be included in the therapeutic strategy when feasible." | ( Bellera, C; Blay, JY; Cousin, S; Giraud, A; Honoré, C; Italiano, A; Le Cesne, A; Le Loarer, F; Le Péchoux, C; Meeus, P; Mir, O; Ranchere-Vince, D; Ray-Coquard, I; Sargos, P; Savina, M; Stoeckle, E; Sunyach, MP; Terrier, P; Toulmonde, M, 2017) |
| "The growth, metastasis, and chemotherapy resistance of pancreatic ductal adenocarcinoma (PDAC) is characterized by the activation and growth of tumor-initiating cells in distant organs that have stem-like properties." | ( Centeno, BA; Coppola, D; Husain, K; Malafa, MP; Sebti, SM; Trevino, J, 2017) |
| "Moreover, in an experimental metastases model, treatment with BMS-345541 reduced the lung metastases by > 5-fold." | ( Andreeff, M; Bartholomeusz, C; Battula, VL; Hail, N; Nguyen, K; Pitner, MK; Sun, J; Yuan, B, 2017) |
| "Thus, if the development of metastasis can be prevented through novel therapeutic strategies targeted against this process, then the success of cancer treatment will drastically increase." | ( Damoiseaux, R; France, B; Gbadegesin, MA; Gimzewski, JK; Odunola, OA; Olugbami, JO; Sharma, S; Stieg, AZ, 2017) |
| "Therefore, targeting metastasis is one arm of therapeutic strategies to treat gallbladder cancer." | ( Gong, W; Hu, Y; Jiang, L; Li, H; Liang, H; Liu, Y; Ma, Q; Wang, X; Wang, Z; Xiang, S; Xu, Z; Ye, Y; Zhang, F; Zhang, Y, 2017) |
| "In a mouse model, we found that lung metastasis was decreased after treatment with PBF-509 compared with its control." | ( Allard, B; Antonia, SJ; Castro, J; Chiappori, A; Hernandez, DC; Mediavilla-Varela, M; Noyes, D; Stagg, J, 2017) |
| "Distant metastasis has become the predominant model of treatment failures in patients with locoregionally advanced nasopharyngeal carcinoma." | ( Cheng, ZB; Jin, YN; Ma, J; Mo, HY; Sun, Y; Wang, SY; Yao, JJ; Zhang, F; Zhang, WJ; Zhou, GQ, 2017) |
| "Both distant metastases and loco-regional failures remain important treatment challenge." | ( Alfonsi, M; Aupérin, A; Bardet, E; Bourhis, J; Calais, G; Deprez, P; Geoffrois, L; Gery, B; Graff, P; Grégoire, V; Lapeyre, M; Maingon, P; Martin, L; Pignon, T; Rives, M; Sire, C; Tao, Y; Verrelle, P, 2017) |
| "A total of 38 metastases were treated." | ( de Ridder, M; Engels, B; Everaert, H; Gevaert, T; Guler, OC; Onal, C; Van den Begin, R, 2018) |
| "Multidrug resistance (MDR) and metastasis are considered to be two of the major barriers for successful chemotherapy." | ( Deng, Y; He, C; Jin, Y; Li, X; Liu, Y; Qu, X; Wang, D; Wang, Z; Zhou, Y; Zou, Y, 2017) |
| "The accumulation of liposomes in the metastases peaked at 24 h post the intravenous administration, similar to the time they peaked in the primary tumor." | ( da Silva, D; Goldfeder, M; Goldman, E; Hershkovitz, D; Kajal, A; Schroeder, A; Schroeder, JE; Shainsky-Roitman, J; Vardi-Oknin, D; Yaari, Z; Zinger, A, 2017) |
| "Breast tumor recurrence and metastasis represent the main causes of cancer-related death in women, and treatments are still lacking." | ( Augustin, HG; Berriel Diaz, M; Christian, S; Herzig, S; Hess-Stumpp, H; Maida, A; Mattijssen, F; Müller-Decker, K; Nawroth, PP; Rios Garcia, M; Singhal, M; Srivastava, K; Steinbauer, B, 2017) |
| "The actual resection rate of metastases was significantly associated with treatment setting (P = 0." | ( Becker, T; Bemelmans, M; Bruns, CJ; Denecke, T; Folprecht, G; Gebauer, B; Heinemann, V; Held, S; Lang, H; Modest, DP; Modest, HI; Neumann, UP; Pratschke, J; Rentsch, M; Ricard, I; Seehofer, D, 2018) |
| "The primary and largest metastases at diagnosis were delineated on pretreatment scans with GLCM energy extracted using imaging biomarker explorer (IBEX) software." | ( Court, LE; Fried, DV; Gomez, DR; Jensen, GL; Mackin, DS; Yost, CM; Zhou, S, 2018) |
| "FDG-PET/CT before immunotherapy showed metastases to thoracic nodes, liver, adrenal gland, and skeleton." | ( Eshghi, N; Kuo, PH; Lundeen, TF, 2018) |
| "Tumor metastasis is the primary obstacle in cancer treatment and is always the leading cause of human death." | ( Cao, D; Ci, T; Ke, X; Liu, H; Sun, H; Wu, H, 2018) |
| "The removal of the metastases that became resectable after chemotherapy further prolonged the patients' survival." | ( Geredeli, C; Yasar, N, 2018) |
| "Cancer metastasis causes approximately 90% of all cancer-related death and independent of the advancement of cancer therapy, a majority of late stage patients suffers from metastatic cancer." | ( Al Mismar, R; Ben Hamidane, H; Bhagwat, AM; Choi, S; Goswami, N; Graumann, J; Sun, L, 2018) |
| "Nearly half of heavily pretreated RCC metastases may harbor mutations in components of the PI3K-AKT-mTOR pathway." | ( Bhatt, RS; Catalano, PJ; Choueiri, TK; Gao, X; George, DJ; Gray, C; Jegede, O; Kwiatkowski, DJ; McDermott, DF; McKay, RR; Novak, J; Signoretti, S, 2018) |
| "The rates of liver and lung metastases in UMB-administrated animals were smaller compared to the control." | ( Amani, D; Bazi, A; Jamshidi, H; Khalilnezhad, A; Muhammadnejad, A; Rashidi, M; Ziai, SA, 2018) |
| "Brain metastasis-free survival was also longer in the T790M-positive group or osimertinib-treated group among patients who had no brain metastasis at the time of diagnosis." | ( Hong, MH; Joo, JW; Shim, HS, 2018) |
| "Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment." | ( Chemmalakuzhy, R; Lang, L; Shay, C; Teng, Y; Thakkar, P; Wang, X; Xiong, Y, 2018) |
| "BDMC may have potential as a novel anti-metastasis agent for the treatment of human cervical cancer." | ( Chen, CY; Chu, YL; Chung, JG; Hsu, MJ; Huang, AC; Lai, KC; Liao, CL; Lin, HY; Liu, KC, 2018) |
| "Liver metastases are very common in metastatic breast cancer (MBC); current treatments for these lesions are based on systemic chemotherapy, endocrine- or human epidermal growth factor receptor 2 (HER2)-targeted therapy, and palliative therapy." | ( Febbraro, A; Giordano, G; Pedersini, R; Quaquarini, E; Raffaele, M; Rossello, R; Turletti, A; Villa, F, 2018) |
| "BMI1, a major driver of metastasis, represents a promising therapeutic target for treating advanced prostate cancer in patients (including those belonging to high-risk group)." | ( Astone, M; Beigh, FH; Deng, Y; Ferrari, MG; Ganaie, AA; Hoeppner, LH; Hussain, T; Konety, BR; Koochekpour, S; Maqbool, R; Morrissey, C; Murugan, P; Parray, AS; Saleem, M; Siddique, HR; Umbreen, S, 2018) |
| "Treating systemic metastases at the micrometastatic stage is a potential strategy to inhibit cancer metastasis." | ( Fu, A; Luo, KQ; Ngan, W; Peh, YM; Wei, N, 2018) |
| "Median time from initial diagnosis of metastases to the start of regorafenib and treatment duration was 13." | ( Aranda, E; Benavides, M; Durán, G; Falcó, E; García-Alfonso, P; Gómez, A; López, R; López-Ladrón, A; Montagut, C; Muñoz, A; Rivera, F; Ruiz de Mena, I; Salgado, M; Sastre, J, 2018) |
| "In terms of visceral metastasis, a stratification factor, there were no TTP differences according to treatment arm." | ( Ahn, JH; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kim, GM; Kim, JH; Kim, JY; Kim, S; Kim, SB; Kim, SH; Kim, TY; Lee, KH; Lee, KS; Park, IH; Park, YH; Ro, J; Sohn, J, 2018) |
| "To treat metastasis from breast and many other cancer types, chemotherapy is one of the most extensively used methods." | ( Becceneri, AB; Cominetti, MR; da Silva, JA; Fuzer, AM; Martin, ACBM; Vieira, PC, 2019) |
| "Further strategies for brain metastasis should be developed to improve outcomes despite encouraging results with PTT treatment." | ( Aksoy, S; Aktas, BY; Alacacioglu, A; Aliyev, A; Artac, M; Basaran, G; Beypinar, I; Bilen, E; Bilici, A; Cabuk, D; Cetin, B; Cicin, I; Cil, T; Degirmencioglu, S; Demir, A; Demir, H; Demirci, U; Er, O; Erdur, E; Eren, T; Erturk, I; Esin, E; Evrensel, T; Gumusay, O; Haksoyler, V; Harputluoglu, H; Imamoglu, I; Kaplan, MA; Karaagac, M; Karadurmus, N; Kocer, M; Korkmaz, T; Kostek, O; Oksuzoglu, B; Olgun, P; Oyan, B; Ozdemir, O; Paydas, S; Pilanci, KN; Sakalar, T; Sakin, A; Seker, M; Sumbul, AT; Tanrikulu, E; Urun, Y; Yetisir, E; Yildirim, N; Yilmaz, H; Yumuk, PF, 2019) |
| "In total 196 liver metastases were delineated on the pre-treatment CT, of which 99 (51%) lesions showed a decrease in size of more than 65% (PR)." | ( Klaassen, R; Lambin, P; Larue, RTHM; Mearadji, B; Stoker, J; van der Woude, SO; van Laarhoven, HWM, 2018) |
| "L747), only the presence of brain metastases at diagnosis or during TKI treatment was associated with shorter PFS but not with worse OS." | ( Beretta, GD; Bonomi, M; Cerchiaro, E; Ceresoli, GL; D'Argento, E; Di Noia, V; Finocchiaro, G; Rossi, S; Santoro, A; Toschi, L, 2019) |
| "Tumor recurrences or metastases occurring during follow-up were defined as treatment failure; sites and data of first treatment failure were recorded." | ( Chen, C; Chen, KN; Cheng, Y; Fei, K; Huang, C; Li, J; Li, XF; Liu, LX; Liu, YY; Liu, ZD; Ma, HT; Mao, WM; Shen, Y; Wang, BH; Wang, J; Wang, Q; Wu, L; Wu, YL; Xi, JJ; Xu, L; Xu, S; Xu, SD; Xu, ST; Yan, HH; Yang, XN; Yin, JC; Yu, P; Zhang, YX; Zhong, WZ, 2019) |
| "Patients with recurrence or metastasis within 6 months after cisplatin administration were considered platinum-resistant and those with no recurrence or metastasis within 6 months were considered platinum-sensitive." | ( Fushimi, C; Hanyu, K; Katsube, Y; Kondo, T; Miura, K; Okada, T; Okamoto, I; Sato, H; Shimizu, A; Tsukahara, K, 2019) |
| "Forty-four NSCLC patients with distant metastasis that received MSCT (administration of chemotherapy regimen following induced hypoglycemia) plus ketogenic diet, hyperthermia and HBOT combination were included in this retrospective study." | ( Iyikesici, MS, 2019) |
| "Workup of suspected chest metastasis based on PET/CT findings significantly delays primary treatment initiation and may cause serious complications." | ( Bone, TM; Byrd, JK; Groves, MW; Leto, CJ; Liebman, RM; Sharbel, D; Wang, CW, 2019) |
| "Growing evidence suggests that metastasis-directed therapy (MDT) and/or local therapy targeted to the primary tumour (ie, prostate) may be of benefit in the setting of oligometastatic disease." | ( Battaglia, A; De Meerleer, G; Devos, G; Everaerts, W; Joniau, S; Moris, L; Tosco, L; Van den Broeck, T, 2019) |
| "As a result, FucOMDs prevent metastasis formation and efficiently suppress both primary-tumor growth and metastasis formation when combined with targeted chemotherapy." | ( Chen, J; Chen, L; Chen, Y; Gao, X; Gu, X; Huang, Y; Jiang, T; Liang, K; Liu, S; Lu, H; Ma, F; Pei, Y; Song, Q; Wang, J; Xu, M; Zhou, S, 2019) |
| "Hepatocellular carcinoma (HCC) metastases to the zygomatic bone are extremely uncommon, and the treatment of target drugs against such case is unknown." | ( Chen, H; Deng, F; Fu, R; Hu, J; Lei, Q; Li, J; Wang, F; Zhen, Z; Zheng, H, 2019) |
| "Because of its anti-metastasis capacity, further structure modifications of LYRM03 will be of interest for its use alone or in combination as a therapy in cancer." | ( Du, LD; Feng, MQ; He, P; Shen, DD; Wan, DJ; Wang, P; Wang, T; Yang, YK, 2019) |
| "On multivariate analysis, metastasectomy and objective response or stable disease achieved with first-line chemotherapy were indicators for better overall survival." | ( Cornillie, J; Debiec-Rychter, M; Hompes, D; Langmans, C; Schöffski, P; Sciot, R; van Cann, T; Vandenbempt, I; Wozniak, A, 2019) |
| "The latter leads to metastasis and chemotherapy resistance." | ( Baker, D; Hao, Y; Ten Dijke, P, 2019) |
| "When diagnosed with pulmonary metastasis, the patient received combined chemotherapy regimen of MAID (mesna, adriamycin, ifosfamide and dacarbazine) for 6 cycles." | ( Li, D; Liu, Y; Qiao, L; Sun, M; Wang, L; Xu, S, 2019) |
| "Chemoresistance and metastasis are the main cause of treatment failure." | ( Rongrong, S; Sun, S; Xiaowu, L; Yangmei, Z; Youwei, Z; Yuan, Y, 2019) |
| "In order to treat bone metastases of lung cancer, we reported a docetaxel (DTX)-loaded nanoparticle, DTX@AHP, which could target dually at osteoclasts and bone metastatic tumor cells." | ( Bai, SB; Cheng, Y; Cui, H; Cui, MX; Liu, DZ; Liu, M; Mei, QB; Zhang, BL; Zhou, SY, 2019) |
| "However, postsurgical metastasis poses an immense setback in cancer therapy." | ( Himmel, LE; Jyotsana, N; King, MR; Yu, F; Zhang, Z, 2019) |
| "Prediction of lymph node metastasis (LNM) for early colorectal cancer (CRC) is critical for determining treatment strategies after endoscopic resection." | ( Chino, A; Ishikawa, Y; Kawachi, H; Saito, S; Takamatsu, M; Takazawa, Y; Takeuchi, K; Ueno, M; Yamamoto, N, 2019) |
| "Treatment of B/U liver metastases from CRC with conversion chemotherapy using mFLOX regimen followed by surgical resection was associated with a high R0 resection rate and favorable survival outcomes." | ( Amor Divino, PH; Bonadio, RC; Capareli, FC; Hoff, PM; Kruger, JAP; Lima, KCA; Obando, JSM; Recchimuzzi, DZ; Saragiotto, DF, 2019) |
| "Cancer recurrence and metastasis are worldwide challenges but current bimodular strategies such as combined radiotherapy and chemotherapy (CTX), and photothermal therapy (PTT) and immunotherapy have succeeded only in some limited cases." | ( Liu, RT; Sun, XM; Xu, ZP; Zhang, LX, 2019) |
| "In contrast, the extent of metastasis on the peritoneum was significantly increased by low-dose gemcitabine compared to the untreated control (p=0." | ( Bouvet, M; Chawla, SP; Higuchi, T; Hoffman, RM; Kawaguchi, K; Miyake, K; Oshiro, H; Park, JH; Singh, SR; Sugisawa, N; Unno, M; Zhang, Z, 2019) |
| "Patients with CNS metastases were included if these metastases were asymptomatic and did not require steroid therapy." | ( Cao, L; Chen, J; Chen, Y; Ding, L; Fan, Y; Fang, J; Feng, J; Feng, W; Fu, Y; Gong, Y; Guo, Y; Hu, Y; Li, G; Liu, X; Liu, Y; Ma, K; Mao, L; Selvaggi, G; Song, W; Song, Y; Wang, T; Wu, G; Wu, N; Xiao, S; Yang, Y; Ye, F; Yu, Z; Yuan, X; Zhang, L; Zhang, S; Zhang, Y; Zhao, J; Zhao, S; Zhao, Y; Zheng, Z; Zhong, W; Zhou, C; Zhou, J; Zhuang, W, 2020) |
| "Twenty-two patients with CNS metastases treated by MTX (3 g/m2) between April 2004 and October 2009 were enrolled." | ( Bazan, F; Chaigneau, L; Curtit, E; Dobi, E; Mansi, L; Menneveau, N; Meynard, G; Paillard, MJ; Pivot, X; Royer, B; Villanueva, C, 2019) |
| "Thus, early prediction of metastases in OS management plans is crucial for better-adapted treatments and survival rates." | ( Byun, BH; Cho, WH; Kim, W; Kong, CB; Lim, I; Lim, SM; Sheen, H; Song, WS; Woo, SK, 2019) |
| "Postoperative SIR-induced tumor metastasis have been clearly evidenced in our experimental model, and the administration of nicaraven may ameliorate the SIR-induced tumor metastasis by suppressing inflammatory responses." | ( Goto, S; Guo, CY; Kawabata, T; Li, TS; Liu, KX; Moriwaki, T; Zhang, X, 2020) |
| "Treatment of bone metastases currently focusses on symptom relief and prevention and treatment of skeletal complications." | ( Anand, A; Brown, J; Brown, S; Coleman, R; Flanagan, L; Howell, S; Kendall, J; MacPherson, I; Palmieri, C; Rathbone, E; Reid, A; Twelves, C, 2020) |
| "The invasion and metastasis linked signaling was also blocked by LYW-6 treatment." | ( Chen, S; Guan, L; Lai, M; Li, J; Liu, Z; Wang, H; Yu, W, 2020) |
| "Preventing cancer metastasis is one of the remaining challenges in cancer therapy." | ( Gu, W; Liu, J; Movahedi, F; Wu, Y; Xu, T; Xu, ZP, 2020) |
| "Compared to primary tumor cell lines, metastasis-derived cell lines were more chemoresistant to doxorubicin, but equally susceptive to carboplatin treatment." | ( Hewicker-Trautwein, M; Junginger, J; Mohr, A; Murua Escobar, H; Nolte, I; Packeiser, EM; Schille, JT; Thiemeyer, H, 2020) |
| "The correct staging of distant metastasis is crucial in deciding an adequate course of therapy for cancer patients." | ( Li, J; Pang, X; Song, F; Wei, Z; Zhang, X; Zhou, H, 2020) |
| "In mice, morphine promoted TNBC metastasis and angiogenesis, decreased TSP-1 expression and increased c-Myc expression, while co-administration of ketorolac significantly reversed the phenotypes above (p < ." | ( Cao, M; Cheng, S; Fu, G; Ji, F; Liu, Z; Wang, C, 2020) |
| "Treatment directed towards painful metastases must be considered." | ( Klepstad, P; Løhre, ET; Thronæs, M, 2020) |
| "Peritoneal metastasis from pancreatic cancer (PM-PC) may be treated with repeated pressurised intraperitoneal aerosol chemotherapy (PIPAC)." | ( Detlefsen, S; Ellebæk, SB; Fristrup, C; Graversen, M; Kristensen, TK; Mortensen, MB; Nielsen, M; Pfeiffer, P, 2021) |
| "The studies on the treatment of brain metastases from esophageal cancer by radiotherapy combined with temozolomide (TMZ) are even rarer." | ( Cui, G; Li, N; Liu, C; Liu, M; Qie, S; Ran, Y; Sun, W; Sun, X; Tian, Y; Yang, H, 2020) |
| "Primary tumor metastasis remains to be a tough obstacle for clinical breast cancer treatment." | ( Chen, C; Huang, Y; Li, Q; Lin, X; Yang, J; Zhou, M; Zhou, Z, 2020) |
| "Importantly, breast tumour growth and metastasis dissemination was significantly reduced upon CD-NHF treatments in a syngeneic mouse model and is associated with down-regulation of Ki67 and HSP90 expression." | ( Butura, M; Coroaba, A; Luta, G; Stan, CS; Stanciu, GD; Tiron, A; Tiron, CE; Ursu, EL; Zugun-Eloae, F, 2020) |
| "Proportion of patients with distant metastases was also calculated and its impact on intended treatment was assessed." | ( Agrawal, A; Jiwnani, S; Karimundackal, G; Kumar, R; Pramesh, CS; Purandare, NC; Puranik, A; Rangarajan, V; Shah, S, 2020) |
| "It is prone to develop unpredictable metastases even with proper treatment." | ( Li, YL; Lin, NM; Wang, W; Wu, LW; Zeng, LH; Zhang, C; Zhang, ZY, 2020) |
| "Lung metastasis area could be ameliorated after SBW (615 mg/kg) and scutellarin (7 mg/kg) treatments by 23." | ( Chan, YY; Gao, S; Lau, CB; Lau, KM; Lee, JK; Liu, W; Wong, CW; Yue, GG, 2021) |
| "The presence of visceral metastases is associated with poor prognosis in patients of metastatic castration-resistant prostate cancer (mCRPC) treated with hormonal therapy and chemotherapy." | ( Mittal, BR; Satapathy, S; Sood, A, 2020) |
| "Presence of visceral metastases was associated with poor response and survival outcomes in patients of mCRPC treated with Lu-PSMA RLT." | ( Mittal, BR; Satapathy, S; Sood, A, 2020) |
| "Survival of PDAC liver metastasis mice was significantly prolonged by the combination therapy (median survival, 66 days) when compared with that of GEM alone treatment (median survival, 56 days)." | ( Ho, TTB; Honda, M; Inui, H; Kaneko, S; Kawaguchi, K; Kitamura, Y; Komura, T; Kozaka, T; Mizukoshi, E; Nasti, A; Sakai, Y; Seki, A; Shiba, K; Wada, T; Yamashita, T, 2020) |
| "However, the higher risk of tumor metastasis caused by the severe hypoxic state during phototherapy is a threat in practical use." | ( Cao, D; Ci, T; Feng, N; Li, H; Luo, Y, 2021) |
| "We treat human liver metastases slices with 5-fluorouracil (5-FU) plus either irinotecan or oxaliplatin, then perform single-cell transcriptome analyses." | ( Baloni, P; Bergey, D; Hood, LE; Jabbari, N; Kenerson, HL; Lausted, C; Meng, C; Pillarisetty, VG; Sullivan, KM; Tian, Q; Yan, X; Yeung, RS, 2020) |
| "Bone metastases frequently occur in breast cancer patients and lack appropriate treatment options." | ( Baranowsky, A; Clezardin, P; Hinz, N; Horn, M; Jücker, M; Kriegs, M; Lange, T; Schinke, T; Sibbertsen, F; Smit, DJ, 2021) |
| "The updated 5-year distant metastasis-free survival rate for patients with high clinical risk and low genomic risk receiving no chemotherapy (primary test population, n=644) was 95·1% (95% CI 93·1-96·6), which is above the predefined non-inferiority boundary of 92%, supporting the previous analysis and proving MINDACT as a positive de-escalation trial." | ( Bogaerts, J; Brain, E; Cardoso, F; Causeret, S; Delaloge, S; Delorenzi, M; Fumagalli, D; Glas, AM; Hilbers, F; Knox, S; Kümmel, S; Lopes Cardozo, JMN; Matos, E; Meulemans, B; Neijenhuis, PA; Peric, A; Piccart, M; Pierga, JY; Poncet, C; Ravdin, P; Rubio, IT; Rutgers, EJT; Smilde, TJ; Sotiriou, C; Thompson, AM; Tryfonidis, K; van 't Veer, LJ; Viale, G; Vrijaldenhoven, S; Vuylsteke, P; Zaman, K; Zoppoli, G, 2021) |
| "Foci of metastasised CML and AML cells in ovarian cortex tissue were severely affected by a 24h ex vivo treatment with an AURKB/C inhibitor, leading to the formation of multi-nuclear syncytia and large-scale apoptosis." | ( Beerendonk, C; Braat, D; Eijkenboom, L; Koorenhof-Scheele, T; Mulder, C; Peek, R; van der Reijden, B; van Leersum, J; van Mello, N, 2021) |
| "Gastric cancer (GC) metastasis determines the prognosis of patients, and exploring the molecular mechanism of GC metastasis is expected to provide a theoretical basis for clinical treatment." | ( An, W; Chen, Q; Pan, S; Tan, Y; Xing, Y; Xu, H; Zhang, C, 2021) |
| "A 61-year-old woman with a history of metastasis breast cancer was admitted to our hospital for the second cycle of chemotherapy with lapatinib and vinorelbine." | ( Bai, Y; Cheng, Y; Cui, Y; Duan, X; Liu, Q; Liu, Y; Qin, N; Xiang, Q; Xu, L; Zhang, J; Zhang, Z, 2021) |
| "Iris metastases were treated with 40 Gray of radiation therapy and concurrent chemotherapy." | ( Horiuchi, N; Kuribayashi, T; Kurihara, T; Ozawa, H; Smith, LEH; Takano, Y; Tomita, Y; Tsubota, K; Usui, Y, 2021) |
| "Viable bone metastases and osteoblastic change induced by the treatment effect were identified in 53 (94." | ( Hanasaki, T; Kanematsu, A; Kawanaka, Y; Kitajima, K; Komoto, H; Nagasawa, S; Shimatani, K; Taguchi, M; Yamada, Y; Yamakado, K; Yamamoto, S, 2021) |
| "It remains challenging to treat tumor metastasis currently in the light of multiple cascade processes of tumor metastasis." | ( Du, J; Hu, Q; Li, K; Li, W; Li, X; Li, Y; Liu, S; Wang, C; Yu, Z; Zhang, C, 2021) |
| "A 70s woman with pancreatic metastases of HER2-negative breast cancer was being treated with bevacizumab plus paclitaxel." | ( Fujisaki, K; Miyoshi, T; Ootsubo, Y; Sai, G; Shiina, N; Wakabayashi, Y; Yokomizo, J, 2021) |
| "Leptomeningeal metastasis (LM) is one of the most serious complications of non-small cell lung cancer (NSCLC) without standard treatment guidelines and is always accompanied by poor prognosis." | ( Feng, J; Jiang, C; Li, H; Lin, Y; Qian, X; Xie, Y; Yin, Z; Yu, T; Zheng, S, 2022) |
| "The treatment of the remaining liver metastasis could be completed by RFA." | ( Bartels, A; Gaertner, FC; Glowka, T; Gonzalez-Carmona, MA; Kalff, J; Knipper, P; Kupczyk, P; Mahn, R; Manekeller, S; Meyer, C; Sadeghlar, F; Strassburg, CP; Toma, M; Vilz, T; Weismüller, T; Zhou, T, 2021) |
| "The HCC shrank, but the adrenal metastasis grew bigger after the fourth course, so we changed the therapy to LEN." | ( Aikata, H; Amioka, K; Ando, Y; Arihiro, K; Fujino, H; Imamura, M; Johira, Y; Kawaoka, T; Kobayashi, T; Kodama, K; Kosaka, M; Kosaka, Y; Kuroda, S; Miura, R; Mori, K; Murakami, E; Murakami, S; Nakahara, T; Naruto, K; Ohdan, H; Ohno, A; Okamoto, W; Shirane, Y; Uchikawa, S; Yamaoka, K; Yamauchi, M; Yano, S, 2021) |
| "Patients with osteoblastic metastases from high risk osteosarcoma continue to have a poor prognosis after progression from standard-of-care multi-agent chemotherapy." | ( Anderson, P; Kairemo, K; Macapinlac, HA; Rao, A; Ravizzini, G; Roszik, J; Subbiah, V, 2021) |
| "Lung metastasis mouse model was established, and DHE was administered orally for 14 days." | ( Han, YH; Hong, SH; Jeon, HD; Kee, JY; Lee, YG; Mun, JG; Yoon, DH, 2022) |
| "Elucidating the mechanism for high metastasis capacity of triple negative breast cancers (TNBC) is crucial to improve treatment outcomes of TNBC." | ( Chu, Y; Fang, S; Lei, Y; Li, G; Tong, Q; Wang, GY; Wang, L; Wang, Y; Xie, X; Yu, H; Yu, X; Zhang, J; Zhou, X; Zhu, T, 2022) |
| "Age, ER/PR status, sites of metastasis, surgical resection of primary tumor, and initial treatment were analyzed." | ( Ko, NY; Marcom, PK; Mitri, Z; Smith, CEP, 2022) |
| "Senescence is associated with tumor metastasis and chemotherapy resistance, yet the mechanisms remain elusive." | ( Chen, KL; Chen, L; He, QM; Li, JY; Li, Q; Li, YQ; Liang, YL; Liu, N; Ma, J; Qiao, H; Xu, C; Zhao, Y; Zhao, YH, 2023) |
| "Furthermore, we verified that metastasis was suppressed by juglone treatment." | ( Chen, X; Ding, S; Gao, X; Jin, J; Le, Y; Matunda, C; Wang, H; Wang, L; Yu, Y; Zou, C, 2023) |
| "Of 56 patients with adrenal metastases treated with adrenal RT, eight (14." | ( Bancos, I; Hallemeier, C; Herndon, J; Jethwa, K; Shariff, A, 2023) |
| "RDH16 could be used as a pro-metastasis biomarker in the treatment of HCC with DNA methyltransferase inhibitors." | ( Chunmeng, M; Hasnat, M; Le, L; Luyong, Z; Qinwei, Y; Qipeng, W; Zhenzhou, J, 2023) |
| "Single-organ pulmonary metastasis was a strong predictor of progression-free survival and overall survival in patients with metastatic colorectal cancer treated with folinic acid, 5-fluorouracil, irinotecan, and vascular endothelial growth factor inhibitors as second-line chemotherapy; this provides preliminary evidence for medical guidelines and clinical decision-making on novel therapeutic strategies for these patients." | ( Chin, K; Fukuda, K; Fukuoka, S; Nakayama, I; Ogura, M; Ooki, A; Osumi, H; Shinozaki, E; Takahari, D; Wakatsuki, T; Yamaguchi, K; Yoshino, K, 2023) |